

WEST Search History

DATE: Monday, March 22, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L32	l31 not l10	100
<input type="checkbox"/>	L31	L30 with l1	100
<input type="checkbox"/>	L30	clostrid\$ or neurotoxin	6508
	<i>DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L29	L28 and l15	65
<input type="checkbox"/>	L28	clostrid\$ not l25	2003
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L27	US-20030166238-A1.did.	1
	<i>DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L26	L25 and l15	25
<input type="checkbox"/>	L25	neurotoxin	405
<input type="checkbox"/>	L24	l20 and l21 and l22 and l23	9
<input type="checkbox"/>	L23	endocyt\$6 or transport\$4	354269
<input type="checkbox"/>	L22	cleav\$ or protease or proteinase	41377
<input type="checkbox"/>	L21	bind\$4	389299
<input type="checkbox"/>	L20	L19 or l17	11724
<input type="checkbox"/>	L19	L18 with l15	161
<input type="checkbox"/>	L18	"single chain"	1387
<input type="checkbox"/>	L17	L16 with l15	11675
<input type="checkbox"/>	L16	gene or plasmid or protein	250407
<input type="checkbox"/>	L15	fus\$4 or chimera\$3	225808
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L14	L13 same l12 same l8 not l10	2
<input type="checkbox"/>	L13	l5 same (l6 or l7)	15844
<input type="checkbox"/>	L12	l1 same l11	4544
<input type="checkbox"/>	L11	"single chain"	10437
<input type="checkbox"/>	L10	L9 and l3	25
<input type="checkbox"/>	L9	l5 same l6 same l7 same l8	35
<input type="checkbox"/>	L8	cleav\$ or protease or proteinase	97654
<input type="checkbox"/>	L7	endocyt\$6	3603
<input type="checkbox"/>	L6	transport\$	420621
<input type="checkbox"/>	L5	bind\$4	338897
<input type="checkbox"/>	L4	bnid\$4	15

<input type="checkbox"/>	L3	11 with L2	27127
<input type="checkbox"/>	L2	gene or plasmid or protein	174117
<input type="checkbox"/>	L1	fus\$4 or chimera\$3	238926

END OF SEARCH HISTORY

File 155:MEDLINE(R) 1966-2004Jan W2 (c) format only 2004 The Dialog Corp.

Set Items Description

Ref Items RT Index-term
 E1 0 1 FUSION PROTEINS, RECOMBINANT
 E20 1 FUSION PROTEINS, VIRAL
 E30 *FUSION PROTEIN
 E40 1 FUSION REGULATORY PROTEIN 1, HEAVY CHAIN
 E50 1 FUSION REGULATORY PROTEIN-1
 E6 1 FUSIONA
 E7 1 FUSIONABILITY
 E8 6 FUSIONABLE
 E9 1 FUSIONADAS
 E10 1 FUSIONADO
 E11 4 FUSIONADOS
 E12 349 FUSIONAL
 S1 39072 'RECOMBINANT FUSION PROTEINS'
 S2 28703 NEUROTOX?
 S3 126 S1 AND S2
 S4 32438 'TOXINS'
 S5 480 S1 AND S4
 S6 449 S5 NOT S3
 S7 328 S6 AND PY<2000
 S8 133 KEX OR YSC
 S9 0 S7 AND S8
 S10 11 S1 AND S8
 Ref Items Type RT Index-term
 R1 18851 1 *PROTEASES
 R2 37428 X 81 ENDOPEPTIDASES
 Ref Items Type RT Index-term
 R1 37428 81 *ENDOPEPTIDASES
 R2 125 X DC=D8.811.277.656.300. (ENDOPEPTIDASES)

R30 X 1 *PEPTIDE PEPTIDOHYDROLASES
 R4 18851 X 1 PROTEASES
 R5 7695 X 1 PROTEINASES
 R6 18978 B 107 PEPTIDE HYDROLASES
 R7 777 N 3 ACROSN
 R8 433 N 10 ANCRD
 R9 468 N 12 ANSTREPLASE
 R10 2467 N 11 ASPARTIC ENDOPEPTIDASES
 R11 385 N 11 BATROXOBIN
 R12 39 N 5 BRINOLASE
 S11 37428 'ENDOPEPTIDASES'
 S12 9 S11 AND S7
 S13 1096 S1 AND S11
 S14 30746 MEMBRANE(GN) BIND?
 S15 62079 TRANSLOCAT?
 S16 3 S13 AND S14 AND S15
 S17 72 S15 AND S13 NOT S16
 S18 50 S17 NOT SECRET?
 S19 28490 BOTULIN? OR TETAN?
 S20 178 S1 AND S19
 S21 5 S20 AND S11
 Ref Items Index-term
 E12 AU=FRANCIS ISSAC R
 E2 1 AU=FRANCIS ISSAM M
 E3 161 *AU=FRANCIS J
 E4 2 AU=FRANCIS JA
 E5 9 AU=FRANCIS JB
 E6 8 AU=FRANCIS JC
 E7 6 AU=FRANCIS JD
 E8 51 AU=FRANCIS JE
 E9 1 AU=FRANCIS JF
 E10 7 AU=FRANCIS JG
 E11 1 AU=FRANCIS JH
 E12 5 AU=FRANCIS JI
 E13 5 AU=FRANCIS JK
 E14 89 AU=FRANCIS JL

E15 1 AU=FRANCIS J LYNN
 E16 41 AU=FRANCIS JM
 E17 4 AU=FRANCIS JN
 E18 1 AU=FRANCIS JP
 E19 10 AU=FRANCIS JR
 E20 17 AU=FRANCIS JS
 E21 4 AU=FRANCIS JT
 E22 1 AU=FRANCIS JV
 E23 34 AU=FRANCIS JW
 E24 1 AU=FRANCIS JACKIE
 E25 1 AU=FRANCIS JACQUELINE
 E26 3 AU=FRANCIS JAMES
 E27 3 AU=FRANCIS JAMES N
 E28 2 AU=FRANCIS JANE
 E29 4 AU=FRANCIS JANE M
 E30 1 AU=FRANCIS JASMINE H
 E31 2 AU=FRANCIS JENNELLE
 E32 2 AU=FRANCIS JENNIFER
 E33 1 AU=FRANCIS JENNIFER D
 E34 3 AU=FRANCIS JENNIFER L
 E35 1 AU=FRANCIS JEREMY S
 E36 2 AU=FRANCIS JOANNA C
 E37 9 AU=FRANCIS JOHN L
 E38 1 AU=FRANCIS JONATHAN M
 E39 3 AU=FRANCIS JONATHAN W
 E40 10 AU=FRANCIS JOSEPH
 E41 1 AU=FRANCIS JOSEPH P
 E42 2 AU=FRANCIS JOSEPH T
 E43 1 AU=FRANCIS JOSHUA
 E44 1 AU=FRANCIS JUDITH
 E45 3 AU=FRANCIS JULIUS
 E46 63 AU=FRANCIS K
 E47 1 AU=FRANCIS K A
 E48 10 AU=FRANCIS K C
 S22 221 E3,E23-E26, E28, E31-E32, E40, E43-E45
 S23 4 S19 AND S22

3/6/1 15802233 PMID: 12854151
 Inhibition of HBV targeted ribonuclease enhanced by introduction of linker. Jul 2003

3/6/2 15377227 22613949 PMID: 12727273
 Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. May 2003

3/6/3 15317414 22773060 PMID: 12890769
 Reversible suppression of glutamatergic neurotransmission of cerebellar granule cells in vivo by genetically manipulated expression of tetanus neurotoxin light chain. Jul 30 2003

3/6/4 15077658 22672620 PMID: 12787071
 Two serine residues distinctly regulate the rescue function of Humanin, an inhibiting factor of Alzheimer's disease-related neurotoxicity : functional potentiation by isomerization and dimerization. Jun 2003

3/6/5 14856159 22420361 PMID: 12532462
 Targeted ribonuclease can inhibit replication of hepatitis B virus. Feb 2003

3/6/6 14819242 22509330 PMID: 12622404
 PTEN regulates Akt kinase activity in hippocampal neurons and increases their sensitivity to glutamate and apoptosis. 2002

3/6/7 14722296 22483980 PMID: 12595242
 Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Jan 2003

3/6/8 14682585 22454963 PMID: 12565753
 Expression of a functional recombinant P1oneuria nigriverter toxin active on K⁺ channels. Mar 1 2003

3/6/9 14613403 22394042 PMID: 12504599
 Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta1 against NMDA-induced necrosis. Dec 2002

3/6/10 14546728 22135753 PMID: 12140266
 Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis. Aug 15 2002

3/6/11 14423490 22394087 PMID: 12505422
 Activation of GABA(A) receptors by gamma-hydroxybutyrate: a novel pathophysiological mechanism. Nov 2002

3/6/12 14150739 22278759 PMID: 12291613
 Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. Nov 1 2002

3/6/13 14124312 22317806 PMID: 12430716
 HIV-1 gp120 proteins and gp150 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain a HIV-associated dementia. Nov 2002

3/6/14 14109856 22287190 PMID: 12399596
 Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Oct 25 2002

3/6/15 13924267 22143702 PMID: 12148278
 [Expression and purification of recombinant huwentoxin-I in Pichia pastoris] Jan 2002

3/6/16 11912150 99355417 PMID: 10426463
 Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of Bungarus fasciatus by genetic recombination Jul 16 1999

- 3/6/17 11874546 99316188 PMID: 10387025
The functional role of positively charged amino acid side chains in alpha-bungarotoxin revealed by site-directed mutagenesis of a His-tagged recombinant alpha-bungarotoxin. Jun 15 1999
- 3/6/18 11837792 99278136 PMID: 10346912
Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and diethylether. May 25 1999
- 3/6/19 11773090 99211386 PMID: 10197529
Neurexins are functional alpha-latrotoxin receptors. Mar 1999
- 3/6/20 11730254 99167063 PMID: 10069533
Ischemia induces metallothionein III expression in neurons of rat brain. 1999
- 3/6/21 11723801 99160489 PMID: 10049679
Recombinant and truncated tetanus neurotoxin light chain cloning, expression, purification, and proteolytic activity. Mar 1999
- 3/6/22 11685533 99121035 PMID: 9922280
EmrE, a small *Escherichia coli* multidrug transporter, protects *Saccharomyces cerevisiae* from toxins by sequestration in the vacuole. Feb 1999
- 3/6/23 11624177 99057603 PMID: 9838137
cDNA sequence analysis and expression of four long neurotoxin homologues from *Naja naja atra*. Nov 26 1998
- 3/6/24 11593846 99026267 PMID: 9806860
Conjugative transfer of the *Escherichia coli*-*Clostridium perfringens* shuttle vector pJIR1457 to *Clostridium botulinum* type A strains. Nov 1998
- 3/6/25 11497567 98381840 PMID: 9717740
Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B. Jul 1998
- 3/6/26 11496293 98380521 PMID: 9712688
Ganglioside GT1b as a complementary receptor component for *Clostridium botulinum* neurotoxins. Aug 1998
- 3/6/27 11494208 98378355 PMID: 9714553
Functional characterization of mongOOSE nicotinic acetylcholine receptor alpha-subunit: resistance to alpha-bungarotoxin and high sensitivity to acetylcholine. Jul 24 1998
- 3/6/28 11387700 98268836 PMID: 9607820
Recombinant human eosinophil-derived neurotoxin (RNase 2) functions as an effective antiviral agent against respiratory syncytial virus. Jun 1998
- 3/6/29 11203393 98086179 PMID: 9426210
Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. Dec 8 1997
- 3/6/30 11139735 98015419 PMID: 9353935
Recombinant SNAP-25 is an effective substrate for *Clostridium botulinum* type A toxin endopeptidase activity in vitro. Oct 1997
- 3/6/31 11110445 971404680 PMID: 9261392
Glycoprotein Ems of pestiviruses induces apoptosis in lymphocytes of several species. Sep 1997
- 3/6/32 11083093 971444337 PMID: 9298966
A new potassium channel toxin from the sea anemone *Heteractis magnifica*: isolation, cDNA cloning, and functional expression. Sep 23 1997
- 3/6/33 11063272 97141717 PMID: 9268675
High-level production and isotope labeling of snake neurotoxins, disulfide-rich proteins. Aug 1997
- 3/6/34 11050445 971404680 PMID: 9261392
Glycoprotein Ems of pestiviruses induces apoptosis in lymphocytes of several species. Sep 1997
- 3/6/35 11026724 97380307 PMID: 9237097
Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Jun 1997
- 3/6/36 10970079 97322809 PMID: 9179289
In vitro folding and functional analysis of an anti-insect selective scorpion depressant neurotoxin produced in *Escherichia coli*. Jun 1997
- 3/6/37 10913157 97265242 PMID: 9111179
Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. Apr 1997
- 3/6/38 10891577 97243441 PMID: 9118897
DNA fragmentation and prolonged expression of c-fos, c-jun, and hsp70 in kainic acid-induced neuronal cell death in transgenic mice overexpressing human CuZn-superoxide dismutase. Mar 1997
- 3/6/39 10851392 97202741 PMID: 9050235
Molecular characteristics of mammalian and insect amino acid transporters: implications for amino acid homeostasis. Jan 1997
- 3/6/40 10824716 97175716 PMID: 9023371
Binding of the synaptic vesicle w-SNARE, synaptobrevin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses. Feb 4 1997
- 3/6/41 10790005 97140301 PMID: 8996782
Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins. Dec 24 1996
- 3/6/42 10667816 97016880 PMID: 8863493
Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. Nov 1996
- 3/6/43 10605337 96422925 PMID: 8825526
Effects of chlorotrifluoroethylene oligomer fatty acids on recombinant GABA receptors expressed in *Xenopus oocytes*. Jan 1996
- 3/6/44 10436837 96243500 PMID: 8711755
Facile production of native-like kappa-bungarotoxin in yeast: an enhanced system for the production of a neuronal nicotinic acetylcholine receptor probe. Feb 1996
- 3/6/45 10421671 96228050 PMID: 8647268
Botulinum neurotoxin light chains inhibit both Ca^{2+} -induced and GTP analogue-induced catecholamine release from permeabilised adrenergic cells. May 20 1996
- 3/6/46 10357280 96160045 PMID: 8562308
Clinical trials of targeted toxins. Oct 1995
- 3/6/47 10356144 96158928 PMID: 8562075
A strongly interacting pair of residues on the contact surface of charybotoxin and a Shaker K⁺ channel. Jan 1996
- 3/6/48 10348836 96151333 PMID: 8559190
Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Oct 1995
- 3/6/49 10304915 96106945 PMID: 8535163
Expression in *Escherichia coli* and purification of human eosinophil-derived neurotoxin with ribonuclease activity. Oct 1995
- 3/6/50 10272824 96074594 PMID: 7488184
cDNA sequence analysis and expression of alpha-bungarotoxin from Taiwan banded krait (*Bungarus multicinctus*). Nov 22 1995
- 3/6/51 10271008 96072756 PMID: 7578132
Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxic after reconstitution with the heavy chain. Nov 21 1995
- 3/6/52 10261998 96063633 PMID: 7488136
17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Nov 13 1995
- 3/6/53 10224506 96025759 PMID: 7592578
High affinity binding of alpha-latrotoxin to recombinant neurexin I alpha. Oct 13 1995
- 3/6/54 10216937 96018129 PMID: 7570631
Cloning and expression of mamba toxins. Apr 1995
- 3/6/55 10165787 22168883 PMID: 12180969
Characterization of scorpion alpha-like toxin group using two new toxins from the scorpion *Leiurus quinquestriatus hebraeus*. Aug 2002
- 3/6/56 10156787 22152946 PMID: 12027804
Cytotoxic potency of cardiotoxin from *Naja sputatrix*: development of a new cytolytic assay. Aug 15 2002
- 3/6/57 10149075 22140381 PMID: 12145319
Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly. Aug 2 2002
- 3/6/58 10148812 22140034 PMID: 12145198
Calmodulin and lipid binding to synaptobrevin regulates calcium-dependent exocytosis. Aug 1 2002
- 3/6/59 10088963 22043136 PMID: 12047391
Refolding of the *Escherichia coli* expressed extracellular domain of alpha 7 nicotinic acetylcholine receptor. Jun 2002
- 3/6/60 09954415 21871794 PMID: 11880503
Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death a

- exposure to methylcyclopentadienyl manganese tetracarboxylate. Mar 1 2002
- 3/6/61 09938303 21850743 PMID: 11861082
A unique approach for high level expression and production of a recombinant cobra neurotoxin in *Escherichia coli*. Apr 11 2002
- 3/6/62 09809576 21618056 PMID: 11767952
A recombinant scFv/streptavidin-binding peptide fusion protein for the quantitative determination of the scorpion venom neurotoxin Aa1h. Nov 2001
- 3/6/63 09803835 21611849 PMID: 11746436
Biologically active sequence (KQD) mediates the neurite outgrowth function of the gamma-1 chain of laminin-1. Dec 15 2001
- 3/6/64 09798253 21606007 PMID: 11736750
Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins. Dec 12 2001
- 3/6/65 09770747 21575763 PMID: 11719263
Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy. Oct-Nov 1 2001
- 3/6/66 09865280 21477243 PMID: 11592857
The neuronal calcium sensor protein VILP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Oct 2001
- 3/6/67 09642153 21429356 PMID: 11543686
Properties and interaction of heterologously expressed glutamate decarboxylase (isoenzymes GAD(65kDa) and GAD(67kDa) from human brain with ginkgoxin and its 5-phosphate. Sep 13 2001
- 3/6/68 09626046 21421248 PMID: 11520908
Neurotrophins prevent HIV-1-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. Aug 2001
- 3/6/69 09588916 21372669 PMID: 11478968
Expression of an active recombinant lysine 49 phospholipase A(2) myotoxin as a fusion protein in bacteria. Oct 2001
- 3/6/70 09580364 21363578 PMID: 11470830
A stoichiometric complex of neuexins and cystotyocyan in brain. Jul 23 2001
- 3/6/71 0967149 21354618 PMID: 11461976
Role of alpha2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental factor? Jul 2001
- 3/6/72 09490505 21267040 PMID: 11356871
A common exocytic mechanism mediates axonal and dendritic outgrowth. Jun 1 2001
- 3/6/73 09439297 21210796 PMID: 11299302
Human immunodeficiency virus type 1 Tat protein decreases cyclic AMP synthesis in rat microglia cultures. Apr 2001
- 3/6/74 09410039 21176902 PMID: 11281322
Sup3p, yeast prion-like protein as an adapter for production of the Gag-p55 antigen of HIV-1 and the L-chain of botulinum neurotoxin in *Saccharomyces cerevisiae*. Jan-Feb 2001
- 3/6/75 09352619 21114032 PMID: 11160457
Amyloid (beta)A42 activates a G-protein-coupled chemotactant receptor, FFR-like-1. Jan 15 2001
- 3/6/76 09349876 21111022 PMID: 11178934
Inhibition of neuronal nitric oxide synthase by N-phenacyl imidazoles. Feb 2001
- 3/6/77 09348692 21109370 PMID: 11161470
Akt1/PKBalpha protects PC12 cells against the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium and reduces the levels of oxygen-free radicals. Jan 2001
- 3/6/78 09237059 20549560 PMID: 10973942
Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. Nov 17 2000
- 3/6/79 09203799 20513018 PMID: 11059270
Expression and characterization of two kinds of recombinant snake neurotoxins. May 2000
- 3/6/80 09177907 20483654 PMID: 11027615
The amino acid region 115-119 of ammodytoxins plays an important role in neurotoxicity. Oct 5 2000
- 3/6/81 09112657 20411243 PMID: 10954418
Membrane localization and biological activity of SNAP-25 cysteine mutants in insulin-secreting cells. Sep 2000
- 3/6/82 09092184 20389730 PMID: 10930684
Cloning, expression and evaluation of a recombinant sub-unit vaccine against *Clostridium botulinum* type F toxin. Sep 15 2000
- 3/6/83 09035114 20329465 PMID: 10873064
Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Jun 2000
- 3/6/84 09030890 20324939 PMID: 10865133
Measurement of exocytosis by amperometry in adrenal chromaffin cells: effects of clostridial neurotoxins and activation of protein kinase C fusion pore kinetics. May 2000
- 3/6/85 09002366 20294906 PMID: 10833399
Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A. Jun 2000
- 3/6/86 08856185 20141225 PMID: 10675534
Identification and characterization of functional subunits of *Clostridium botulinum* type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. Feb 11 2000
- 3/6/87 08853128 20137998 PMID: 10672018
Functional characterization and mechanism of action of recombinant human tyrosine 3-hydroxylase. Feb 2000
- 3/6/88 08835257 20119217 PMID: 10652444
Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Feb 15 2000
- 3/6/89 08812762 20095669 PMID: 10630205
Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Nov 1999
- 3/6/90 08792663 20074908 PMID: 10606730
An in vivo assay for the identification of target proteases which cleave membrane-associated substrates. Dec 17 1999
- 3/6/91 08767091 20069083 PMID: 10600453
Expression and purification of the Bmk1M1 neurotoxin from the scorpion *Buthus maritellii* Karsch. Dec 1999
- 3/6/92 08769428 20050851 PMID: 10581396
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Nov 10 1999
- 3/6/93 08766143 20047427 PMID: 10582602
Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis. Dec 1999
- 3/6/94 08763553 20044741 PMID: 10574958
Variability among the sites by which curareimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the function residues of alpha-dobtoxins. Dec 3 1999
- 3/6/95 08688676 95377281 PMID: 7649153
Recombinant and chemical derivatives of apamin. Implication of post-transcriptional C-terminal amidation of apamin in biological activity. Aug 1995
- 3/6/96 08660219 95348616 PMID: 7623136
Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. Jul 1995
- 3/6/97 08622454 95310981 PMID: 7790908
Kainic acid-induced neuronal death is associated with DNA damage and a unique immediate-early gene response in c-fos-lacZ transgenic rats. Jun 1995
- 3/6/98 08546027 95234326 PMID: 7718248
A mutated acetylcholine receptor subunit causes neuronal degeneration in *C. elegans*. Apr 1995
- 3/6/99 08525400 95213678 PMID: 7599335
Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. Apr 1 1995
- 3/6/100 08374166 950627139 PMID: 7526378
Engineering of protein epitopes: a single deletion in a snake toxin generates full binding capacity to a previously unrecognized antibody. Jul 1
- 3/6/101 08371481 95059454 PMID: 7969473
Structural determinants of the blockade of N-type calcium channels by a peptide neurotoxin. Nov 17 1994
- 3/6/102 08326592 95014532 PMID: 7929408
Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferin receptor sFv. Oct 28 1994

3/6/103 08303720 94373331 PMID: 7522104
Competitive antagonism by phenylglycine derivatives at type I metabotropic glutamate receptors. Jun 1994

3/6/104 08267296 94333357 PMID: 8055534
Production of active, insect-specific scorpion neurotoxin in yeast. Jul 15 1994

3/6/105 08236041 94301996 PMID: 7518082
Engineering a uniquely reactive thiol into a cysteine-rich peptide. Apr 1994

3/6/106 08198098 94264020 PMID: 7911329
A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Jun 7 1994

3/6/107 08169290 94235190 PMID: 8179645
Structure, function and expression of voltage-dependent sodium channels. Fall-Winter 1993

3/6/108 08143419 94209288 PMID: 8157645
Functional expression and site-directed mutagenesis of a synthetic gene for alpha-bungarotoxin. Apr 15 1994

3/6/109 08093322 94159078 PMID: 8114918
Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Jan 13 1994

3/6/110 08001602 94067319 PMID: 8247129
Synaptic vesicle fusion complex contains unc-18 homologue bound to syntaxin. Nov 25 1993

3/6/111 07985762 94051479 PMID: 8233724
Potentiation of N-methyl-D-aspartate-mediated brain injury by a human immunodeficiency virus-1-derived peptide in perinatal rodents. Aug 1993

3/6/112 07924263 93385055 PMID: 8373764
Effects of mutations of Torpedo acetylcholine receptor alpha 1 subunit residues 184-200 on alpha-bungarotoxin binding in a recombinant fusion protein. Sep 21 1993

3/6/113 07724190 93179465 PMID: 8095049
Characterization of a distinct binding site for the prokaryotic chaperone, GroEL, on a human granulocyte ribonuclease. Feb 25 1993

3/6/114 07611265 93065342 PMID: 1438289
Deposition of betaA4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Nov 15 1992

3/6/115 07573392 93028327 PMID: 1409549
Insertion of a disulfide-containing neurotoxin into E. coli alkaline phosphatase: the hybrid retains both biological activities. Apr 1992

3/6/116 07478586 92342135 PMID: 1635553
Molecular neurotoxicology of trimethyltin: identification of stannin, a novel protein expressed in trimethyltin-sensitive cells. Jul 1992

3/6/117 07386559 92249751 PMID: 1577256
Cloning of a Clostridium botulinum type B toxin gene fragment encoding the N-terminus of the heavy chain. Feb 1 1992

3/6/118 07281817 92144540 PMID: 1736394
Substitution of Torpedo acetylcholine receptor alpha 1-subunit residues with snake alpha 1- and rat nerve alpha 3-subunit residues in recombinant fusion proteins: effect on alpha-bungarotoxin binding. Feb 11 1992

3/6/119 07268584 92131247 PMID: 1837849
Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. 1991

3/6/120 07165311 92027518 PMID: 1658845
Calcium channel antagonists and human immunodeficiency virus coat protein-mediated neuronal injury. Jul 1991

3/6/121 07131767 91372981 PMID: 1910014
Characterization of the C3 gene of Clostridium botulinum types C and D and its expression in Escherichia coli. Oct 1991

3/6/122 06763084 91002534 PMID: 2207082
Comparison of the toxin binding sites of the nicotinic acetylcholine receptor from Drosophila to human. Jul 10 1990

3/6/123 06739929 90365970 PMID: 1365462
Expression and secretion of a functional scorpion insecticidal toxin in cultured mouse cells. Apr 1990

3/6/124 06680484 90306371 PMID: 2365072
A recombinant snake neurotoxin generated by chemical cleavage of a hybrid protein recovers full biological properties. Jun 18 1990

3/6/125 06458371 90083145 PMID: 2687847

Direct expression in E. coli of a functionally active protein A—snake toxin fusion protein. Nov 1989

3/6/126 06343017 89359352 PMID: 2670934
Cloning and expression of a synthetic gene for Cerebrallus laevis neurotoxin B-IV. Sep 15 1989

3/7/28 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11496293 98380521 PMID: 9712688
Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins.
Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S
Department of Veterinary Science, College of Agriculture, Osaka Prefecture University, Sakai, Osaka, 599-8531, USA.
Microbial pathogenesis [ENGLAND] Aug 1998, 25 (2) p19-1, ISSN 0882-4010 Journal Code: 8606191
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
Clostridium botulinum type B neurotoxin (BoNT/B), recognizes a complex of synaptobrevin II and ganglioside GT1b or GD1a at the high-affinity toxin binding site. Recombinant deletion mutants of synaptobrevin II allowed us to demonstrate that the N-terminal domain including the transmembrane region retains BoNT/B binding activity while the C-terminal domain is not involved in constituting the BoNT/B receptor. BoNT/B binding to reconstituted lipid vesicles containing synaptobrevin II and ganglioside showed that GT1b and GD1a confer the difference in the maximum binding capacity but not in the dissociation constant. The direct binding of GT1b to the deletion mutants revealed that the transmembrane region is required to bind GT1b, suggesting that synaptobrevin II binds to the ceramide portion of gangliosides within the plasma membrane. A monoclonal antibody against GT1b effectively inhibited not only BoNT/B binding to the reconstituted lipid vesicles and brain synaptosomes but also type A BoNT (BoNT/A) binding to brain synaptosomes. In addition, the monoclonal antibody antagonized the action of both BoNT/A and BoNT/B on synaptic transmission of rat superior cervical ganglion neurons. These results suggest that GT1b functions as a component of the receptor complex. Copyright 1998 Academic Press Record Date Created: 19980929 Record Date Complete 19980929

3/7/61 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

09938303 21850743 PMID: 11861082
A unique approach for high level expression and production of a recombinant cobra neurotoxin in Escherichia coli.
Wang Yongbao, Jing Liu, Xu Kangsen
School of Life Science, University of Science and Technology of China, Hefei, Anhui province, Peoples Republic of China, yjwanq@hncpp.org.cn
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
In this report, we describe a simple approach to produce a large quantity of a recombinant cobra neurotoxin containing four p of disulfide bonds. A cDNA encoding the toxin was fused, in frame, to the carboxyl termini of thioredoxin via a linker sequence encoding two amino acids, Asp and Pro. Due to the presence of thioredoxin, a soluble form of the fusion protein was expressed in a compartment, sensitive to osmotic pressure, in Escherichia coli. The fusion protein was released into the solution with low ionic strength under an osmotic shock treatment, and purified in a single step using an ion exchange chromatography column. The purified protein was treated in diluted hydrochloric acid to induce hydrolysis of the protein at the Asp-Pro linker site. Then, the recombinant neurotoxin was purified by gel filtration of the acid-treated sample. When the biological activity of the purified toxin was assayed, it was as potent as the natural toxin. Using this protocol, approximately 12 mg of pure recombinant neurotoxin can be produced from one liter of bacterial culture. More importantly, this protocol can be easily used for the production of the toxin at a larger scale with low cost. The approach outlined in this report will be suitable for the production of other recombinant proteins especially those of the three-finger family. Record Date Created: 20020225 Record Date Complete 20020517

3/7/117 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

07386559 92249751 PMID: 1577256
Cloning of a Clostridium botulinum type B toxin gene fragment encoding the N-terminus of the heavy chain.
Jung H H, Rhee S D, Yang K H
Department of Life Science, Korea Advanced Institute of Science and Technology, Taejeon, Korea.
FEEMS microbiology letters [NETHERLANDS] Feb 1 1992, 70 (1) p69-72, ISSN 0378-1097 Journal Code: 7705721
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
Two lambda g11 clones of the toxin gene of Clostridium botulinum type B were identified by the monoclonal antibody specific to the heavy chain of type B toxin. Neither of the expressed fusion proteins from the lysates of *lysogenic* E. coli Y1089 showed a botulinum toxic activity. One of the clones hybridized to the oligonucleotide probe which was synthesized according to the amino acid sequence of N-terminus of heavy chain. The sequence analysis revealed that highly homologous regions in N-terminus of heavy chain exist among botulinum neurotoxins (type A, B) and tetanus toxin on the amino acid sequence level. Record Date Created: 19920611 Record Date Completed: 19920611

3/7/124 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

06680484 90306371 PMID: 2365072
A recombinant snake neurotoxin generated by chemical cleavage of a hybrid protein recovers full biological properties.

Protein--genetics--GE; Mice; Molecular Sequence Data; Nerve Tissue Protein--genetics--GE; Pro-Opomelanocortin--genetics--GE; Protein Conformation; Protein Structure; Tertiary; Recombinant Fusion Proteins--genetics--GE; Recombinant Fusion Proteins--metabolism--ME; Tumor Cells; Cultured; CAS Registry No.: 0 (Antigens, Surface); 0 (Botulinum Toxins); 0 (Membrane Proteins); 0 (Nerve Tissue Proteins); 0 (Recombinant Fusion Proteins); 0 (SNAR receptor); 0 (botulinum toxin type E); 0 (synaptosomal-associated protein 25); 0 (syntaxin 1); 0 (vesicle-associated membrane protein); 52-90-4 (Cysteine); 66786-54-1 (Pro-Opomelanocortin); 7440-70-2 (Calcium)

Record Date Created: 20020725 Record Date Completed: 20030311

3/5/17 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11874546 99316188 PMID: 10387025

The functional role of positively charged amino acid side chains in alpha-bungarotoxin revealed by site-directed mutagenesis of a His-tagged recombinant alpha-bungarotoxin.

Rosenthal J A; Levandoski M M; Chang B; Potts J F; Shi Q L; Hawrot E
Department of Molecular Pharmacology, Physiology, and Biotechnology, Division of Biology and Medicine, Brown University, Providence, Rhode Island 02912, USA.

Contract/Grant No.: GM076071; GM; NIGMS; GM326929; GM; NIGMS; NS34348; NS; NINDS Document type: Journal Article
Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

A polyhistidine tag was added to the N-terminus of alpha-bungarotoxin (Bgtx) recombinantly expressed in *E. coli*. The His-tagged Bgtx was identical to native, venom-derived Bgtx in its apparent affinity for the nicotinic acetylcholine receptor (nAChR) Torpedo electric organ membranes. Furthermore, in a physiological assay involving mouse muscle nAChR expressed in *Xenopus oocytes*, the His-tagged Bgtx was as effective as authentic Bgtx at blocking acetylcholine-evoked currents. Ala-substitution mutagenesis of His-tagged Bgtx was used to evaluate the functional contribution of Arg36, a residue that is invariant among all alpha-neurotoxins. Replacement with Ala resulted in a 30-fold decrease in the apparent affinity for the Torpedo nAChR and a corresponding 150-fold increase in the IC50 for block of heterologously expressed mouse muscle nAChR, demonstrating the critical importance of this positive charge for the binding and functional activity of a long alpha-neurotoxin. The observed decrease in affinity corresponds to a DeltaDeltaG of 2.7 kcal/mol and indicates that Arg36 makes a major contribution to complex formation. This finding is consistent with the proposal that Arg36 mimics the positive charge found on acetylcholine and directs the toxin to interact with receptor sites normally involved in acetylcholine recognition. In comparison, Ala-substitution of the highly conserved Lys26 resulted in only a 9-fold decrease in apparent affinity. Truncation of the His-tag Bgtx following residue 67 produces a toxin lacking the seven C-terminal residues including the two positively charged residues Lys70 and Arg72. Truncation leads to a 7-fold decrease in apparent binding affinity.

Tags: Animal; Support; U.S. Gov't; P.H.S. Descriptors: Amino Acids--physiology--PH; Bungarotoxins--physiology--PH; Histidine--genetics--G *Mutagenesis; Site-Directed; *Recombinant Fusion Proteins--metabolism--ME; Amino Acid Substitution--genetics--GE; Amino Acids--genetic GE; Amino Acids--metabolism--ME; Bacteriophage T4--genetics--GE; Binding; Competitive--genetics--GE; Bungarotoxins--genetics--GE; Bungarotoxins--metabolism--ME; Escherichia coli--genetics--GE; Genetic Vectors--metabolism--ME; Genetic Vectors--pharmacology--PD; Histidine--metabolism--ME; Hydrogen Ion Concentration; Mice; Muscle; Skeletal--drug effects--DE; Muscle; Skeletal--metabolism--ME; Nicotinic Antagonists--pharmacology--PD; Receptors; Nicotinic--biosynthesis--BI; Recombinant Fusion Proteins--isolation and purification--Recombinant Fusion Proteins--pharmacology--PD; Sequence Deletion; Torpedo; Viral Protein--genetics--GE; CAS Registry No.: 0 (Amino Acids); 0 (Bungarotoxins); 0 (Genetic Vectors); 0 (Nicotinic Antagonists); 0 (Receptors; Nicotinic); 0 (Recombinant Fusion Proteins); 0 (Viral Proteins); 147258-48-8 (bacteriophage T4 gene 9 protein); 71-00-1 (Histidine)

Record Date Created: 19990715 Record Date Completed: 19990715

3/5/21 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11723801 99160489 PMID: 10049679

Recombinant and truncated tetanus neurotoxin light chain: cloning, expression, purification, and proteolytic activity.

Tonello F; Pellizzari R; Pasqualato S; Grandi G; Peggion E; Montecucco C
Dipartimento di Scienze Biomediche, Università di Padova, Padova I-35121, Italy.
Protein expression and purification (UNITED STATES) Mar 1999, 15 (2) p221-7. ISSN 1046-5928 Journal Code: 910149
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
Subfile: INDEX MEDICUS

Tetanus neurotoxin (TeNT) consists of two disulfide-linked polypeptide chains, heavy (H) and light (L). The L chain is a zinc endopeptidase protein highly specific for vesicle-associated membrane protein (VAMP), which is an essential component of the exocytosis apparatus. Here we describe the cloning of the L chain of TeNT from *Clostridium tetani* strain Y-143 (WS 15) and its expression in *Escherichia coli* as a glutathione S-transferase fusion protein. The full-length recombinant L chain, corresponding to residues 1-157, was obtained as a mixture of proteins of slightly different mass with identical N-terminal ends. To obtain a product useful for structural analysis and crystallization, a COOH-terminally truncated L chain (residues 1-127) was cloned, expressed, and purified with high yield. This truncated L chain is more active than the full-length and wild-type proteins in the hydrolysis of VAMP. Preliminary experiments of crystallization of the truncated recombinant L chain gave encouraging results. Copyright 1999 Academic Press

Tags: Human; Support; Non-U.S. Gov't; Descriptors: *Metalloendopeptidases--genetics--GE; *Tetanus Toxin--genetics--GE; Cloning; Molecular; Crystallization; Escherichia coli; Gene Expression; Membrane Protein--metabolism--ME; Metalloendopeptidases--biosynthesis--B Metalloendopeptidases--isolation and purification--IP; Metalloendopeptidases--metabolism--ME; Peptide Fragments--biosynthesis--BI; Peptide Fragments--genetics--GE; Peptide Fragments--isolation and purification--IP; Peptide Fragments--metabolism--ME; Recombinant Fusion Proteins--biosynthesis--I; Recombinant Fusion Proteins--genetics--GE; Recombinant Fusion Proteins--isolation and purification--IP;

Boyet P; Pillet L; Ducancel F; Boulain J C; Tremeau O; Menez A
Département de Biologie, Laboratoire d'ingénierie des Protéines C.E.N., Gif-sur-Yvette, France.
FEBS letters (NETHERLANDS) Jun 18 1990, 266 (1-2) p87-90. ISSN 0014-5793 Journal Code: 0155157

Eratium in FEBS Lett 1990 Oct 1;271(1-2):258 Document type: Journal Article Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

We previously reported the production of a fused snake neurotoxin composed of protein A and erabutoxin a in *E. coli*. The hybrid had much lower toxicity and affinity for the acetylcholine nicotinic receptor than natural erabutoxin. By treating the hybrid with cyanogen bromide we generated a toxin which was purified in a single step by RP-HPLC. This compound, produced in a good yield, recovered all properties of native erabutoxin a, implying that the lower toxic activities of the hybrid were due to the bulky protein A and not to an incorrect folding of the toxin. This work serves as a basis for future studies of toxin-receptor interactions using engineered toxin mutants. Record Date Created: 19900814 Record Date Completed: 19900814

3/5/2 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
15377227 22613949 PMID: 12727273

Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants.

Jensen M J; Smith T J; Ahmed S A; Smith L A
Division of Toxicology and Aerobiology, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA.

Toxicon - official Journal of the International Society on Toxicology (England) May 2003, 41 (6) p691-701. ISSN 0041-0101
Journal Code: 1307333 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed Subfile: INDEX MEDICUS

Clostridial neurotoxins are potent inhibitors of synaptic function, with the zinc-dependent proteolytic light chain (LC) portion of the toxin cleaving one of three neural SNARE proteins. In nature, the LC is expressed as a part of a much larger toxin and hemagglutinin complex, protecting it from environmental degradation and preserving its catalytic activity. We developed forms of the LC of type A botulinum neurotoxin (BoNT-A) with parts of the larger toxin gene, for use as reagents in high-throughput assays to screen for potential LC antagonists, to further elucidate the toxin's mechanism of action, and to study immunological responses to the toxin. Three BoNT-A constructs were engineered and expressed: the LC, LC with translocation region (LC+H(n)), and the LC with the belt portion of the translocation region (LC+Bel). Purification was optimized to a two-step process, with relatively high yields of all three constructs obtained. Activity assays showed all three constructs to be active, with the LC being the most active. Immunogenic protection against native BoNT-A toxin challenge was observed for all three constructs, with the best protection observed with the LC+H(n) and LC+Bel proteins.

Tags: Animal Descriptors: *Botulinum Toxin Type A--isolation and purification--IP; *Botulinum Toxin Type A--metabolism--ME; *Catalytic Domain; *Gene Expression; *Genetic Engineering; Botulinum Toxin Type A--genetics--GE; Botulinum Toxin Type A--immunology--IM; Enzyme-Linked Immunosorbent Assay; Mice; Protein Transport; Recombinant Fusion Proteins--chemistry--CH; Recombinant Fusion Proteins--immunology--IM; Recombinant Fusion Proteins--isolation and purification--IP; Recombinant Fusion Proteins--metabolism--ME; Temperature; CAS Registry No.: 0 (Botulinum Toxin Type A); 0 (Recombinant Fusion Proteins)

Record Date Created: 20030502 Record Date Completed: 20030917

3/5/10 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
14546728 22135753 PMID: 12140265

Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis.

Kotlova Darshan K; McCarthy Ellen E; Baldini Giulia
Department of Anatomy and Cell Biology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.

Journal of cell science (England) Aug 15 2002, 115 (Pt 16) p3341-51. ISSN 0021-9533 Journal Code: 0052457
Contract/Grant No.: R01-DK53293; DK; NIDDK Document type: Journal Article Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

SNAP-25 is an integral protein of the plasma membrane involved in neurotransmission and hormone secretion. The cysteine-rich domain of SNAP-25 is essential for membrane binding and plasma-membrane targeting. However, this domain is not required for SNARE complex formation and fusion of membranes *in vitro*. In this paper, we describe an 'infect-cell'-based system designed to compare the effect of similar amounts of membrane-bound and soluble SNAP-25 proteins on regulated exocytosis. In transfected neuroblastoma cells, Botulinum neurotoxin E (BoNTE), a protease that cleaves SNAP-25, blocks regulated release of hormone. However, hormone release is rescued by expressing a wild-type SNAP-25 protein resistant to the toxin. BoNTE-resistant SNAP-25 proteins lacking the cysteine-rich domain or with all the cysteines substituted by alanines do not form SNARE complexes or rescue regulated exocytosis when expressed at the same level as membrane-bound SNAP-25, which is approximately four-fold higher than the endogenous protein. We conclude that the cysteine-rich domain of SNAP-25 is essential for Ca(2+)-dependent hormone release because, by targeting SNAP-25 to the plasma membrane, it increases its local concentration, leading to the formation of enough SNARE complexes to support exocytosis.

Tags: Animal; Support; U.S. Gov't; P.H.S. Descriptors: *Cell Membrane--metabolism--ME; *Exocytosis--physiology--PH; *Membrane Protein--metabolism--ME; Nerve Tissue Protein--metabolism--ME; *Protein Transport--physiology--PH; Amino Acid Sequence; Antigens, Surface--metabolism--ME; Botulinum Toxin--metabolism--ME; Calcium--metabolism--ME; Cysteine--metabolism--ME; Genes, Reporter; Membrane

Recombinant Fusion Proteins--metabolism--ME. Spectrometry. Fluorescence. Substrate Specificity. Tetanus Toxin-biosynthesis-Bi. Tetanus Toxin--isolation and purification-IP. Tetanus Toxin-metabolism--ME. CAS Registry No.: 0 (Membrane Proteins); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Tetanus Toxin); 0 (vesicle-associated membrane protein). Enzyme No.: EC 3.4.24 (Metalloendopeptidases); EC 3.4.24. (zinc-endopeptidase, tetanus neurotoxin)
Record Date Created: 19990511 Record Date Completed: 19990511

7/6/1 14867997 22451921 PMID: 1263791
[Association expression of genes encoding gsl of Schistosoma japonicum and enterotoxigenic Escherichia coli] 1999

7/6/2 12007058 99452975 PMID: 10521470
Involvement of small GTPases in Mycoplasma fermentans membrane lipoproteins-mediated activation of macrophages. Oct 22 1999

7/6/3 11999258 99444908 PMID: 10517320
The transcriptional activator CorR is involved in biosynthesis of the phytotoxin coronatine and binds to the omaABT promoter region in a temperature-dependent manner. Sep 1999

7/6/4 11976922 99427861 PMID: 10491008
IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmune in nonobese diabetic mice. Oct 1 1999

7/6/5 11974124 99419014 PMID: 10488072
Neosynthesis and activation of Rho by Escherichia coli cytotoxic necrotizing factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho. Sep 24 1999

7/6/6 11954727 99399090 PMID: 10470104
Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed toxin chimeras in vitro and in vivo. May-Jun 1999

7/6/7 11942739 99386678 PMID: 10455034
Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimeric G-proteins. Sep 1 1999

7/6/8 11919256 99362764 PMID: 10430949
The Xanthomonas Hrp type III system secretes proteins from plant and mammalian bacterial pathogens. Aug 3 1999

7/6/9 11914297 99357644 PMID: 10427035
Activation process of dipteran-specific insecticidal protein produced by Bacillus thuringiensis subsp. israelensis. Aug 1999

7/6/10 11905255 99348366 PMID: 10419539
Yersinia enterocolitica type III secretion. On the role of YscE in targeting YopE into HeLa cells. Jul 30 1999

7/6/11 11905231 99348332 PMID: 10419515
Ion channel activity of the Bti3 only Bti-2 family member, BtiD. Jul 30 1999

7/6/12 11897702 99340543 PMID: 10417128
The 5' region of cmt1 harbours a translational regulatory mechanism for CNF1 synthesis and encodes the cell-binding domain of the toxin. Jul 1999

7/6/13 11887991 99330177 PMID: 10403383
Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. Jun 18 1999

7/6/14 11882109 99323920 PMID: 10393809
Rst167p, the budding yeast homolog of amphiphysin, colocalizes with actin patches. Aug 1999

7/6/15 11865823 99307182 PMID: 10377103
Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Jul 1999

7/6/16 11862205 99303467 PMID: 10376974
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (K4-GSfV)-ETA) is a potent immunotoxin against a Hodgkin-derived cell line. Jun 1999

7/6/17 11853098 99294094 PMID: 10367674
Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Jan-Feb 1999

7/6/18 11847433 99288230 PMID: 10336877
High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. Jun 1999

7/6/19 11815887 99255537 PMID: 10322014
Direct interaction of the EpsC and EpsM proteins of the general secretion apparatus in Vibrio cholerae. May 1999

7/6/20 11814001 99253640 PMID: 10321723
Cloning and cytotoxicity of fusion proteins of EGF and angiogenin. 1999

7/6/21 11799440 99238511 PMID: 10220447

Intranuclear delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin. Apr 27 1999

7/6/22 11795381 99234368 PMID: 10216313
Crystallization and preliminary X-ray diffraction studies of the 51 kDa protein of the mosquito-larvicidal binary toxin from Bacillus sphaericus. Ma 1999

7/6/23 11775824 99214180 PMID: 10196187
A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. Apr 16 1999

7/6/24 11771897 99210155 PMID: 10195780
Novel modifications to the C-terminus of LT-B that facilitate site-directed chemical coupling of antigens and the development of LT-B as a carrier for mucosal vaccines. Mar 17 1999

7/6/25 11759374 99196993 PMID: 10095114
A new series of PET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Mar 18 1999

7/6/26 11755179 99192697 PMID: 10089527
Crystallization and preliminary X-ray diffraction studies of alpha-toxin from two different strains (NCTC8237 and CER89143) of Clostridium perfringens. Nov 1 1998

7/6/27 11753200 99190638 PMID: 10092217
Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport: may determine cell hypersensitivity to verotoxin glycohaosyl ceramide fatty acid isoform traffic. Dec 1998

7/6/28 11752309 99189747 PMID: 10089877
Solution structure of BtD, an intracellular amplifier of apoptotic signaling. Mar 5 1999

7/6/29 11747698 99185011 PMID: 10085027
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Apr 1999

7/6/30 11747681 99184994 PMID: 10085010
An Arcanobacterium (Achromyces) pyrogenes mutant deficient in production of the pore-forming cytotoxin pyrolysin has reduced virulence. Apr 1999

7/6/31 11720993 99157583 PMID: 10048023
Expression and properties of an aerolysin-Clostridium septicum alpha toxin hybrid protein. Feb 1999

7/6/32 11720819 99157408 PMID: 10047878
Differential activity of cholera toxin and E. coli enterotoxin: construction and purification of mutant and hybrid derivatives. Nov 1998

7/6/33 11680321 99115680 PMID: 9914169
The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. Feb 1999

7/6/34 11680158 99115517 PMID: 9916051
Deamidation of Cdc42 and Rac by Escherichia coli cytotoxic necrotizing factor 1: activation of c-Jun N-terminal kinase in HeLa cells. Feb 19

7/6/35 11672041 99107223 PMID: 9882205
Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Jan 1 1999

7/6/36 11657978 99092760 PMID: 9876333
Stepwise translocation of an active site loop between heat-labile enterotoxins LT-II and LT-I and characterization of the obtained hybrid toxins. Nov 1998

7/6/37 11635815 99069581 PMID: 9852324
Gating of skeletal and cardiac muscle sodium channels in mammalian cells. Jan 15 1999

7/6/38 11626571 99060051 PMID: 9843379
Characterization of membrane translocation by anthrax protective antigen. Nov 10 1998

7/6/39 11606274 99039034 PMID: 9821593
Positive selection vectors to generate fused genes for the expression of his-tagged proteins. Nov 1998

7/6/40 11596318 99028905 PMID: 9812362
Functional interactions between ctpB and parD, two homologous conditional killer systems found in the Escherichia coli chromosome and in plasmid R1. Nov 1 1998

7/6/41 11593608 98455677 PMID: 9782357
Prokaryotic expression of porcine epidemic diarrhoea virus ORF3. 1998

7/6/42 11546114 98437626 PMID: 9757112

- Crystallization of ccdB. Sep 1 1998
- 7/6/43 11531599 98422764 PMID: 9750370
Bacterial phospholipases. 1998
- 7/6/44 11512796 98401141 PMID: 9731188
Differences in cytotoxicity of native and engineered RfPs can be used to assess their ability to reach the cytoplasm. Aug 28 1998
- 7/6/45 11503002 98387897 PMID: 9719644
Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. Sep 4 1998
- 7/6/46 11502057 98386734 PMID: 9720265
Recombinant antibody fragments. Aug 1998
- 7/6/47 11496172 98380400 PMID: 9712803
Acino bacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells. Sep 1998
- 7/6/48 11469699 98353391 PMID: 9687463
Phage display of a biologically active Bacillus thuringiensis toxin. Aug 1998
- 7/6/49 11436654 98318336 PMID: 9655624
Nicotinic agonists competitively antagonize serotonin at mouse 5-HT3 receptors expressed in *Xenopus* oocytes. May 15 1998
- 7/6/50 11430324 98312844 PMID: 9650824
Affluent signals to the CNS appear not to condition the modulation of interleukin-1 receptors in the hippocampus. Sep-Dec 1997
- 7/6/51 11412641 98294443 PMID: 9630987
An *Escherichia coli* hemolysin transport system-based vector for the export of polypeptides: export of Shiga-like toxin IIb subunit by *Salmonella typhimurium* ar.O. Jun 1996
- 7/6/52 11386068 98248937 PMID: 9587366
Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology] Immunotoxines recombinantes et toxines chimeres pour une therapie ciblée en oncologie. Dec 1997
- 7/6/53 11350445 98230732 PMID: 9563949
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. May 1 1998
- 7/6/54 11343319 98223384 PMID: 9563895
Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Apr 1998
- 7/6/55 11337192 98217169 PMID: 9558086
Increasing immunogenicity of antigens fused to Ig-binding proteins by cell surface targeting. Apr 15 1998
- 7/6/56 11325272 98204871 PMID: 9535863
A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery. Apr 10 1998
- 7/6/57 11310748 98190040 PMID: 9521785
The biochemistry of hemolysin toxin activation: characterization of HlyC, an internal protein acyltransferase. Mar 31 1998
- 7/6/58 11308636 98167903 PMID: 9529054
The N-terminal part of the enzyme component (C2) of the binary *Clostridium botulinum* C2 toxin interacts with the binding component 2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Apr 1998
- 7/6/59 11308445 98167712 PMID: 9528863
Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4: correlation of EGFR for cytotoxic activity. Mar 5 1998
- 7/6/60 11301954 98181049 PMID: 9514636
Involvement of glutamic acid residue at position 7 in the formation of the intramolecular disulfide bond of *Escherichia coli* heat-stable enterotoxin I_p in vivo. Mar 1998
- 7/6/61 11298186 98177234 PMID: 9508786
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Feb 1998
- 7/6/62 11275933 98154422 PMID: 9493371
Production of a non-toxic site-directed mutant of *Clostridium perfringens* epsilon-toxin which induces protective immunity in mice. Feb 1998
- 7/6/63 11274724 98153310 PMID: 9485477
Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. Mar 3 1998
- 7/6/64 11274632 98153118 PMID: 9485385
- Streptolysin C: a proposed model of allosteric interaction between a pore-forming protein and its target lipid bilayer. Feb 24 1998
- 7/6/65 11269315 98147722 PMID: 9488398
Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition. Mar 1998
- 7/6/66 11248187 98125736 PMID: 9466260
Regulated transcription of *Clostridium difficile* toxin genes. Jan 1998
- 7/6/67 11233753 98111100 PMID: 9450639
Site directed mutagenesis of histidine residues in anthrax toxin lethal factor binding domain reduces toxicity. Dec 1997
- 7/6/68 11219501 98096687 PMID: 9435018
Construction and characterization of versatile cloning vectors for efficient delivery of native foreign proteins to the periplasm of *Escherichia coli*. 1997
- 7/6/69 11190167 98066714 PMID: 9403010
Gening plant toxins to fuse. Oct 1997
- 7/6/70 11182550 98059966 PMID: 9395513
Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins Dec 12 1997
- 7/6/71 11168636 98044819 PMID: 9383562
Bifunctional lacZ alpha-codB genes for selective cloning of PCR products. Nov 1997
- 7/6/72 11130131 98004523 PMID: 9342362
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Oct 2 1997
- 7/6/73 11129676 98003948 PMID: 9343949
Cytotoxicity of anthrax lethal factor microinjected into macrophage cells through Sendai virus envelopes. Feb-Apr 1997
- 7/6/74 11094612 97388302 PMID: 9247136
Phage display of Bacillus thuringiensis Cry(Aa) insecticidal toxin. Jul 7 1997
- 7/6/75 11093669 97387249 PMID: 9243285
A recombinant GM-CSF-PE40 ligand toxin is functionally active but not cytotoxic to cells. Jun 1997
- 7/6/76 11073103 97427938 PMID: 9284126
- 7/6/77 11072462 97427296 PMID: 9282328
Epitope conservation and immunohistochemical localization of the guanylin/stable toxin peptide receptor, guanylyl cyclase C. Sep 15 1997
- 7/6/78 11071892 97426721 PMID: 9287265
Immune modulation and sepsis. Jun 1997
- 7/6/79 11034612 97388302 PMID: 9247136
Phage display of Bacillus thuringiensis Cry(Aa) insecticidal toxin. Jul 7 1997
- 7/6/80 11033669 97387249 PMID: 9243285
A recombinant GM-CSF-PE40 ligand toxin is functionally active but not cytotoxic to cells. Jun 1997
- 7/6/81 11010370 97363719 PMID: 9220012
Molecular localization of the *Escherichia coli* cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains. Jun 1997
- 7/6/82 10994209 97347435 PMID: 9202074
Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. Jul 1 1997
- 7/6/83 10963780 97336906 PMID: 9193653
Using secondary structure predictions and site-directed mutagenesis to identify and probe the role of potential active site motifs in the RT6 monof(ADP-ribosyl)transferases. 1997
- 7/6/84 10982592 97336105 PMID: 9192900
Gin 63 of Rho is deamidated by *Escherichia coli* cytotoxic necrotizing factor-1. Jun 12 1997
- 7/6/85 10974561 97327728 PMID: 9210405
Construction, expression and characterization of chimeric toxins containing the ribonucleolytic toxin restriction: intracellular mechanism of act
- 7/6/86 10961209 97313862 PMID: 9170263

- Cleavage of the synaptobrevin-vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of Clostridium botulinum type B toxin. May 15 1997
- 7/6/87 10837344 97289728 PMID: 9144199
Channel formation by antiapoptotic protein Bcl-2. May 13 1997
- 7/6/88 10820130 97272276 PMID: 9114042
Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Apr 29 1997
- 7/6/89 10811411 97283493 PMID: 9109408
Characterization and receptor specific toxicity of two diphtheria toxin-related interleukin-3 fusion proteins DAB389-nIL-3 and DAB399-(Gly4Ser)-nIL-3. Apr 7 1997
- 7/6/90 10899020 97250967 PMID: 9096650
Intra-tumoral application of a heparin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects. Mar 17 1997
- 7/6/91 10887084 97283939 PMID: 9083117
A mechanism for toxin insertion into membranes is suggested by the crystal structure of the channel-forming domain of colicin E1. Mar 15 1997
- 7/6/92 10866676 97218154 PMID: 9065815
In vitro effects of a recombinant toxin, MSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers. Feb 26 1997
- 7/6/93 10853874 97205237 PMID: 9052741
HNF1 alpha activates the rat UDP-glucosyltransferase UGT2B1 gene promoter. Feb 1997
- 7/6/94 10851131 97202479 PMID: 9049998
Nucleotide sequence of a gene encoding the novel *Yersinia enterocolitica* heat-stable enterotoxin that includes a pro-region-like sequence in its mature toxin molecule. Feb 1997
- 7/6/95 10836413 97187652 PMID: 9035105
A new class of antigen-specific killer cells. Jan 1997
- 7/6/96 10819657 97109543 PMID: 8951823
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin. Nov 1996
- 7/6/97 10812920 97102795 PMID: 8947035
Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode *Caenorhabditis elegans*. Nov 15 1996
- 7/6/98 10803648 97053160 PMID: 8938722
Interaction of Ca^{2+} -activated K^{+} channels with refolded charybotoxins mutated at a central interaction residue. 1996
- 7/6/99 10803569 97053081 PMID: 8938643
Molecular and biochemical characterization of a heat-labile cytotoxic enterotoxin from *Aeromonas hydrophila*. Nov 1996
- 7/6/100 10801193 97090693 PMID: 8938601
Use of *Vibrio* spp. for expression of *Escherichia coli* enterotoxin B subunit fusion proteins: purification and characterization of a chimera containing a C-terminal fragment of DNA polymerase from herpes simplex virus type 1. Nov 1996
- 7/6/101 10795314 97084797 PMID: 8931131
Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. Oct 1996
- 7/6/102 10787943 97138224 PMID: 8938520
Potent antitumor activity of a new class of tumour-specific killer cells. Jan 2 1997
- 7/6/103 10776687 97126817 PMID: 8971711
Comparative analysis of the violence control systems of *Bordetella pertussis* and *Bordetella bronchiseptica*. Dec 1996
- 7/6/104 10776116 97126244 PMID: 8971168
Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated *Pseudomonas* exotoxin for therapy of malignant astrocytoma. Dec 15 1996
- 7/6/105 10759657 97105543 PMID: 8951823
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin. Nov 1996
- 7/6/106 10752920 97102795 PMID: 8947035
- Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode *Caenorhabditis elegans*. Nov 15 1996
- 7/6/107 10743648 97093160 PMID: 8938722
Interaction of Ca^{2+} -activated K^{+} channels with refolded charybotoxins mutated at a central interaction residue. 1996
- 7/6/108 10743569 97093081 PMID: 8938643
Molecular and biochemical characterization of a heat-labile cytotoxic enterotoxin from *Aeromonas hydrophila*. Nov 1996
- 7/6/109 10741193 97090693 PMID: 8938601
Use of *Vibrio* spp. for expression of *Escherichia coli* enterotoxin B subunit fusion proteins: purification and characterization of a chimera containing a C-terminal fragment of DNA polymerase from herpes simplex virus type 1. Nov 1996
- 7/6/110 10735314 97084797 PMID: 8931131
Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. Oct 1996
- 7/6/111 10729076 97078529 PMID: 8919453
Identification and characterization of an extracellular protease activity produced by the marine *Vibrio* sp. 60. Feb 1 1996
- 7/6/112 10703540 97052810 PMID: 8897439
Recombinant immunotoxins: protein engineering for cancer therapy. Oct 1996
- 7/6/113 10667118 97016182 PMID: 8862819
Positive selection of recombinant DNA by *CodB*. Aug 1996
- 7/6/114 10597761 96415308 PMID: 8818275
Construction of new insecticidal *Bacillus thuringiensis* recombinant strains by using the sporulation non-dependent expression system of *cpIIA* and a site specific recombination vector. Jul 18 1996
- 7/6/115 10591049 96405954 PMID: 8810079
Use of translational fusions to the maltose-binding protein to produce and purify proteins in *Pseudomonas syringae* and assess their activity in vivo. Sep 1996
- 7/6/116 10579239 96391952 PMID: 8794167
Protein engineering and design for drug delivery. Aug 1996
- 7/6/117 10575341 96387501 PMID: 8795010
Heparin-binding capacity of the HIV-1 NEF-protein allows one-step purification and biochemical characterization. Jun 1996
- 7/6/118 10540323 96351741 PMID: 8741987
Studies on the activity of barnase toxins in vitro and in vivo. Jan-Feb 1996
- 7/6/119 10522249 96333343 PMID: 8757837
Escherichia coli hemolysin mutants with altered target cell specificity. Aug 1996
- 7/6/120 10516807 96327868 PMID: 8735086
Serodiagnosis of listeriosis based upon detection of antibodies against recombinant truncated forms of listeriolysin O. Jun 1996
- 7/6/121 10513000 96323624 PMID: 8739196
A recombinant *Escherichia coli* heat-stable enterotoxin b (STb) fusion protein eliciting neutralizing antibodies. Apr 1996
- 7/6/122 10512619 96323240 PMID: 8710899
Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of antitoxin protective antigen. Aug 6 1996
- 7/6/123 10500026 96310688 PMID: 8740563
The performance of e23(Fv)PEs recombinant toxins targeting the erbB-2 protein. Apr 1996
- 7/6/124 10489724 96300228 PMID: 8706664
A recombinant insect-specific alpha-toxin of *Buthus occitanus tunetanus* scorpion confers protection against homologous mammalian toxins. Jun 1996
- 7/6/125 10480514 96299937 PMID: 8660841
A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated *Salmonella* induces serum and secretory immunity. Mar 1996
- 7/6/126 10480824 96290247 PMID: 8725098
A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated *Salmonella* induces serum and secretory immunity. Mar 1996

An improved circularly permuted interleukin 4 toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma chain in RCC cells does not improve sensitivity. Jul 10 1996

7/6/128 10468062 96275213 PMID: 8787077

Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. 1996

7/6/129 10429777 96236208 PMID: 8787415

New gene from nine *Bacillus sphaericus* strains encoding highly conserved 35.8-kilodalton mosquitoicidal toxins. Jun 1996

7/6/130 10428664 96234995 PMID: 8639641

Role of C&S, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis. May 28 1996

7/6/131 10427576 96234003 PMID: 8654560

Translational fusion of heat labile enterotoxin chain B and beta-subunit of human chorionic gonadotropin: periplasmic expression in *Escherichia coli* and its immunogenicity. May 27 1996

7/6/132 10404014 96209978 PMID: 8631856

Target: cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. May 3 1996

7/6/133 10403662 96209219 PMID: 8633853

Domain III substitution in *Bacillus thuringiensis* delta-endotoxin CryIA(b) results in superior toxicity for *Spodoptera exigua* and altered membrane protein recognition. May 1996

7/6/134 10399063 96204514 PMID: 8628234

Analysis of cryIIa expression in *sigE* and *sigK* mutants of *Bacillus thuringiensis*. Apr 10 1996

7/6/135 10395435 96200861 PMID: 8621095

A *Bacillus sphaericus* gene encoding a novel type of mosquitoicidal toxin of 31.8 kDa. Apr 17 1996

7/6/136 10394691 96200113 PMID: 8631720

Plasmid RK2 toxin protein *ParE*: purification and interaction with the *ParD* antitoxin protein. Mar 1996

7/6/137 10382592 96187879 PMID: 8609372

Cytotoxicity of KDEL-terminated ricin toxins correlates with distribution of the KDEL receptor in the Golgi. Feb 1996

7/6/138 10373241 96178238 PMID: 8617218

A specific targeting domain in mature exotoxin A is required for its extracellular secretion from *Pseudomonas aeruginosa*. Jan 15 1996

7/6/139 10364229 96167453 PMID: 8608178

IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. Nov-Dec 1995

7/6/140 10360272 96163461 PMID: 8575456

Lipid interaction of the 37-kDa and 58-kDa fragments of the *Helicobacter pylori* cytotoxin. Dec 15 1995

7/6/141 10357255 96160040 PMID: 8562903

Targeting diptheria toxin to growth factor receptors. Oct 1995

7/6/142 10345443 96147920 PMID: 8575044

[Construction and expression of the gene CD4V1V2-PE40, coding for a molecular targeted protein against AIDS] Aug 1995

7/6/143 10332216 96134516 PMID: 8527136

Improved expression of toxic proteins in *E. coli*. Aug 1995

7/6/144 10328564 96130835 PMID: 8594322

Identification by in vitro complementation of regions required for cell-invasive activity of *Bordetella pertussis* adenylate cyclase toxin. Sep 1995

7/6/145 10326603 96128870 PMID: 8596120

Disruption of herpes simplex virus ribonucleotide reductase quaternary structure by peptide inhibitors as a novel approach to antiviral therapy. Oct 1995

7/6/146 10294589 96096516 PMID: 8522171

Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic *Escherichia coli*. Nov 20 1995

7/6/147 10285718 96087571 PMID: 8522489

Experimental therapies in the treatment of cutaneous T-cell lymphoma. Oct 1995

7/6/148 10249633 96051174 PMID: 8527486

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. 1995

7/6/149 10240727 96042092 PMID: 7599281

A modified two-component regulatory system is involved in temperature-dependent biosynthesis of the *Pseudomonas syringae* phytotoxin coronatine. Nov 1995

7/6/150 10230019 96032221 PMID: 7549113

Identification of the essential regions for LukS- and H gamma II-specific functions of staphylococcal leukocidin and gamma-hemolysin. Aug 19

7/5/4 DIALOG(R)/File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11976922 99421861 PMID: 10491008

IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice

Zheng X X; Steele A W; Hancock W W; Kawaroto K; Li X C; Nickerson P W; Li Y; Tian Y; Strom T B

Department of Medicine, Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 02215, USA.

Journal of Immunology (Baltimore, Md. : 1950) (UNITED STATES) Oct 1 1999 , 163 (7) p4041-8, ISSN 0022-1767

Record type: Completed Subfile: AIM; INDEX MEDICUS; AIDS/HIV

Journal Code: 2985171R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

High affinity IL-2R5 is present on recently activated but not on resting or memory T cells. Selective targeting of T cells bearing high affinity IL-2R is an attractive therapy for many T cell-dependent cytopathic disease processes. A variety of rodent mAbs directed against the alpha-chain of the IL-2R, as well as IL-2 fusion toxins, have been used in animals and humans to achieve selective immunosuppression. Here we report on the development of a novel IL-2R targeting agent, a cytolytic chimeric IL-2/Fc fusion protein. This immunoligand binds specifically and with high affinity to IL-2R and is structurally capable of recruiting host Ab-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities. The Ig component ensures an extended circulating 1/12 of 25 h following systemic administration. To subsequently explore the mechanisms of the antibalistic effects of IL-2/Fc, we have mutated the FcR binding and complement C1q binding (Fc-/+) domains of the Fc fragment to render the Fc unable to direct Ab-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities. In a model of passive transfer of diabetes in nonobese diabetic mice, lytic IL-2/Fc, but not nonlytic IL-2/Fc-/-, exhibit striking antibalistic effects. Together with the negligible potential of IL-2/Fc for immunogenicity, this finding forecasts that cytolytic IL-2/Fc may offer a new therapeutic approach for selective targeting of auto and alloimmune T cells.

Tags: Animal, Female, Male; Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Descriptors: Cytotoxicity; Immunologic-genetics-GE; "Diabetes Mellitus; Insulin-Dependent--immunology-IM; "Diabetes Mellitus; Insulin-Dependent--prevention and control-FC; "Gene Therapy; "Immunoglobulins; Fe-genetics-GE; "Interleukin-2-genetics-GE; "Receptors; Interleukin-2-genetics-GE; "Recombinant Fusion Proteins immunology-IM; Adoptive Transfer; Antibodies; Monoclonal--administration and dosage-AD; Antigens, CD4--immunology-IM; Binding Western; CD4 Lymphocyte Count; Diabetes Mellitus; Insulin-Dependent-genetics-GE; "Diabetes Mellitus; Insulin-Dependent--pathology-P Gene Targeting; Hsf1-Like; Immunoglobulin s, Fc--therapeutic use--TU; Injections, Intraperitoneal; Interleukin-2--therapeutic use--TU; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Recombinant Fusion Proteins--blood-BL; Recombinant Fusion Proteins--chemistry-CM; Recombinant Fusion Proteins--therapeutic use--TU CAS Registry No.: 0 (Antibodies; Monoclonal); 0 (Antigens CD4); 0 (Immunoglobulins Fc); 0 (Interleukin-2); 0 (Receptors; Interleukin-2); 0 (Recombinant Fusion Proteins)

Record Date Created: 19991021 Record Date Completed: 19991021

7/5/13 DIALOG(R)/File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11887991 99330177 PMID: 10403383

Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway.

Noakes K L; Taisserenc H T; Lord J M; Dunbar P R; Cerundolo V; Roberts L M

Department of Biological Sciences, University of Warwick, Coventry, UK.

FEBS letters (NETHERLANDS) Jun 18 1999 , 453 (1-2) p85-9, ISSN 0014-5793 Journal Code: 0155157

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Subfile: INDEX MEDICUS

Shiga-like toxin 1 (SLT1) from *Escherichia coli* O157:H7 enters mammalian cells by endocytosis from the cell surface to the endoplasmic reticulum before translocating into the cytosol. Here, SLT1 was engineered at its N- or C-terminus to carry a peptide derived from influenza virus Matrix protein for delivery to major histocompatibility complex (MHC) class I molecules. We show that SLT1 N-Ma was capable of sensitizing cells for lysis by appropriate cytotoxic T-lymphocytes whilst no killing of SLT1-resista cells was observed. Our results demonstrate that peptide was liberated intracellularly and that retrograde transport of a disasm cytotoxic protein can intersect the MHC class I presentation pathway.

Tags: Support, Non-U.S. Gov't Descriptors: Antigen Presentation; "Antigens, Viral--metabolism-ME; "Bacterial Toxins--immunology-IM; "Histocompatibility Antigens Class I; "Viral Matrix Proteins--immunology-IM; Antigens, Viral--genetics-GE Antigens, Viral--immunology-IM; Bacterial Toxins--genetics-GE; Bacterial Toxins--metabolism-ME; Biological Transpo Cytotoxicity; Immunologic; Endoplasmic Reticulum--metabolism-ME; Recombinant Fusion Proteins--immunology-IM; Recombinant Fusion Proteins--metabolism-ME; Shiga-Like Toxin 1; T-Lymphocytes; Cytotoxic--immunology-IM; Viral Matrix Proteins--genetics-GE; Viral Matrix Proteins--metabolism-ME CAS Registry No.: 0 (Antigens, Viral); 0 (Bacterial Toxins (Histocompatibility Antigens Class I)); 0 (Recombinant Fusion Proteins); 0 (Shiga-Like Toxin 1); 0 (Viral Matrix Proteins); 0 (Influenza virus membrane protein)

Record Date Created: 19990802 Record Date Completed: 19990802

7/5/17 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11853088 992924094 PMID: 10367574

Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.

Puri R K

Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.

Toxicologic pathology (UNITED STATES) Jan-Feb 1999, 27 (1) p53-7, ISSN 0192-6233 Journal Code: 7905007 Document type: Journal Article Review, Review, Tutorial Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed Subfile: INDEX MEDICUS

About 12,000 Americans are diagnosed with malignant astrocytoma each year. Despite surgery, radiotherapy, and chemotherapy, the prognosis of these patients remains poor. Targeted toxins based on the identification of novel antigens or receptors provide a promising new approach to treating cancer. We have identified one such cell surface protein in the form of interleukin (IL)-4 receptors (IL-4R) on human malignant astrocytoma. Normal brain tissues from frontal cortex and temporal lobe cortex do not express IL-4R. To target IL-4R, we generated a chimeric fusion protein composed of IL-4 and Pseudomonas exotoxin (IL-4-PE). This toxin is highly cytotoxic to IL-4R-bearing human brain cancer cells. Preclinical toxicologic experiments were performed in mice, rats, and guinea pigs to determine an maximum tolerated dose. Intrathecal administration in cynomolgus monkeys produced high cerebrospinal fluid levels without any central nervous system or other abnormalities. When IL-4-PE was injected into the right frontal cortex of rats, localized necrosis was observed at 1,000 but not < or = 100 microg/ml doses. Intravenous administration of this biologic to monkeys produced reversible grade 3 or grade 4 elevations of hepatic enzymes in a dose-dependent manner. These results indicate that localized administration can produce nontoxic levels of IL-4-PE that may have significant activity against astrocytoma. In vivo experiments with nude mice have demonstrated that IL-4-PE has significant antitumor activity against human glioblastoma tumor model. Intratumor administration of IL-4-PE has been initiated for the treatment of malignant astrocytoma in a phase I clinical trial. (28 Refs.)

Tags: Animal, Human, Descriptors: Brain Neoplasms--therapy--1-H, Exotoxins--pharmacology--PD, Glioblastoma--therapy--1-H, Interleukin-4--pharmacology--PD, Pseudomonas--genetics--GE, Bacterial Proteins--genetics--GE, Brain Neoplasms--metabolism--ME, Drug Design, Exotoxins--chemical synthesis--CS, Exotoxins--therapeutic use--TU, Glioblastoma--metabolism--ME, Interleukin-4--chemical synthesis--CS, Interleukin-4--therapeutic use--TU, Recombinant Fusion Proteins--chemical synthesis--CS, Recombinant Fusion Proteins--pharmacology--PD, Recombinant Fusion Proteins--therapeutic use--TU CAS Registry No.: 0 (Bacterial Proteins); 0 (Exotoxins); 0 (IL-4-PE-40 chimeric protein); 0 (Recombinant Fusion Proteins); 20137-55-2 (Interleukin-4); Enzyme No.: EC 2.4.2.31 (exotoxin A, Pseudomonas aeruginosa) Record Date Created: 19990729 Record Date Completed: 19990729

7/5/18 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11847433 99288230 PMID: 10336877

High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.

Frankel A. E; Ranjani A; Feely T; Delatite S; Hall P; Tagge E; Kreitman R; Williamson M

Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.

afra@wfu.edu

Protein expression and purification (UNITED STATES) Jun 1999, 16 (1) p190-201, ISSN 1046-5928 Journal Code: 9101496 Contract/Grant No.: NIHRO176738; HR: NHLBI Document type: Clinical Trial; Clinical Trial, Phase I; Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

A genetically engineered fusion toxin targeted to acute myeloid leukemia (AML) blasts was designed with the first 388 amino acid residues of diphtheria toxin with an H-milner fused to human granulocyte-macrophage colony-stimulating factor. The cDNA was subcloned in the pRK bacterial expression plasmid and used to transform BL21 (DE3) Escherichia coli harboring pUBS500 plasmid. Transformants were grown in Superbroth and induced with IPTG. Inclusion bodies were isolated, washed, and denatured in guanidine hydrochloride with dithioerythritol. Recombinant protein was obtained after anion-exchange size exclusion on FPLC and polyvinylidene difluoride chromatography. The final material was filter sterilized, aseptically vialled, and stored at -80 degrees C. Fifty-four 3-liter bacterial culture preparations were made and pooled into 27 batches. The final product was characterized by Coomassie Plus protein assay, Coomassie-stained SDS-PAGE, limulus amoebocyte lysate endotoxin assay, human AML HL60 cell cytotoxicity assay, HPLC TSK3000, N-terminal sequencing, E. coli DNA contamination, C57BL/6 mouse toxicity, and immunohistochemistry. Yields were 23 mg/liter bacterial culture of denatured fusion toxin. After refolding and chromatography, final yields were 24 +/- 4% or 5 mg/liter. Vialled product was sterile and 1.7 +/- 0.4 mg/ml in PBS. Purity by SDS-PAGE was 99 +/- 1%. Aggregates by HPLC were <1%. Potency revealed a 24-h IC50 of 2.7 +/- 0.5 pM on HL60 cells.

Endotoxin levels were 1 eu/liter. The N-terminal sequence was confirmed and E. coli DNA was <1.3 pg/liter. The LD10 in mice was 110 microg/kg/day x5. There was no evidence of loss of solubility, proteolysis, aggregation, or loss of potency over 3 months at -80 and -20 degrees C. Further, the drug was stable at 4, 25, and 37 degrees C in human serum for 48 h. Drug reacted only with human monocytes, granulocytes, and myeloid precursors in frozen human tissue sections by immunohistochemistry. The synthesis of this protein drug should be useful for production for clinical phase I/II clinical trials and may be suitable for other diphtheria fusion toxins indicated for clinical development. This is the first report of the scaleup of a recombinant fusion toxin for clinical trials. Copyright 1999 Academic Press

Tags: Animal, Human, Support, Non-U.S. Gov't, Support, U.S. Gov't, P.H.S. Descriptors: Diphtheria Toxin--isolation and purification--JP, Diphtheria Toxin--therapeutic use--TU, Granulocyte-Macrophage Colony-Stimulating Factor--isolation and purification--JP, Granulocyte-Macrophage Colony-Stimulating Factor--therapeutic use--TU, Acute Disease, Amino Acid Sequence, Base Sequence, DNA, Recombinant--

genetics--GE, Diphtheria Toxin--genetics--GE, Drug Evaluation, Preclinical, Escherichia coli--genetics--GE, Gene Expression, Granulocyte-Macrophage Colony-Stimulating Factor--genetics--GE, HL-60 Cells, Lethal Dose 50, Leukemia, Myeloid--drug therapy--DT, Mice, Mice, Inbred C57BL, Molecular Sequence Data, Plasmids--genetics--GE, Recombinant Fusion Proteins--genetics--GE, Recombinant Fusion Proteins--isolation and purification--JP, Recombinant Fusion Proteins--therapeutic use--TU CAS Registry No.: 0 (DNA, Recombinant); 0 (Diphtheria Toxin); 0 (Plasmids); 0 (Recombinant Fusion Proteins); 83693-55-1 (Granulocyte-Macrophage Colony-Stimulating Factor) Record Date Created: 19990712 Record Date Completed: 19990712

7/7/20 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11814001 99253640 PMID: 10321723

Cloning and cytotoxicity of fusion proteins of EGF and angiogenin.

Yoon J M; Han S H; Kwon O B; Kim S H; Park M H; Kim B K

Department of Microbial Chemistry, College of Pharmacy, Seoul National University, Kwanak-Gu, South Korea. Life sciences (ENGLAND) 1999, 64 (16) p1435-45, ISSN 0024-3205 Journal Code: 0375521 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Targeted toxins represent a new approach to specific cytotoxic therapy. Immunotoxins based on plant and microbial toxins are very immunogenic. To develop a targeted therapy that is less immunogenic and easily invades target tissues, four fusion proteins containing human angiogenin targeted by human EGF have been constructed. EGF is a single chain polypeptide, which binds epidermal growth factor receptor (EGFR) and is known to be internalized by endocytosis. Angiogenin has been separately fused either at the amino terminus or the carboxyl terminus of EGF via linkers, giving rise to angiogenin-gly-EGF, angiogenin-gly/45 EGF and EGF-angiogenin, EGF-gly-angiogenin, respectively. The fusion proteins were over-expressed in Escherichia coli and purified from periplasmic eluents by affinity chromatography. EGF-angiogenin and EGF-gly-angiogenin maintained receptor-binding activity of EGF and RNase activity of angiogenin in a single peptide and actively inhibited growth of human EGFR-positive target cells in culture. They are expected to have a very low immunogenic potential in humans because of their endogenous origin and also to have another potential therapeutic advantage because these fusion proteins may have overcome conventional immunotoxin and possess increased ability to penetrate because of their small size. Record Date Created: 19990526 Record Date Completed: 19990526

7/7/21

DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11799440 99238311 PMID: 10220447

Intracellular delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin.

Loregian A; Papini E; Saini B; Marston H S; Hirst T R; Palu G

Institute of Microbiology, University of Padua, 35121 Padua, Italy.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Apr 27 1999, 96 (p5221-6, ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

We report an intracellular peptide delivery system capable of targeting specific cellular compartments. In the model system we constructed a chimeric protein consisting of the nontoxic B subunit of Escherichia coli heat-labile enterotoxin (EtxB) fused to a 27-mer peptide derived from the DNA polymerase of herpes simplex virus 1. Viral DNA synthesis takes place in the nucleus and requires the interaction with an accessory factor, UL42, encoded by the virus. The peptide designated Poi is able to dissociate this interaction. The chimeric protein, EtxB-Poi, retained the functional properties of both EtxB and peptide components and was shown to inhibit viral DNA polymerase activity in vitro via disruption of the polymerase-UL42 complex. When added to virally infected cells, EtxB-Poi had no effect on adenovirus replication but specifically interfered with herpes simplex virus 1 replication. Further studies showed that the antiviral peptide localized in the nucleus, whereas the EtxB component remained associated with vesicular compartments. The results indicate that the chimeric protein entered through endosomal acidic compartments and that the Poi peptide was cleaved from the chimeric protein before being translocated into the nucleus. The system we describe is suitable for delivery of peptides that specifically disrupt protein-protein interactions and may be developed to target specific cellular compartments. Record Date Created: 19990610 Record Date Completed: 19990610

7/7/23 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11775824 99214180 PMID: 10196187

A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins.

Chaves-Olarte E; Low P; Freer E; Norlin T; Weidmann M; von Eichel-Streiber C; Theisstem M

Microbiology and Tumorkbiology Center, Karolinska Institutet, S-171 77 Stockholm, Sweden.

Journal of biological chemistry (UNITED STATES) Apr 16 1999, 274 (16) p1046-52, ISSN 0021-9258 Journal Code: 29851212R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The large clostridial cytotoxins (LCTs) constitute a group of high molecular weight clostridial cytotoxins that inactivate cellular small GTP-binding proteins. We demonstrate that a novel LCT (TcdB-1470) from Clostridium difficile strain 1470 is a functional hybrid between "reference" TcdB-10463 and Clostridium sorrelleii TcdL-1522. It bound to the same specific receptor as TcdB-10463 but glycosylated the same GTP-binding proteins as TcdL-1522. All three toxins had equal enzymatic potencies but were equally cytotoxic only when microinjected. When applied extracellularly TcdB-1470 and TcdB-10463 were considerably more potent cytotoxins than TcdL-1522. The small GTP-binding protein R-Ras was identified as a target for Tcd -1470 and also for TcdL-1522 but not for Tcd -10463. R-Ras is known to control integrin-extracellular mat

interactions from inside the cell. Its glucosylation may be a major determinant for the cell rounding and detachment induced by the two R-Ras-attacking toxins. In contrast, fibroblasts treated with Tcd3-10463 were aborized and remained attached, with phosphotyrosine containing structures located at the cell-to-cell contacts and beta3-integrin remaining at the tips of cellular protrusions. These components were absent from cells treated with the R-Ras-inactivating toxins. The novel hybrid toxin will broaden the utility of the LCTs for clarifying the functions of several small GTPases, now including also R-Ras. Record Date Created: 19990517 Record Date Completed: 19990517

777/29 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11747698 99185011 PMID: 10085027

Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Singh Y, Kimpel K R, Goel S, Swain P K, Leppla S H
Centre for Biochemical Technology, Delhi 110007, India.
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
The protective antigen (PA) protein of anthrax toxin binds to a cellular receptor and is cleaved by cell surface trypsin to produce a 63-kDa fragment (PA63). The receptor-bound PA63 oligomerizes to a heptamer and acts to translocate the catalytic moieties of the toxin, lethal factor (LF) and edema factor (EF), from endosomes to the cytosol. In this report, we used nonfluorescent gel electrophoresis to show that each PA63 subunit in the heptamer can bind one LF molecule. Studies using PA-immobilized on a plastic surface showed that monomeric PA63 is also able to bind LF. The internalization of PA and LF by cells was studied with radiolabeled and biotinylated proteins. Uptake was relatively slow, with a half-time of 30 min. The number of moles of LF internalized was nearly equal to the number of moles of PA subunit internalized. The essential role of PA oligomerization in LF translocation was shown with PA protein cleaved at residues 313-314. The oligomers formed by these proteins during uptake into cells were not as stable when subjected to heat and detergent as were those formed by native PA. The results show that the structure of the toxin proteins and the kinetics of proteolytic activation, LF binding, and internalization are balanced in a way that allows each PA63 subunit to internalize an LF molecule. This set of proteins has evolved to achieve highly efficient internalization and membrane translocation of the catalytic components, LF and EF. Record Date Created: 19990426 Record Date Completed: 19990426

777/31 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11720983 99157583 PMID: 10048023

Expression and properties of an aerolysin-Clostridium septicum alpha toxin hybrid protein. Diep D B, Nelson K L, Lawrence T S, Seliman B R, Tweten R K, Buckley J T
Department of Biochemistry and Microbiology, University of Victoria, BC, Canada.
Molecular microbiology (ENGLAND) Feb 1999, 31 (3) p785-94. ISSN 0950-382X Journal Code: 8712028
Contract/Grant No.: A137657. AI: NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM
Record type: Completed

Aerolysin is a bilocal channel-forming toxin secreted by *Aeromonas hydrophila*. The alpha toxin produced by *Clostridium septicum* is homologous to the large lobe of aerolysin. However, it does not contain a region corresponding to the small lobe of the *Aeromonas* toxin, leading us to ask what the function of the small lobe is. We fused the small lobe of aerolysin to alpha toxin, producing a hybrid protein that should structurally resemble aerolysin. Unlike aerolysin, the hybrid was not secreted when expressed in *Aeromonas salmonicida*. The purified hybrid was activated by proteolytic processing in the same way as both parent proteins and, after activation, it formed oligomers that corresponded to the aerolysin heptamer. Like aerolysin, the hybrid was far more active than alpha toxin against human erythrocytes and mouse T lymphocytes. Both aerolysin and the hybrid bound to human glycoprotein, and both were inhibited by preincubation with this erythrocyte glycoprotein, whereas alpha toxin was unaffected. We conclude that aerolysin contains two receptor binding sites, one for glycosyl-phosphatidylinositol-anchored proteins that is located in the large lobe and is also found in alpha toxin, and a second site, located in the small lobe, that binds a surface carbohydrate determinant. Record Date Created: 19990506 Record Date Completed: 19990506

777/32 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11720819 99157408 PMID: 10047878

Differential activity of cholera toxin and *E. coli* enterotoxin: construction and purification of mutant and hybrid derivatives. Rodighiero C, Aman A T, Lencer W J, Hirst T R
University of Bristol, Department of Pathology and Microbiology, School of Medical Sciences, UK.
Biochemical Society transactions (ENGLAND) Nov 1998, 26 (4) pS364. ISSN 0300-5122 Journal Code: 7506897
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
Record Date Created: 19990413 Record Date Completed: 19990413

777/33 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11680321 99115580 PMID: 9914159

The KDEL retrieval system is exploited by *Pseudomonas* exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. Jackson M E, Simpson J C, Gird A, Peppetok R, Roberts L M, Lord J M

Department of Biological Sciences, University of Warwick, Coventry, CV4 7AL, UK. m1@dnha.bio.warwick.ac.uk
Journal of cell science (ENGLAND) Feb 1999, 112 (Pt 4) p467-75. ISSN 0021-9533 Journal Code: 0052457
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

To investigate the role of the KDEL receptor in the retrieval of protein toxins to the mammalian cell endoplasmic reticulum (ER) lysosome variants containing AARL or KDEL C-terminal tags, or the human KDEL receptor, have been expressed in toxin-treated COS 7 and HeLa cells. Expression of the lysosome variants and the KDEL receptor was confirmed by immunofluorescence. When such cells were challenged with diphtheria toxin (DT) or *Escherichia coli* Shiga-like toxin 1 (SLT-1) there was no observable difference in their sensitivities as compared to cells which did not express these exogenous proteins; contrast, the cytotoxicity of *Pseudomonas* exotoxin A (PE) is reduced by expressing lysosome-KDEL, which causes a redistribution of the KDEL receptor from the Golgi complex to the ER, and cells are sensitised to this toxin when they express additional KDEL receptors. These data suggest that, in contrast to SLT-1, PE can exploit the KDEL receptor in order to reach ER lumen where it is believed that membrane transfer to the cytosol occurs. This contention was confirmed by microinjecting iVero cells antibodies raised against the cytoplasmically exposed tail of the KDEL receptor. Immunofluorescence confirmed that these antibodies prevented the retrograde transport of the KDEL receptor from the Golgi complex to the ER, and this in turn reduced the cytotoxicity of PE, but not that of SLT-1, to these cells. Record Date Created: 19990720 Record Date Completed: 19990720

777/36 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11657978 99092760 PMID: 9876933

Stepwise translocation of an active site loop between heat-labile enterotoxins LT-II and LT-I and characterization of the obtained hybrid toxins.

Fell I K, Platas A A, van den Akker F, Reddy R, Merritt E A, Storm D R, Ho W G

Howard Hughes Medical Institute, Department of Biological Structure, University of Washington, Seattle 98195-7742, USA
Protein engineering (ENGLAND) Nov 1998, 11 (11) p103-9. ISSN 0269-2139 Journal Code: 8801484

Contract/Grant No.: A1 34501. AI: NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM
Record type: Completed

Members of the cholera toxin family, including *Escherichia coli* heat-labile enterotoxins LT-I and LT-II, catalyze the covalent modification of intracellular proteins by transfer of ADP-ribose from NAD to a specific arginine of the target protein. The ADP-ribosylating activity of these toxins is located in the A-subunit, for which LT-I and LT-II share a 63% sequence identity. The flexible loop in LT-I, ranging from residue 47 to 66, closes over the active site cleft. Previous studies have shown that point mutations in this loop have dramatic effects on the activity of LT-I. Yet, in LT-II the sequence of the equivalent loop differs at 10 positions from LT-I. Therefore five mutants of the active site loop were created by a stepwise replacement of the loop sequence in LT-I with virtually all the corresponding residues in LT-II. Since we discovered that LT-II had no activity versus the artificial substrate diethylamino-benzyl-L-arginoguanidine (DEABAG) while LT-I does, our active site mutants most likely probe the NAD binding, not the arginine binding region of the active site. The five hybrid toxins obtained (Q49A, F52N, V53T, Q49V/F52 and Q49V/F52N/V53T) show (i) great differences in holotoxin assembly efficiency, (ii) decreased cytotoxicity in Chinese hamster ovary cells, and (iii) increased *in vitro* enzymatic activity compared with wild type LT-I. Specifically, the three mutants containing the F52N substitution display a greater Vmax for NAD than wild type LT-I. The enzymatic activity of the V53T mutant is significantly higher than that of wild type LT-I. Apparently this subtle variation at position 53 is beneficial, in contrast to several other substitutions at position 53 which previously had been shown to be deleterious for activity. The most striking result of this study is that the active site loop of LT-I, despite great sensitivity for point mutations, can essentially be replaced by the active s loop of LT-II, yielding an active 'hybrid enzyme' as well as 'hybrid toxin'. Record Date Created: 19990308 Record Date Completed: 19990308

777/38 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11626571 99060051 PMID: 9843379

Characterization of membrane translocation by anthrax protective antigen.

Wesche J, Elliott J L, Falnes P O, Osnes S, Collier R J

Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.
Biochemistry (UNITED STATES) Nov 10 1998, 37 (45) p15737-46. ISSN 0006-2960 Journal Code: 0370623

Contract/Grant No.: A120271. AI: NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM
Record type: Completed

Solving the crystallographic structure of the ring-shaped heptamer formed by protective antigen (PA), the B moiety of anthrax toxin, has focused attention on understanding how this oligomer mediates membrane translocation of the toxin's A moieties. We have developed an assay for translocation in which radiolabeled ligands are bound to proteolytically activated PA (PA63) at the surface of CHO or L6 cells, and translocation across the plasma membrane is induced by lowering the pH. The cells are then treated with Pronase E to degrade residual surface-bound material, and protected ligands are quantified after fractionation by SDS-PAGE. Translocation was most efficient (35%-50%) with LFN, the N-terminal PA binding domain of the anthrax lethal fac (LF). Intact LF, edema factor (EF), or fusion proteins containing LFN fused to certain heterologous proteins [the diphtheria toxin A chain (DTA) or dihydrofolate reductase (DHFR)] were less efficiently translocated (15%-20%), and LFN fusions to several other proteins were not translocated at all. LFN with different N-terminal residues was found to be degraded according to the N end rule by the proteasome, and translocation of LFN fused to a mutant form of DHFR with a low affinity for methotrexate (MT

protected cells from the effects of MTX. Both results are consistent with a cytosolic location of protected proteins. Evidence that a protein must unfold to be translocated was obtained in experiments showing that (i) translocation of LFNDR1A was blocked by introduction of an artificial disulfide into the DTA moiety, and (ii) translocation of LFNDR1A was blocked by their ligands (MTX and adenine, respectively). These results demonstrate that the acid-induced translocation by anthrax toxin closely resembles that of diphtheria toxin, despite the fact that these two toxins are unrelated and form pores by different mechanisms. Record Date Created: 19981221 Record Date Completed: 19981221

777/39 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11606274 99039034 PMID: 9821553

Positive selection vectors to generate fused genes for the expression of his-tagged proteins.
Van Reeth T, Dieze P L, Szprier C, Gabant P
Université Libre de Bruxelles, Rhode-Saint-Genese, Belgium.

BioTechniques (UNITED STATES) Nov 1998, 25 (5) p898-904, ISSN 0736-6205 Journal Code: 8306785
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
Epitope tagging simplifies detection, characterization and purification of proteins. Gene fusion to combine the coding region of a well-characterized epitope with the coding region for a protein of interest generally requires several subcloning steps. Alternatively, a PCR strategy can be used to generate such a chimeric gene. In addition to its simplicity, this approach allows one to limit the size of the multiple cloning sites present in conventional expression vectors, thus reducing the introduction of artifactual amino-acid sequences into the fused protein. In this communication, we describe new vectors that allow PCR cloning and selection of chimeric genes coding for N- or C-terminal His-tagged proteins. These vectors are based on the control of cell death CcdB direct selection technology and are well adapted to the cloning of blunt-ended PCR products that were generated by using thermostable polymerases that provide proofreading activity. Record Date Created: 19990119 Record Date Completed: 19990119

775/52 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11368068 98248937 PMID: 9587386

Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology
Immunotoxins recombinantes et toxines chimères pour une thérapie ciblée en oncologie.

Chiron MF
Rhône-Poulenc Rorer Gencell, Centre de recherche de Vitry-Alfortville, France.
Bulletin du cancer (FRANCE) Dec 1997, 84 (12) p135-40, ISSN 0007-4551 Journal Code: 0072416
Document type: Journal Article, Review, Tutorial, English Abstract Languages: FRENCH
Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

Immunotoxins and chimeric toxins are hybrid molecules constituted of antibodies, growth factor or cytokines coupled to peptide toxins. They are designed to selectively eliminate tumor cells. Some of these chimera have been shown to induce complete tumor regressions of human tumor xenografts in immunodeficient mice. In clinical trials, higher anti tumor responses were observed in lymphoma, brain tumor, breast and colon cancers. Problems arose with normal tissue toxicity and the production of neutralising antibodies. However the latest recombinant toxins conceived by rational design, solved these problems, chimeric toxins would be an alternative approach to target tumor cells and vascular endothelial cells in solid tumors. (37 Refs.)
Tags: Animal, Human Descriptors: Antigen-Presenting Cells--drug effects--DE; Immunotoxins--therapeutic use--TU; Neoplasms. Experimental--therapy--TH; Recombinant Fusion Proteins--therapeutic use--TU; Antibodies, Monoclonal--pharmacology--PD; Antibodies, Monoclonal--therapeutic use--TU; Bacterial Toxins--pharmacology--PD; Bacterial Toxins--therapeutic use--TU; Cytotoxicity, Immunologic; Exotoxins--pharmacology--PD; Exotoxins--therapeutic use--TU; Immunotherapy--methods--MT; Immunotoxins--pharmacology--PD; Immunotoxins--toxicity--TO; Mice; Recombinant Fusion Proteins--pharmacology--PD; Recombinant Fusion Proteins--toxicity--TO CAS Registry No.: 0 (Antibodies, Monoclonal); 0 (Bacterial Toxins); 0 (Exotoxins); 0 (Immunotoxins); 0 (Recombinant Fusion Proteins)
Record Date Created: 19980602 Record Date Completed: 19980602

775/55 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11337182 98271769 PMID: 9558086

Increasing immunogenicity of antigens fused to Ig-binding proteins by cell surface targeting
Leonetti M, Thair R, Cotton J, Leroy S, Drevet P, Ducanceal F, Bouliant J C, Menez A
Département d'ingénierie et d'études des protéines, C. E. Saday, Gif-Sur-Yvette, France. leonetti@cea.fr
Journal of immunology (Baltimore, Md. : 1950) (UNITED STATES) Apr 15 1999, 160 (8) p3820-7, ISSN 0022-1767
Journal Code: 2985117R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed Subfile: AIM; INDEX MEDICUS
Fusion of antigenic proteins to Ig-binding proteins such as protein A from *Staphylococcus aureus* and its derived ZZ fragment is known to increase immunogenicity of the fused Ag in vivo. To shed light on the origin of this effect, we used snake toxins as Ags and observed that 1) fusion of toxins to ZZ enhanced their presentation to a toxin-specific T cell hybridoma (T1B2), using A20 B lymphoma cells, splenocytes, or peritoneal exudate cells as APCs; 2) this enhancement further increased when the number of fused Ig-binding domains varied from two with ZZ to five with protein A; and 3) the phenomenon vanished when the fusion protein was preincubated with an excess of free ZZ or when P388D1 monocytes cells were used as APCs. Therefore, ZZ-fused toxins are likely to be targeted to surface Ig of APCs by their ZZ moiety. Furthermore, ZZ-alpha and toxin alpha stimulated similar profiles of toxin-specific T cells in BALB/c mice, suggesting a comparable processing and presentation in vivo for both

toxin forms. To improve the targeting efficiency, ZZ-alpha was noncovalently complexed to various Igs directed to different cell surface components of APCs. The resulting complexes were up to 10(3)-fold more potent than the free toxin at stimulating T1B. Also, they elicited both a T cell and an Ab response in BALB/c mice, without the need of any adjuvant. This simple approach in find practical applications by increasing the immunogenicity of recombinant proteins without the use of adjuvant.

Tags: Animal, In Vivo Descriptors: Antigens--metabolism--ME; Carrier Proteins--immunology--IM; Carrier Proteins--metabolism--ME; Immunoglobulins--metabolism--ME; Recombinant Fusion Proteins--immunology--IM; Recombinant Fusion Proteins--metabolism--ME Antibody Formation; Antigen Presentation; Antigen-Presenting Cells--immunology--IM; Cell Membrane--immunology--IM; Erythrocytes--immunology--IM; Hybridomas; Immunization; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Peptide Fragments--immunology--IM; Peptide Fragments--metabolism--ME; Staphylococcal Protein A--immunology--IM; Staphylococcal Protein A--metabolism--ME; T-Lymphocytes--immunology--IM CAS Registry No.: 0 (Antigens); 0 (Carrier Proteins); 0 (Erythrocytes); 0 (Immunoglobulins); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Staphylococcal Protein A); 11094-614 (erythrocytes)
Record Date Created: 19980504 Record Date Completed: 19980504

777/63 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11274724 98153210 PMID: 9485477

Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.
Landgraf R, Pegram M, Slamon D J, Eisenberg D
Department of Chemistry and Biochemistry and Division of Hematology-Oncology, University of California--Los Angeles, Box 951570, Los Angeles, California 90095-1570, USA.
Biochemistry (UNITED STATES) Mar 3 1998, 37 (9) p3220-8, ISSN 0006-2960 Journal Code: 0370623
ContractGrant No.: 1K12 CA01714; CA; NC; GM31299; GM; NIGMS Document type: Journal Article
Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

As a step in the design of directed toxins, aimed at cells that overexpress HER receptors, particularly breast carcinoma cells, we studied the properties of a chimera of diphtheria toxin (DT) and heregulin beta1. The EGF-like growth hormone heregulin is ligand for the HER3 and HER4 receptors and their heterodimers with HER2. The 60-residue EGF-like domain (hrg) of heregulin elicits a biological response and binds to these receptors primarily through its N terminus. We tested a fusion protein in which replaces the C-terminal receptor-binding domain of DT (DT(389)hrg) and an alternative design in which this domain is fused to the N terminus of DT(389). Of those two constructs, the N-terminal fusion was not active as a directed toxin but elicited a grow response. The C-terminal fusion of hrg to DT(389) yielded a functional toxin and showed cell line specific cytotoxicity that is consistent with heregulin specificity. The binding of hrg to its cognate receptor is not impaired as shown by receptor activation direct binding, and competition with free hrg. Cytotoxicity is dependent on high-affinity binding of DT(389)hrg to HER3 and HE receptors and is not mediated by HER2 overexpression alone. For those cell lines exhibiting high-affinity binding sites, the level of cytotoxicity correlates with the rate of internalization. Thus DT(389)hrg chimeras offer a possible avenue toward directed toxins against cells that overexpress HER receptors. Record Date Created: 19980403 Record Date Completed: 19980403

777/65 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11269315 98147722 PMID: 9488398

Chimeric clostridial cytotoxins: Identification of the N-terminal region involved in protein substrate recognition.
Hofmann F, Busch C, Aktories K
Institut für Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Germany.
Infection and immunity (UNITED STATES) Mar 1998, 66 (3) p1076-81, ISSN 0019-9567 Journal Code: 0246127
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Clostridium sordeili lethal toxin is a member of the family of large clostridial cytotoxins that glucosylate small GTPases. In contrast to Clostridium difficile toxins A and B, which exclusively modify Rho subfamily proteins, C. sordeili lethal toxin also glucosylates Ras subfamily proteins. By deletion analysis and construction of chimeric fusion proteins of C. sordeili lethal toxin and C. difficile toxin B, we localized the enzyme activity of the lethal toxin to the N terminus of the holotoxin and identified the region involved in protein substrate specificity. The toxin fragment of the N-terminal 546 amino acid residues of C. sordeili lethal toxin glucosylated Rho and Ras subfamily proteins, as the holotoxin did. Deletion of a further 30 amino acid residues from the terminus of this active fragment drastically reduced glucotransferase activity and blocked glycosylase activity. Exchange of amino acid residues 364 through 516 of lethal toxin for those in the active toxin B fragment (1 to 546) allowed glucosylation of Ras subfamily proteins. In contrast, the chimera with amino acids 1 to 364 from toxin B, 365 to 468 from lethal toxin, and 469 to 546 from toxin B exhibited markedly reduced modification of Ras subfamily proteins, whereas modification of Rac and Cdc42 was hardly changed. The data indicate that the region of amino acid residues 364 through 516 primarily defines the substrate specificity of C. sordeili lethal toxin. Record Date Created: 19980312 Record Date Completed: 19980312

777/92 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
10866676 97218154 PMID: 9065815

In vitro effects of a recombinant toxin, mSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers
Nishida K, Seto M, Takahashi T, Oshima Y, Asano S, Tojo A, Ueda R
Laboratory of Chemotherapy, Aichi Cancer Center Research Institute, Nagoya, Japan.
Cancer letters (IRELAND) Feb 26 1997, 113 (1-2) p153-8, ISSN 0304-3835 Journal Code: 7600053
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Most small cell lung cancers (SCLCs) ectopically express high levels of the c-kit receptor. We have examined if the receptor can serve as a target for a chimeric toxin, mSCF-PE40 composed of murine stem cell factor (SCF) genetically fused to the N terminus of a modified form of Pseudomonas exotoxin (PE) lacking its cell recognition domain. Selective cytotoxicity was found for human c-kit receptor-negative cells. This agent thus warrants further evaluation for therapy of human SCLCs. Record Date Created: 19970407 Record Date Completed: 19970407

77/96 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
10819657 97109563 PMID: 8951823

Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin.

Chiron M F; Ogata M, Fitzgerald D J

Biotherapy Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Molecular microbiology (ENGLAND) Nov 1996, 22 (4) p769-78, ISSN 0950-382X Journal Code: 8712028

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

To be toxic for mammalian cells Pseudomonas exotoxin (PE) requires proteolytic cleavage between Arg-279 and Gly-280. Cleavage, which is mediated by the cellular protease furin, generates an active C-terminal fragment which translocates to the cytosol and inhibits protein synthesis. In vitro, furin-mediated cleavage is optimal at pH 5.5 with a relatively slow turnover rate. Within cells, only 5-10% of cell-associated PE is cleaved. To investigate the reasons for this inefficient cleavage, the amino acid composition near the cleavage site was altered to resemble more closely the arginine-rich sequence from the functionally similar region of diphtheria toxin (DT). Four PE-DT mutants were generated, whereby 1, 5, 6 or 8 amino acids at the PE-cleavage site were changed to amino acids found at the DT-cleavage site. Mutant proteins were expressed in *Escherichia coli*, purified and then analysed for their susceptibility to cleavage by furin and trypsin, susceptibility to cell-mediated cleavage, and cytotoxic activity relative to wild-type PE. At pH 5.5, the rate of both furin-mediated cleavage and trypsin-mediated cleavage increased dramatically when amino acids in PE were altered to resemble the DT sequence. This increase did not alter the pH optimum for furin-mediated cleavage of PE toxins, which remained at pH 5.0-5.5. When radioactive versions of selected PE-DT proteins were added to intact cells, an increase in the percentage of molecules that were cleaved relative to wild-type PE was also seen. However, changes that favoured increased proteolysis apparently interfered with other important toxin functions because none of the PE-DT proteins exhibited enhanced toxicity for cells when compared with the activity of wild-type PE. Record Date Created: 19970331 Record Date Completed: 19970331

106/1 14408705 22309410 PMID: 12421321

YscE allows secretion of YopE-DHFR hybrids by the *Yersinia enterocolitica* type III Ysc system. Nov 2002

106/2 11633291 99067023 PMID: 9651698

Determinants of the fidelity of processing glucosylase-lysozyme fusions by *Aspergillus niger*. Nov 15 1998

106/3 10701557 97050825 PMID: 8895554

Status of YopM and YopN in the *Yersinia* Yop virulon: YopM of *Y. enterocolitica* is internalized inside the cytosol of PU-5.8 macrophages by the YopB, D, N delivery apparatus. Oct 1 1996

106/4 09859120 21671924 PMID: 11812232

Purification of recombinant human epidermal growth factor secreted from the methylotrophic yeast *Hansenula polymorpha*. Feb 2002

106/5 09795539 21602927 PMID: 11737648

The type III secretion chaperone LcrH co-operates with YopD to establish a negative, regulatory loop for control of Yop synthesis in *Yersinia pseudotuberculosis*. Nov 2001

106/6 08156965 94222840 PMID: 8169210

The *lcrB* (*ycsN*) gene cluster of *Yersinia pseudotuberculosis* is involved in Yop secretion and shows high homology to the *spa* gene clusters of *Shigella flexneri* and *Salmonella typhimurium*. May 1994

106/7 07723384 93178658 PMID: 8440393

Purification and characterization of the trefol peptide human spasmodic polypeptide (hSP) produced in yeast. Mar 8 1993

106/8 07520216 92383946 PMID: 1514325

Efficient secretion in yeast based on fragments from K1 killer prepro toxin. Apr 1992

106/9 07461533 92326077 PMID: 1624469

Structure and regulation of the *Yersinia pestis* *ycsBCDEF* operon. Jul 1992

106/10 06967208 91207691 PMID: 1367012

Efficient KEX2-like processing of a glucanase-interleukin-6 fusion protein by *Aspergillus nidulans* and secretion of mature interleukin-6. Apr 1991

106/11 06441772 90066461 PMID: 2885554

Regulation of alpha-factor production in *Saccharomyces cerevisiae*: alpha-factor phenotype-induced expression of the MF alpha 1 and STE13 genes. Oct 1989

105/7 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

07722334 93178658 PMID: 8440393

Purification and characterization of the trefol peptide human spasmodic polypeptide (hSP) produced in yeast.

Thim L; Noms K; Noms F; Nielsen P F; Bom S E; Christensen M; Petersen J

Department of Protein Chemistry, Pharmaceuticals Research, Novo Nordisk, Novo Alle, Bagsvaerd, Denmark.

FEBS letters (NETHERLANDS) Mar 8 1993, 318 (3) p345-52, ISSN 0014-5793 Journal Code: 0155157

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Subline: INDEX/MEDICUS

Recombinant human spasmodic polypeptide (h-SP) has been produced in relatively large amounts in *Saccharomyces cerevisiae*. The two intronless trefol domains of the hSP-DNA were cloned separately by PCR from human genomic DNA, and the remaining parts of the gene synthesized. Recombinant plasmids were constructed to encode a fusion protein consisting of hybrid leader sequence and the hSP sequence. The leader sequence serves to direct the fusion protein into the secretory pathway of the cell and to expose it to the Kex 2 processing enzyme system. The secreted h-SP was found in a glycosylated and an non-glycosylated form. The two forms of h-SP were purified from the yeast fermentation broth by a combination of ion exchange chromatography and preparative HPLC. The overall yield from 8 litres of fermentation broth was 160 mg h-SP and 219 mg glycosylated h-SP corresponding to 50% and 34%, respectively. The structure of the h-SP and the glycosylated h-SP was determined by amino acid analysis and carbohydrate composition analysis as well as by peptide mapping, amino acid sequencing and mass spectrometric analysis.

Tags: Human Descriptors: Peptides--isolation and purification--IP; * Recombinant Fusion Proteins--isolation and purification--IP; * Saccharomyces cerevisiae--metabolism--ME; Amino Acid Sequence; Amino Acids--analysis--AN; Base Sequence; Carbohydrates--analysis

AN; Chromatography; High Pressure Liquid; Ion Exchange; Cloning; Molecular DNA--genetics--GE; Glycosylation; Growth Substances--chemistry--CH; Growth Substances--genetics--GE; Molecular Sequence Data; Peptide Mapping; Peptides--chemistry--CH;

Peptides--genetics--GE; Plasmids; Polymerase Chain Reaction; Recombinant Fusion Proteins--biosynthesis--BI; Recombinant Fusion Proteins--chemistry--CH; Saccharomyces cerevisiae--genetics--GE; Spectrum Analysis; Mass CAS Registry No.; 0 (Amino Acids); 0

(Carbohydrates); 0 (Growth Substances); 0 (Peptides); 0 (Plasmids); 0 (Recombinant Fusion Proteins); 146046-78-8 (trefol factor); 8298

77-7 (paracitic spasmodic polypeptide); 9007-49-2 (DNA)

Record Date Created: 19930330 Record Date Completed: 19930330

126/1 11130131 98004523 PMID: 9342362

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Oct 2 1997

126/2 10729076 97078529 PMID: 8919453

Identification and characterization of an extracellular protease activity produced by the marine *Vibrio* sp. 60. Feb 1 1996

126/3 08567217 95255518 PMID: 7737376

Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. May 1995

126/4 08370202 95058175 PMID: 7366813

Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the *Escherichia coli* Shiga-like toxin I A subunit is not essential for cytotoxicity. Oct 1993

126/5 08332655 95020625 PMID: 7394910

Genetic identification of exported proteins in *Streptococcus pneumoniae*. Sep 1993

126/6 08171538 94237439 PMID: 8181710

Efficient extracellular production of hybrid *E. coli* heat-labile enterotoxin B subunits in a marine *Vibrio*. Mar 15 1994

126/7 07905627 93386458 PMID: 8359916

Expression of the *Pasteurella haemolytica* leukotoxin is inhibited by a locus that encodes an ATP-binding cassette homology. Sep 1993

126/8 07458879 92332425 PMID: 1629152

Secretion of *Cyad*-PrTB and *HlyA*-PrTB fusion proteins in *Escherichia coli*: involvement of the glycine-rich repeat domain of *Erm*ina chrysinthrin protease B. Aug 1992

126/9 05844070 88198014 PMID: 3129403

Association of degradation and secretion of three chimeric polypeptides in *Escherichia coli*. May 1988

166/1 10064164 22008109 PMID: 12011465

The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. May 14 2

166/2 08627536 95316063 PMID: 7795711

SecA-dependence of the translocation of a large periplasmic loop in the *Escherichia coli* MalF inner membrane protein is a function of sequence context. Apr-Jun 1995

166/3 08542996 95231294 PMID: 7715449

Topological and mutational analysis of KpsM, the hydrophobic component of the ABC-transporter involved in the export of polysialic acid in *Escherichia coli* K1. Dec 1994

18/6/1 15677795 22877033 PMID: 12853446

Caspase-activated PAK-2 is regulated by subcellular targeting and proteasomal degradation. 07 09 2003

18/6/2 15413188 22787241 PMID: 12904216

Why green fluorescent fusion proteins have not been observed in the vacuoles of higher plants. Aug 2003

18/6/3 14599955 22423774 PMID: 12535522

ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Jan 2003

18/6/4 14599946 22423765 PMID: 12535513

Dissecting various ATP-dependent steps involved in proteasomal degradation. Jan 2003

18/6/5 14197767 22267310 PMID: 12177052

PCZ domains facilitate binding of high temperature requirement protease A (HtrA) and tail-specific protease (Tsp) to heterologous substrates through recognition of the small stable RNA A (ssrA)-encoded peptide. Oct 18 2002

18/6/6 14104297 22297623 PMID: 12408919

Multiple associated proteins regulate proteasome structure and function. Sep 2002

18/6/7 13957875 22220065 PMID: 12234933

Alternating translocation of protein substrates from both ends of ClpXP protease. Sep 16 2002

18/6/8 11880069 99321840 PMID: 10393320

Multi-ubiquitination of a nascent membrane protein produced in a rabbit reticulocyte lysate. Jul 1999

18/6/9 1626266 99059723 PMID: 9843491

Characterization of intermediates in the process of plant peroxisomal protein import. Dec 1 1998

18/6/10 11530405 98421510 PMID: 9748263

UDP-galactose 4-epimerase is a class I integral membrane protein of the endoplasmic reticulum. Oct 2 1998

18/6/11 11516471 98405098 PMID: 9733748

Prodomain-dependent nuclear localization of the caspase-2 (Nedd2) precursor. A novel function for a caspase prodomain. Sep 18 1998

18/6/12 11130131 98004523 PMID: 9342362

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-antitoxin fusion protein. Oct 28 1997

18/6/13 11098716 97392455 PMID: 9250669

Anionic phospholipids are determinants of membrane protein topology. Jul 16 1997

18/6/14 11038716 97392455 PMID: 9250669

Anionic phospholipids are determinants of membrane protein topology. Jul 16 1997

18/6/15 10846212 97197505 PMID: 9045801

Regulation of the proteinase B structural gene PRB1 in *Saccharomyces cerevisiae*. Mar 1997

18/6/16 10417616 96223976 PMID: 8626744

Ricin A chain fused to a chloroplast-targeting signal is unfolded on the chloroplast surface prior to import across the envelope membranes. Feb 23 1996

18/6/17 10412427 96218725 PMID: 8635058

Stabilization of a Hema-Laz hybrid protein against proteolysis during carbon starvation in alp mutants of *Salmonella typhimurium*. Apr 1996

18/6/18 10405531 96211529 PMID: 8648731

Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1. Jun 1996

18/6/19 10404174 96210138 PMID: 8625976

Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor-kappa B. Apr 1996

18/6/20 10396906 96202337 PMID: 8643690

Signal transduction by activated mNoc1: importance of proteolytic processing and its regulation by the extracellular domain. Feb 20 1996

18/6/21 10394660 96200283 PMID: 8634315

Rapid transmembrane movement of C6-NBD-labeled phospholipids across the inner membrane of *Escherichia coli*. Apr 3 1996

18/6/22 10394680 96200102 PMID: 8631709

Topological characterization of the essential *Escherichia coli* cell division protein FtsN. Mar 1996

18/6/23 10113842 22080068 PMID: 12085229

Analysing c-Myc internalization using a functional c-Myc-EGFP chimera containing the fluorochrome within the extracellular domain. Jul 4 2002

18/6/24 09856371 21668973 PMID: 11809791

Role for the adaptor protein Gp10 in the activation of Akt. Feb 2002

18/6/25 09573677 21356495 PMID: 11454738

Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. Jul 2001

18/6/26 09483802 21260031 PMID: 11359933

Ligand-dependent degradation of SmeD3 by a ubiquitin ligase complex of ROC1 and associated proteins. May 2001

18/6/27 09461606 21234971 PMID: 11336669

The human peroxisomal targeting signal receptor, Pex5p, is translocated into the peroxisomal matrix and recycled to the cytosol. Apr 20 2001

18/6/28 09453302 21225521 PMID: 11325926

Fosprote-specific transcription of the lonB gene during sporulation in *Bacillus subtilis*. May 2001

18/6/29 09382476 21145823 PMID: 11248057

The nucleoporin Nup98 associates with the intranuclear filamentous protein network of TPR. Mar 13 2001

18/6/30 09374452 21137192 PMID: 11238907

Proteasome inhibition induces nuclear translocation and transcriptional activation of the dioxin receptor in mouse embryo primary fibroblasts: the absence of xenobiotics. Mar 2001

18/6/31 09186681 20493582 PMID: 10922368

The amino-terminal domain of apolipoprotein B does not undergo retrograde translocation from the endoplasmic reticulum to the cytosol. Proteasomal degradation of nascent apolipoprotein B begins at the carboxyl terminus of the protein, while apolipoprotein B is still in its original translocon. Oct 13 2000

18/6/32 09186594 20493281 PMID: 11038175

Characterization of the signal that directs Tom20 to the mitochondrial outer membrane. Oct 16 2000

18/6/33 08590412 95278726 PMID: 7758939

C-terminal glycine-histidine tagging of the outer membrane protein Iga beta of *Neisseria gonorrhoeae*. Apr 1 1996

18/6/34 08575242 95263544 PMID: 7744847

Import of transcription factor MTF1 into the yeast mitochondria takes place through an unusual pathway. May 19 1995

18/6/35 08370202 95058175 PMID: 766513

Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the *Escherichia coli* Shiga-like toxin I A subunit is not essential for cytotoxicity. Oct 1993

18/6/36 08367435 95045406 PMID: 7957078

Molecular chaperones cooperate with PIM1 protease in the degradation of misfolded proteins in mitochondria. Nov 1 1994

18/6/37 08332655 95020625 PMID: 7934910

Genetic identification of exported proteins in *Streptococcus pneumoniae*. Sep 1993

18/6/38 08321998 95009968 PMID: 7925307

Translocation of N-terminal tails across the plasma membrane. Oct 3 1994

18/6/39 07932600 93393433 PMID: 8379852

Semliki Forest virus capsid protein expressed by a baculovirus recombinant. 1993

18/6/40 07536266 92404727 PMID: 2136629

Nuclear transport of plant polyviral proteins. Oct 1990

18/6/41 07501464 92365167 PMID: 1501298

Regulation of nuclear transport of a plant polyviral protein by autophagy. Sep 1992

18/6/42 07469940 92332486 PMID: 1321129

Carboxy-terminal sequences can influence the in vitro import and intragaugellar targeting of chloroplast protein precursors. Jul 15 1992

18/6/43 07453560 92317095 PMID: 1377688

Sequestration of an artificial precursor protein across the two mitochondrial membranes. Jul 5 1992

18/6/44 07426279 92289698 PMID: 1600950

Selective extracellular release of cholera toxin B subunit by *Escherichia coli*: dissection of *Neisseria* Iga beta-mediated outer membrane transport. Jun 1992

186/45 07411152 92274449 PMID: 1350514
Cytochromes c1 and b2 are sorted to the intermembrane space of yeast mitochondria by a stop-transfer mechanism. May 29 1992

186/46 07179659 92041980 PMID: 1657948
Protein import into the yeast mitochondrial matrix. A new translocation intermediate between the two mitochondrial membranes. Nov 5 1991

186/47 06973915 91214407 PMID: 2151020

Aberrant mitochondrial processing of chimeric import precursors containing subunits 8 and 9 of yeast mitochondrial ATP synthase. Dec 1990

186/48 06638675 90264273 PMID: 2188944
SecY, a multispanning integral membrane protein, contains a potential leader peptidase cleavage site. Jun 1990

186/49 06019639 89304426 PMID: 3053734

Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein gp160 in microsomal membranes. Nov 1988

186/50 06902842 88257183 PMID: 3290220
Signal and membrane anchor functions overlap in the type II membrane protein I gamma CAT. Jun 1988

187/20 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

10396906 96202337 PMID: 8643690

Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain.

Kopan R, Schroeder E H; Weintraub H; Nye J S

Division of Dermatology, Department of Molecular Biology and Pharmacology, Washington University, St. Louis, MO 63110, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Feb 20 1996, 93 (4) p1683-8, ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

Previous studies imply that the intracellular domain of Notch1 must translocate to the nucleus for its activity. In this study, we demonstrate that a mNotch1 mutant protein that lacks its extracellular domain but retains its membrane-spanning region becomes proteolytically processed on its intracellular surface and, as a result, the activated intracellular domain (mNotchIC) is released and can move to the nucleus. Proteolytic cleavage at an intracellular site is blocked by protease inhibitors. Intracellular cleavage is not seen in cells transfected with an inactive variant, which includes the extracellular lin-Notch-grip repeats. Collectively, the studies presented here support the model that mNotch1 is proteolytically processed and the cleavage product is translocated to the nucleus for mNotch1 signal transduction. Record Date Created: 19960717 Record Date Completed: 19960717

187/21 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

10394860 96200283 PMID: 8634315

Rapid transmembrane movement of C6-NBD-labeled phospholipids across the inner membrane of *Escherichia coli*.

Huijbrechts R P; de Kroon A I; de Kruijff B

Department Biochemistry of Membranes, Centre for Biomembranes and Lipid Enzymology, Institute of Biomembranes, Utrecht University, The Netherlands.

Biochimica et biophysica acta (NETHERLANDS) Apr 3 1996, 1280 (1) p41-50, ISSN 0006-3002 Journal Code: 0217513 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

In this study we have investigated the transmembrane movement of short chain fluorescently labeled phospholipids across the inner membrane of *Escherichia coli*. Exogenously added C6-NBD-labeled phospholipids rapidly flip across the inner membrane of *E. coli*, as was shown by a dithionite reduction assay applied to inverted inner membrane vesicles (ILMV) isolated from wild type *E. coli* cells. The rate of transmembrane movement of the phospholipid probes incorporated into ILMV is temperature dependent, and shows no phospholipid head group specificity. C6-NBD-labeled phospholipids translocate across the membrane of ILMV incubated at 37 degrees C with a t1/2 of 7 min. After the incorporation into ILMV C6-NBD-PG is partially converted to CL by CL-synthase. If ILMV are pretreated with proteinase K the conversion of this fluorescent probe to C6-NBD-CL is not observed anymore, suggesting that the catalytic domain of CL-synthase is at the cytoplasmic site of the plasma membrane of *E. coli*. Newly synthesized C6-NBD-CL also flips across the inner membrane although at a slower rate than the other phospholipid probes. The transmembrane movement occurs in both directions and is not influenced by treatment of the ILMV with a sulphydryl reagent or a proteinase, nor by the presence of ATP, or a delatph across the membrane of the ILMV. However, the transmembrane movement of the C6-NBD-labeled phospholipid probes is not observed in LUVETs (large unilamellar vesicles made by extrusion technique) prepared of wild type *E. coli* lipids, indicating that the rapid transmembrane movement of phospholipids across the inner membrane of *E. coli* is a protein-mediated process. Record Date Created: 19960710 Record Date Completed: 19960710

187/33 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
00370202 95058175 PMID: 7968513

Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the *Escherichia coli* Shiga-like toxin I A subunit is not essential for cytotoxicity.

Burgess B J; Roberts L M

Department of Biological Sciences, University of Warwick, Coventry, UK.

Molecular microbiology (ENGLAND) Oct 1993, 10 (1) p171-9, ISSN 0950-382X Journal Code: 8712028

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Escherichia coli Shiga-like toxin I is a type I ribosome-inactivating protein composed of an A subunit with RNA-specific N-glycosidase activity, non-covalently associated with a pentamer of B subunits possessing affinity for galactose-containing glycolipids. The A subunit contains a single intrachain disulphide bond encompassing a hydrophobic sequence containing two tyrosin-sensitive arginine residues. By analogy with other bacterial toxins it has been proposed that proteolytic nicking, deemed essential for a cytotoxic effect, occurs within this disulphide-bonded loop to generate the A1 and A2 fragments. Reduced A1 is then believed to translocate an internal membrane to inactivate protein synthesis in the cytosol. In this report, the disulphide-to arginines of the SLT I A subunit were mutated to block the specific proteolysis presumed to occur. However, the mutant generated remained an effective toxin having similar catalytic activity to wild-type toxin and only a marginally reduced cytotoxic towards cultured cells. We conclude that the disulphide-loop arginine residues are not the unique and essential processing site previously assumed, but that processing may occur at alternative accessible sites to compensate for loss of target sites within the loop. Record Date Created: 19941129 Record Date Completed: 19941129

206/1 16123688 PMID: 1464278

Regulating the conducting states of a mammalian serotonin transporter. Oct 30 2003

206/2 15440652 22793392 PMID: 12913111

Rho-specific Bacillus cereus ADP-ribosyltransferase C3ser cloning and characterization. Aug 19 2003

206/3 15377227 22613949 PMID: 12727273

Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. May 2003

206/4 15348009 22756599 PMID: 12750364

Entrapment of Rho ADP-ribosylated by Clostridium botulinum C3 exoenzyme in the Rho-guanine nucleotide dissociation inhibitor-1 complex. 05 2003

206/5 15317414 22773060 PMID: 12890789

Reversible suppression of glutamatergic neurotransmission of cerebellar granule cells in vivo by genetically manipulated expression of tetanus neurotoxin light chain. Jul 30 2003

206/6 15311407 22758990 PMID: 12853568

Intra cellions between synaptic vesicle fusion proteins explored by atomicforce microscopy. 07 09 2003

206/7 15120030 22538130 PMID: 12850831

Prostaglandin F(2alpha) stimulation of cyclooxygenase-2 promoter activity by the FP(2B) prostanoid receptor. Mar 28 2003

206/8 15004649 22617621 PMID: 12731878

Channel formation by the binding component of Clostridium botulinum C2 toxin: glutamate 307 of C2II affects channel properties in vitro a pH-dependent C2I translocation in vivo. May 13 2003

206/9 14937497 22435569 PMID: 12547349

A single dose of recombinant Salmonella typhimurium induces specific humoral immune responses against heterologous *Elmeria lenella* antigens in chicken. Jan 2003

206/10 14928003 22331471 PMID: 12444490

The uptake machinery of clonitridal actin ADP-ribosylating toxins--a cel delivery system for fusion proteins and polypeptide drugs. 09 24 2002

206/11 14915304 22576820 PMID: 12691734

The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mar 2003

206/12 14790045 22560265 PMID: 12672406

Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse. Feb 2003

206/13 14712165 22482024 PMID: 12593858

Activation of phospholipase D1 by ADP-ribosylated RhoA. Feb 28 2003

206/14 14706307 22148892 PMID: 12154081

Leukotriene D(4) induces stress-fibre formation in intestinal epithelial cells via activation of RhoA and PkCdelta. Sep 1 2002

206/15 14667953 22477381 PMID: 12588974

Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways: integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mar 2003

- 206/6 14619818 22516246 PMID: 12629174
A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. Mar 1 2003
- 206/17 14554070 22443989 PMID: 12555353
Tetanus toxin abolishes exocytosis of ROMK1 induced by inhibition of protein tyrosine kinase. 12.30.2002
- 206/18 14546728 22135753 PMID: 12140285
Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis. Aug 15 2002
- 206/19 14464053 22127360 PMID: 12126902
Recombinant *Lactobacillus johnsonii* as a mucosal vaccine delivery vehicle. Jul 28 2002
- 206/20 14387371 22012452 PMID: 12018391
Cdc42 antagonizes inductive action of cAMP on cell shape, via effects of the myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK) on myosin light chain phosphorylation. Apr 2002
- 206/21 14283907 22323262 PMID: 12237298
Sarcolipin overexpression in rat slow twitch muscle inhibits sarcoplasmic reticulum Ca^{2+} uptake and impairs contractile function. 09.16.2002
- 206/22 14236806 22313557 PMID: 12221101
Clostridium perfringens iota toxin: Mapping of the Ia domain involved in docking with Ib and cellular internalization. 09.06.2002
- 206/23 14150739 22278759 PMID: 12391613
Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carntine. Nov 1 2002
- 206/24 14124259 22316781 PMID: 12429212
Hybrid tetanus toxin C fragment-diphtheria toxin translocation domain allows specific gene transfer into PC12 cells. Sep 2002
- 206/25 14106775 21960967 PMID: 11963655
EphA4 catalytic activity causes inhibition of RhoA GTPase in *Xenopus laevis* embryos. Mar 2002
- 206/26 13966482 22233515 PMID: 12296860
Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Oct 2002
- 206/27 13963781 22223651 PMID: 12244189
Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. Oct 1 2002
- 206/28 13954466 22213398 PMID: 12225361
Insight into the potential for DNA idiotype fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. Sep 2002
- 206/29 13948465 22202601 PMID: 12213444
In vivo neuronal tracing with GFP-TTC gene delivery. Aug 2002
- 206/30 11981772 99426801 PMID: 10496883
Humoral and cellular immune responses in mice immunized with recombinant *Mycobacterium bovis* Bacillus Calmette-Guérin producing a pertussis toxin- tetanus toxin hybrid protein. Oct 1999
- 206/31 11974144 99419034 PMID: 10488092
Galp1a(3) stimulates Rho-dependent activation of the cyclooxygenase-2 promoter. Sep 24 1999
- 206/32 11974724 99419014 PMID: 10488072
Neosynthesis and activation of Rho by *Escherichia coli* cytotoxic necrotizing factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho. Sep 24 1999
- 206/33 11966074 99410778 PMID: 10479598
Relative contribution of endogenous neurotrophins in hippocampal long-term potentiation. Sep 15 1999
- 206/34 11962231 99406730 PMID: 10477565
Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant Gram-positive bacteria to CD4+ T lymphocytes. Sep 15 1999
- 206/35 11948316 99392459 PMID: 10463173
Antigenic variants in *Bordetella pertussis* strains isolated from vaccinated and unvaccinated children. Aug 1999
- 206/36 11945631 99388884 PMID: 10460261
Neuropil pattern formation and regulation of cell adhesion molecules in *Drosophila* optic lobe development depend on synaptobrevin. Sep 1 1999
- 206/37 11942945 99388886 PMID: 10465940
Cell surface-exposed tetanus toxin fragment C produced by recombinant *Bacillus anthracis* protects against tetanus toxin. Sep 1999
- 206/38 11925624 99369242 PMID: 10442633
The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by Galp1a2. Aug 5 1999
- 206/39 11909065 99352288 PMID: 10423269
Rho-kinase (ROK) promotes CD44v3-6-10-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. 1999
- 206/40 11853824 99294858 PMID: 10364548
Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Jun 11 1999
- 206/41 11853404 99294410 PMID: 10367944
Instruments for oral disease-intervention strategies: recombinant *Lactobacillus casei* expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Apr 23 1999
- 206/42 11847220 99286017 PMID: 10359565
The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. Jun 1999
- 206/43 11837792 99276135 PMID: 10346912
Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. May 25 1999
- 206/44 11803560 99242792 PMID: 10225867
Immunogenicity of a *Salmonella typhimurium* α roA α roD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. May 1999
- 206/45 11759317 99199333 PMID: 10094832
Activation of protein kinase C by phorbol esters modulates alpha2beta1 integrin on MC-7 breast cancer cells. Apr 10 1999
- 206/46 11723801 99160459 PMID: 10049679
Recombinant and truncated tetanus neurotoxin light chain: cloning, expression, purification, and proteolytic activity. Mar 1999
- 206/47 11704099 99140154 PMID: 10206702
Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated *Salmonella* vaccine strains. Jan 1999
- 206/48 11620461 99053650 PMID: 9839925
Monitoring of scFv selected by phage display using detection of scFv-P11 fusion proteins in a microtiter scale assay. Nov 1 1998
- 206/49 11602353 99035056 PMID: 98162208
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Mar 1996
- 206/50 11593846 99028267 PMID: 9808660
Conjugative transfer of the *Escherichia coli*-Clostridium perfringens shuttle vector pJIR1457 to Clostridium botulinum type A strains. Nov 1
- 206/51 11592988 99025406 PMID: 9809552
DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nov 1999
- 206/52 11497567 98381640 PMID: 9717740
Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B. Jul 1998
- 206/53 11496293 98380521 PMID: 9712688
Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Aug 1998
- 206/54 11438327 98321222 PMID: 9647788
Localization of RhoA GTPase to endothelial caveolae-enriched membrane domains. Jun 29 1998
- 206/55 11425098 98307523 PMID: 9645616
Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses. May 1998
- 206/56 11415320 98297359 PMID: 9635436
The small GTP-binding protein RhoA regulates a delayed rectifier potassium channel. Jun 12 1998
- 206/57 11383536 98264620 PMID: 9603457
MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. May 1998
- 206/58 11350223 98230504 PMID: 9570577
Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. Feb 1 1998
- 206/59 11336876 98215725 PMID: 9548730

- Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. Apr 20 1998
- 206/60 11336865 98215714 PMID: 9548719
Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase. Apr 20 1998
- 206/61 11308636 98187903 PMID: 9529054
The N-terminal part of the enzyme component (C2) of the binary *Clostridium botulinum* C2 toxin interacts with the binding component 2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Apr 1998
- 206/62 11272296 98150766 PMID: 9491802
The small GTP-binding protein Rho1 is a multifunctional protein that regulates actin localization, cell polarity, and septum formation in the fission yeast *Schizosaccharomyces pombe*. Nov 1997
- 206/63 11209393 98086179 PMID: 9426210
Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. Dec 9 1997
- 206/64 11139735 98015419 PMID: 9353935
Recombinant SNAP-25 is an effective substrate for *Clostridium botulinum* type A toxin endopeptidase activity in vitro. Oct 1997
- 206/65 11129343 98003598 PMID: 9343703
Temperature-induced expression of human-mouse chimeric Fab. 1997
- 206/66 11120921 97415331 PMID: 9271130
Identification of a recombinant synaptobrevin-thioredoxin fusion protein by capillary zone electrophoresis using laser-induced fluorescence detection. Jul 18 1997
- 206/67 11110175 97404407 PMID: 9256494
Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system. Aug 19 1997
- 206/68 11106181 97400359 PMID: 9257853
DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Aug 15 1997
- 206/69 11067813 97422537 PMID: 9278305
Impaired class II expression and antigen uptake in monocytic cells after HIV-1 infection. Sep 1 1997
- 206/70 11060921 97415331 PMID: 9271130
Identification of a recombinant synaptobrevin-thioredoxin fusion protein by capillary zone electrophoresis using laser-induced fluorescence detection. Jul 18 1997
- 206/71 11050175 97404407 PMID: 9256494
Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system. Aug 19 1997
- 206/72 11046181 97400359 PMID: 9257853
DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Aug 15 1997
- 206/73 11019908 97373354 PMID: 9229383
Heterologous expression of the cuticular-glutathione peroxidase of lymphatic filariae in an attenuated vaccine strain of *Salmonella typhimurium* abrogates H-2 restriction of specific antibody responses. Jun 1995
- 206/74 11008552 97361879 PMID: 9218840
Isolation of human anti-c-erbB-2. Fabs from a lymph node-derived phage display library. Jul 1997
- 206/75 10994209 97347435 PMID: 9202074
Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. Jul 1 1997
- 206/76 10961209 97313862 PMID: 9172063
Cleavage of the synaptobrevin-vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of *Clostridium botulinum* type B toxin. May 15 1997
- 206/77 10960533 97313177 PMID: 9169781
Expression and immunogenicity of an *Echinococcus granulosus* fatty acid-binding protein in live attenuated *Salmonella* vaccine strains. Jun 1997
- 206/78 10824716 97175716 PMID: 9023371
Binding of the synaptic vesicle v-SNARE, synaptobrevin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses. Feb 4 1997
- 206/79 10790005 97140301 PMID: 8996782
Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins. Dec 24 1995
- 206/80 10698443 97047656 PMID: 8926085
Expression and immunogenicity of pertussis toxin S1 subunit: tetanus toxin fragment C fusions in *Salmonella typhi* vaccine strain CVD 908. Oct 1996
- 206/81 10662431 97011151 PMID: 8858161
Regulation mechanism of ERK (extracellular/intracellular) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. Oct 1996
- 206/82 10600306 96417858 PMID: 8820649
A *Salmonella typhimurium* thetaA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Feb 1996
- 206/83 10595009 96405413 PMID: 8809553
Factors affecting the immunogenicity of tetanus toxin fragment C expressed in *Lactococcus lactis*. Jun 1996
- 206/84 10421671 96228050 PMID: 8647268
Botulinum neurotoxin light chains inhibit both Ca(2+)-induced and GTP- analogue-induced catecholamine release from permeabilised adren chromaffin cells. May 20 1996
- 206/85 10389160 96194531 PMID: 8617948
Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation. May 1 1996
- 206/86 10369397 96174811 PMID: 8599394
Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. Feb 1 1996
- 206/87 10362180 96165391 PMID: 8571127
Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Feb 2 1996
- 206/88 10361266 96164477 PMID: 8578848
Expression of fragment C of tetanus toxin used to a carboxyl-terminal fragment of diphtheria toxin in *Salmonella typhi* CVD 908 vaccine strain Nov 1995
- 206/89 10348836 96151333 PMID: 8599190
Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Oct 1995
- 206/90 10310362 96112457 PMID: 8678289
Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase. Oct 10 1995
- 206/91 10271008 96072756 PMID: 7578132
Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxic after reconstitution with the heavy chain. Nov 21 1995
- 206/92 10248273 96049754 PMID: 7486581
Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. Sep 29 1995
- 206/93 10228878 96030146 PMID: 7476431
Purification and assay of recombinant C3 transferase. 1995
- 206/94 10149075 22140381 PMID: 12145319
Amsyn, a novel synaptin-binding protein that may regulate SNARE complex assembly. Aug 2 2002
- 206/95 10148812 22140034 PMID: 12145198
Calmodulin and lipid binding to synaptobrevin regulates calcium-dependent exocytosis. Aug 1 2002
- 206/96 10144823 22133754 PMID: 12114537
Retrograde trans-synaptic transfer of green fluorescent protein allows the genetic mapping of neuronal circuits in transgenic mice. Jul 23 2000
- 206/97 10092697 22048404 PMID: 12052960
Trans-synaptic Eph receptor-ephrin signaling in hippocampal mossy fiber LTP. Jun 7 2002
- 206/98 099883262 21909309 PMID: 11912151
Vaccination with DNA encoding a single-chain TCR fusion protein induces antitumor immunity and protects against T-cell lymphoma. Mar 2002
- 206/99 09916932 21826459 PMID: 11741886
The binary *Clostridium botulinum* C2 toxin as a protein delivery system: identification of the minimal protein region necessary for interaction toxin components. Feb 15 2002

2056/100 09860389 21673341 PMID: 1181:4347
Structure-function analysis of the Rho-ADP-ribosylating exoenzyme CstIIaz2 from *Staphylococcus aureus* Feb 5 2002

205/624 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
14124259 22316781 PMID: 12429212

Hydriδ tetanus toxin C fragment-diphtheria toxin translocation domain allows specific gene transfer into PC12 cells.

Barati Shahram, Chegini Fariba, Hurtado Plinio, Rush Robert A, et al

Department of Human Physiology, Centre for Neuroscience, Flinders Medical Research Institute, Flinders University of South Australia, Adelaide, Australia. Shahram.Barati@post.flinders.edu.au

Experimental neurology (United States) Sep 2002 177 (1) p75-87, ISSN 0014-4886 Journal Code: 0370712

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

To study the mechanism by which genes can efficiently be transferred into specific cell types, we have constructed several novel, single-chain multicomponent proteins by recombining the nontoxic C fragment of tetanus toxin and the translocation domain of diphtheria toxin together with the DNA-binding fragment of GAL4 transcription factor, for transposition of plasmid DNA into neuronal cells. The C fragment of tetanus toxin provided neuronal selectivity, the translocation domain of diphtheria toxin permitted endosomal escape, and the GAL4 domain provided binding to DNA. To assess the cellular tasks of each component in gene transfer, different combinations of these fragments were produced by polymerase chain reaction, expressed in *Escherichia coli*, and purified under native conditions from the soluble proteins. We show that only fusion proteins bearing the C fragment of tetanus toxin bind to gangliosides and, followed by their specific binding to differentiated PC12 cells, are internalized within 10 min. These proteins delivered the green fluorescence protein gene to PC12 cells, with the highest transfection efficiency achieved with proteins containing both the C fragment and the translocation domain. Addition of chloroquine elevated the transfection efficiency, which was further increased by incorporation of a nuclear localization signal in the delivery system. In addition, the effect of different DNA-condensing materials (poly-L-lysine, protamine, lysine(7-8)-tyrhyph(7-2)-lysine(7-8)) on gene transfer was investigated.

Tags: Animal, Support, Non-U.S. Govt Descriptors: Diphtheria Toxin--genetics--GE, Gene Transfer Techniques--Peptide Fragments--genetics--GE, *Tetanus Toxin--genetics--GE, Amino Acid Sequence--genetics--GE, Binding Sites--genetics--GE, Cattle Cell Line, Diphtheria Toxin--metabolism--ME, Gene Transfer Techniques--trends--TD, Mice, Molecular Sequence Data, PC12 Cells, Peptide Fragments--metabolism--ME, Protein Transport--genetics--GE, Rats, Recombinant Fusion Proteins--genetics--GE, Recombinant Fusion Proteins--metabolism--ME, Saccharomyces cerevisiae Proteins--genetics--GE, Saccharomyces cerevisiae Proteins--metabolism--ME, Tetanus Toxin--metabolism--ME, Transcription Factors--genetics--GE, Transcription Factors--metabolism--ME, CAS Registry No.: 0 (Diphtheria Toxin), 0 (GAL4 protein, Saccharomyces cerevisiae), 0 (Peptide Fragments), 0 (Recombinant Fusion Proteins), 0 (Saccharomyces cerevisiae Proteins), 0 (Tetanus Toxin), 0 (Transcription Factors), 0 (tetanus toxin fragment C)

Record Date Created: 20021113 Record Date Completed: 20021209

205/27 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
13963781 222239551 PMID: 12244189

Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.

Rice Jason, Buchtan Sarah, Stevenson Freda K, et al

Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton, United Kingdom. j.rice@soton.ac.uk

Journal of immunology (Baltimore, Md. : 1950) (United States) Oct 1 2002 169 (7) p3908-13, ISSN 0022-1767 Journal Code: 2985117R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: AIM, INDEX MEDICUS

DNA vaccines can activate immunity against tumor Ags expressed as MHC class I-associated peptides. However, priming of CD8(+) CTL against weak tumor Ags may require adjuvant molecules. We have used a pathogen-derived sequence from tetanus toxin (fragment C [F(C)]) fused to tumor Ag sequences to promote Ab and CD4(+) T cell responses. For induction of CD8(+) T cell responses, the F(C) sequence has been engineered to remove potentially competitive MHC class I-binding epitopes and to improve presentation of tumor epitopes. The colon carcinoma CT26 expresses an endogenous retroviral gene product, gp70, containing a known H2-L(d)-restricted epitope (A#1). A DNA vaccine encoding gp70 alone was a poor inducer of CTL, and performance was not significantly improved by fusion of full-length F(C). However, use of a minimized domain of F(C), with the A#1 sequence fused to the 3' position, led to rapid induction of high levels of CTL. IFN-gamma-producing epitope-specific CTL were detectable *ex vivo* and these killed CT26 targets *in vitro*. The single epitope vaccine was more effective than GM-CSF-transfected CT26 tumor cells in inducing an A#1-specific CTL response and equally effective in providing protection against tumor challenge. Levels of A#1-specific CTL *in vivo* were increased following injection of tumor cells, and CTL expanded *in vitro* were able to kill CT26 cells in tumor bearers. Pre-existing immunity to tetanus toxin had no effect on the induction of A#1-specific CTL. These data demonstrate the power of epitope-specific CTL against tumor cells and illustrate a strategy for priming immunity via a dual component DNA vaccine.

Tags: Animal, Support, Non-U.S. Govt Descriptors: Antigens, Neoplasm--immunology--IM, *Cancer Vaccines--immunology--IM, *Cytotoxicity, Immunologic, *Epitopes, T-Lymphocyte Activation, *Recombinant Fusion Proteins--immunology--IM, T-Lymphocytes, Cytotoxic--immunology--IM, Vaccines, DNA--immunology--IM, Antigens, Neoplasm--administration and dosage--AD, Antigens, Neoplasm--genetics--GE, Cancer Vaccines--administration and dosage--AD, Cancer Vaccines--chemical synthesis--CS, Cancer Vaccines--

genetics--GE, Colonic Neoplasms--immunology--IM, Colonic Neoplasms--pathology--PA, Colonic Neoplasms--prevention and control--PC, Cytotoxicity, Immunologic--genetics--GE, Epitopes, T-Lymphocyte--administration and dosage--AD, Epitopes, T-Lymphocyte--genetics--GE, Growth Inhibitors--administration and dosage--AD, Growth Inhibitors--chemical synthesis--CS, Growth Inhibitors--genetics--GE, Growth Inhibitors--immunology--IM, Injections, Intranasal, Interferon Type II--biosynthesis--BI, Lymphocyte Activation--genetics--GE, Mice, Mice, Inbred BALB C, Neoplasm Transplantation, Recombinant Fusion Proteins--administration and dosage--AD, Recombinant Fusion Proteins chemical synthesis--CS, Recombinant Fusion Proteins--genetics--GE, Retroviridae Proteins, Oncogenic--administration and dosage--AD, Retroviridae Proteins, Oncogenic--genetics--GE, Retroviridae Proteins, Oncogenic--immunology--IM, T-Lymphocytes, Cytotoxic--transplantation--TR, Tetanus Toxoid--administration and dosage--AD, Tetanus Toxoid--immunology--IM, Vaccin DNA--administration and dosage--AD, Vaccines, DNA--chemical synthesis--CS, Vaccines, DNA--genetics--GE, Viral Envelope Proteins--administration and dosage--AD, Viral Envelope Proteins--genetics--GE, Viral Envelope Proteins--immunology--IM, CAS Registry No.: 0 (Antigens, Neoplasm), 0 (Cancer Vaccines), 0 (Epitopes, T-Lymphocyte), 0 (Growth Inhibitors), 0 (Recombinant Fusion Proteins), 0 (Retroviridae Proteins, Oncogenic), 0 (Tetanus Toxoid), 0 (Vaccines, DNA), 0 (Viral Envelope Proteins), 0 (glycoprotein gp70, leukemia virus envelope protein), 82115-62-6 (Interferon Type II)

Record Date Created: 20020923 Record Date Completed: 20021112

205/38 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11925624 99869242 PMID: 10442633

The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by Galpha12.

Nagao M, Kazuo Y, Itoh H

Faculty of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan.

Oncogene (ENGLAND) Aug 5 1999, 18 (31) p4425-34, ISSN 0950-9232 Journal Code: 8711562

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

G12t, a member of alpha subunit of heterotrimeric G protein G12 subfamily, has been shown to stimulate c-Jun N-terminal kinase (JNK) activity through the low molecular weight GTP-binding proteins Ras, Rac, and Cdc42. In this study using the transient expression of a constitutively activated mutant of Galpha12 (Galpha12Q229L) in human embryonic kidney (HEK) 293 cells, we found that Rho and Src family kinase are also involved in the Galpha12-induced activation of JNK. The activation of JNK by Galpha12Q229L was inhibited by dominant-negative RhoA(G14V), and botulinum C3 exoenzyme which specifically inactivates Rho. In addition, the expression of activated RhoA(G14V) elevated JNK activity in HEK 293 cells. The Galpha12Q229L-stimulated activation of JNK was blocked by a specific inhibitor of protein tyrosine kinases (PP2), and C-terminal Src kinase (Csk). Moreover, we observed that Galpha12Q229L stimulated Src family kinase activity and v-Src induce JNK activation. Interestingly, the v-Src-induced activation of JNK was inhibited by dominant-negative RhoA(T19N). In contrast Csk did not inhibit the JNK activation by activated RhoA(G14V). These results suggest that Rho and Src family kinase are required for the Galpha12-induced JNK activation, and that Src family kinase acts upstream of Rho activation in the JNK pathway.

Tags: Animal, Human, Support, Non-U.S. Govt Descriptors: *Ca(2+)-Calmodulin Dependent Protein Kinase--metabolism--ME, GTP-Binding Proteins--metabolism--ME, *Protein-Tyrosine Kinase--metabolism--ME, *Proto-Oncogene Proteins--metabolism--ME, 3T3 Cells, Amino Acid Substitution, COS Cells, Cell Line, DNA Primers, Enzyme Activation, GTP-Binding Proteins--genetics--GE, Mice, Mutagenesis, Site-Directed, Polymerase Chain Reaction, Proto-Oncogene Proteins--genetics--GE, Rats, Recombinant Fusion Proteins--metabolism--ME, Transfection, TrkA GTP-Binding Protein, Src Homology Domains CAS Registry No.: 0 (DNA Primers), 0 (G12-alpha protein), 0 (Proto-Oncogene Proteins), 0 (Recombinant Fusion Proteins), Enzyme No.: EC 2.7.1.112 (Protein-Tyrosine Kinase), EC 2.7.1.123 (Ca(2+)-Calmodulin Dependent Protein Kinase), EC 2.7.10.- (G-Jun amino-terminal kinase), EC 3.6.1.- (GTP-Binding Proteins), EC 3.6.1.- (trkA GTP-Binding Protein)

Record Date Created: 19990830 Record Date Completed: 19990830

207/61 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11592988 99025406 PMID: 9809552

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.

King C. A, Spellerberg M, B, Zhu D, Rice J, Sahota S, Thompson A R, Hamblin T J, Rad J, Stevenson F K

Tenovus Laboratory, Southampton University Hospitals Trust, England.

Nature medicine (UNITED STATES) Nov 1998, 4 (11) p1281-6, ISSN 1078-8956 Journal Code: 9502015

Comment in Nat Med. 1998 Nov 4;1(11) 1239-40. Comment in PMID 9809542 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor th may exist in patients. Record Date Created: 19981130 Record Date Completed: 19981130

207/61 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11308636 98187903 PMID: 9529054

The N-terminal part of the enzyme component (C2) of the binary Clostridium botulinum C2 toxin interacts with the binding component C2I and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin.

Barth H, Hofmann F, Olenik C, Just I, Aktories K
Institut für Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Germany.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Apr 1998, 66 (4) p1364-9. ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The binary actin-ADP-ribosylating Clostridium botulinum C2 toxin consists of the enzyme component C2I and the binding component C2II, which are separate proteins. The active component C2I enters cells through C2II by receptor-mediated endocytosis and membrane translocation. The N-terminal part of C2I (C2IN), which consists of 225 amino acid residues but lacks ADP-ribosyltransferase activity, was identified as the C2II contact site. A fusion protein (C2IN-C3) of C2IN and the full-length C3-like ADP-ribosyltransferase from Clostridium limosum was constructed. The fusion protein C2IN-C3 ADP-ribosylated Rho but not actin in CHO cell lysates. Together with C2II, C2IN-C3 induced complete rounding up of CHO and HeLa cells after incubation for 3 h. No cell rounding was observed without C2II or with the original C3-like transferase from C. limosum. The data indicate that the N-terminal 225 amino acid residues of C2I are sufficient to cause the cellular uptake of C. limosum transferase via the binding component of C2II, thereby increasing the cytotoxicity of the C3-like exoenzyme several hundred-fold. Record Date Created: 19980409 Record Date Completed: 19980409

207/67 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11101775 97404407 PMID: 9256494

Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system.

Coen L, Osta R, Maury M, Brulet P

Unité d'Embryologie Moléculaire, Unité de Recherche Associée 1947, Centre National de la Recherche Scientifique, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 19 1997, 94 (17) p9400-5. ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The nontoxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. We have investigated its potential use as an in vivo neurotropic carrier. In this work we show that a hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e., retrograde transsynaptic transport of the TTC fragment and beta-galactosidase enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy could be used to deliver a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein could also be used to map synaptic connections between neural cells. Record Date Created: 19970917 Record Date Completed: 19970917

207/68 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11106181 97400359 PMID: 9257853

DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.

Speitelberg M B, Zhu D, Thompson A, King C A, Hamblin T J, Stevenson F K

Tenovus Laboratory, Southampton University Hospitals, United Kingdom.

Journal of Immunology (Baltimore, Md. - 1950) (UNITED STATES) Aug 15 1997, 159 (4) p1885-92. ISSN 0022-1767 Journal Code: 2985117R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Idiotypic determinants can act as tumor-associated Ags for B cell lymphoma. Vaccination with idiotypic protein and adjuvant is known to induce specific protection against lymphoma challenge in mice, largely mediated by anti-idiotypic Ab. For facilitating the approach for patients, the V(H) and V(L) genes used to encode the individual idiotypic determinants of each tumor can be obtained by PCR and assembled as single chain Fv (scFv). DNA vaccines containing scFv sequences alone induce low and poorly reproducible levels of anti-idiotypic Ab, likely to be insufficient to suppress tumor in patients. In addition, it may be necessary to break tolerance to Id in tumor bearers. By using the gene for fragment C of tetanus toxin to the C terminus of human scFv, we have promoted the anti-scFv Ab response in mice by >50-fold in three of three cases. The induced Abs are mainly against idiotypic determinants, and react specifically with patients' tumor cells, indicating optimal folding of the scFv molecule in the fusion protein. For both antigenic components of the DNA vaccine, the IgG subclass distribution showed a relative increase in IgG2a as compared with vaccination with IgM protein in adjuvant. In patients, the fusion gene should both promote anti-idiotypic Ab and induce Abs against fragment C of tetanus toxin. The latter response would provide a potentially useful comparative measure of the ability of patients to respond to conventional Ag delivered via DNA. Record Date Created: 19970828 Record Date Completed: 19970828

207/71 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
11050175 97404407 PMID: 9256494

Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system.
Coen L, Osta R, Maury M, Brulet P

Unité d'Embryologie Moléculaire, Unité de Recherche Associée 1947, Centre National de la Recherche Scientifique, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 19 1997, 94 (17) p9400-5. ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The nontoxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. We have investigated its potential use as an in vivo neurotropic carrier. In this work we show that a hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e., retrograde transsynaptic transport of the TTC fragment and beta-galactosidase enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy could be used to deliver a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein could also be used to map synaptic connections between neural cells. Record Date Created: 19970917 Record Date Completed: 19970917

207/76 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
10961209 97313862 PMID: 9170263

Cleavage of the synaptobrevin/vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of Clostridium botulinum type B toxin.

Rhee S D, Jung H H, Yang G H, Moon Y S, Yang K H

Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Taejeon, South Korea.

FEMS microbiology letters (NETHERLANDS) May 15 1997, 150 (2) p203-8. ISSN 0378-1097 Journal Code: 7705721

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The light chain of Clostridium botulinum type B toxin was expressed in Escherichia coli using the expression vector pET-3a containing phage T7 promoter. The expressed protein was then purified by DEAE-cellulose and phosphocellulose chromatography and the proteolytic activity of the purified light chain was studied. The purified recombinant light chain cleaved synaptobrevin when mixed with the mouse brain microsome and the proteolytic activity of the light chain was inhibited if a metal chelating agent such as EDTA or 2,2'-dipyridyl was added. The recombinant light chain cleaved synaptobrevin more effectively than the native type B toxin. When the native toxin was hybridized and was reduced with DTT, its proteolytic activity was similar to that of the recombinant light chain. Record Date Created: 19970714 Record Date Completed: 19970714

207/88 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

10361266 96164477 PMID: 8578848

Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain.

Gomez-Duane O G, Galen J, Chatfield S N, Rappuoli R, Eldais L, Levine M M

Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA.

Vaccine (ENGLAND) Nov 1995, 13 (16) p1596-602. ISSN 0264-410X Journal Code: 8406899 Contract/Grant No.: NO1 A115096; AI; NIAID; NO1 A145251; AI; NIAID; RO1 A129471; PHS Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

We report the expression of fragment C of tetanus toxin (FC) fused to the eukaryotic cell binding domain (the carboxyl-terminus) of diphtheria toxin (FC-bDt fusion) in attenuated Salmonella typhi live vector vaccine strain CVD 908. The FC-bDt protein fusion was constructed using plasmid pET11r15 which carries the gene encoding FC under control of the n1B promoter (n1BP). The open reading frame for FC was modified to incorporate an in-frame glycine-proline hinge region and a set of four restriction sites at the 3' end of the FC gene. A 482 bp DNA fragment encoding the eukaryotic cell binding domain of diphtheria toxin was then inserted at the 3' end of the modified FC gene to create an in-frame FC-bDt fusion gene. The resulting plasmid, pOG215, was able to express the FC-bDt fusion protein in both Escherichia coli DH5a and S. typhi CVD 908, as evidenced by Western immunoblots using anti-FC and anti-C-terminal diphtheria toxin monoclonal antibodies. Maximum expression of the FC-bDt fusion protein was achieved by growing CVD 908(pOG215) at the low oxidation-reduction potential of thioglycollate broth, i.e., conditions that activate n1BP and drive transcription of the FC-bDt fusion gene. Whereas maximum expression of FC alone was also observed using thioglycollate broth, expression of bDt alone was unsuccessful using a variety of growth conditions. FC fusions constitute one strategy to 'rescue' expression of proteins which are otherwise difficult to express. Record Date Created: 19960312 Record Date Completed: 19960312

207/82 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.
10600306 96417858 PMID: 8620649

A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection.

Chabagioty J A, Khan C M, Nash A A, Hommaeche C E

Department of Microbiology, University of Newcastle, Newcastle upon Tyne, UK.

Molecular microbiology (ENGLAND) Feb 1996, 19 (4) p791-801. ISSN 0950-382X Journal Code: 8712028 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Multiple tandem copies of an immunogenic epitope comprising amino acids 8-23 of glycoprotein D of herpes simplex virus (HSV) were expressed as C-terminal fusions to tetanus toxin fragment C (TeC) in different *Salmonella typhimurium* live vaccine strains. Expression of the longer fusions was best in strains harbouring a lesion in *htrA*, a stress protein gene. SL3261, an *araD* strain, did not effectively express the longer fusions. Mice immunised with an S. typhimurium C3 *htrA* mutant expressing fusions with two or four copies of the peptide made an antibody response to both the peptide and TeC, whereas constructs expressing one copy of the peptide only elicited antibody to TeC. A non-immunogenic octanucleotide fusion underwent rearrangements in vivo resulting in a predominantly monomeric fusion. In contrast, the S. typhimurium SL3261 *araD* vaccine expressing the TeC-tetrameric fusion did not elicit antibody to the peptide. Sera from mice immunised with a single dose of the dimer and tetramer fusions in the *htrA* strain neutralised HSV in vitro, and the mice were protected from HSV infection as measured by a reduction in virus load in the ear pinna. We have previously shown that mice vaccinated with salmonella expressing TeC are protected against tetanus toxin and virulent *Salmonella* challenge. These results suggest that it may be possible to develop a multivalent vaccine against salmonellosis, tetanus and HSV. Record Date Created: 19961216 Record Date Completed: 19961216

Gomez-Duarte O-G; Calen J; Chatfield S N; Rappuoli R; Eides L; Levine M M
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA.
Vaccine (ENGLAND) Nov 1998; 13 (16) p1596-602. ISSN 0264-410X. Catalogue Code: 8406889

We report the expression of fragment C of tetanus toxin (FC) fused to the eukaryotic cell binding domain (the carboxy-terminus) of diphtheria toxin (FC-bD₁ fusion), in attenuated *S. typhimurium* DT104 vaccine strain CVD 908. The FC-bD₁ protein fusion was constructed using plasmid pTET1r15 which carries the gene encoding FC, under control of the ntrB promoter (ntrBP). The open reading frame for FC was modified to incorporate an in-frame glycine-proline hinge region and a set of four restriction sites at the 3' end of the FC gene. A 482 bp DNA fragment encoding the eukaryotic cell binding domain of diphtheria toxin was then inserted at the 3' end of the modified FC gene to create an in-frame FC-bD₁ fusion gene. The resulting plasmid, pOG215, was able to express the FC-bD₁ fusion protein in both *Escherichia coli* DH5α and *S. typhimurium* CVD 908, as evidenced by Western immunoblots using anti-FC and anti-C-terminal diphtheria toxin monoclonal antibodies. Maximum expression of the FC-bD₁ fusion protein was achieved by growing CVD 908 (pOG215) at the low oxidation-reduction potential of thioglycollate broth, i.e. in conditions that activate ntrBP and drive transcription of the FC-bD₁ fusion gene. Whereas maximum expression of FC alone was also observed using thioglycollate broth, expression of bD₁ alone was unsuccessful using a variety of growth conditions. FC fusions constitute one strategy to "rescue" expression of proteins which are otherwise difficult to express. Record Date Created: 19960312. Record Date Completed: 19960312.

Expression of a large nonoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen.
LaParrotiere H F, Clayton M A, Middlebrook J L
Toxinology Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702-5011, USA.
Toxicon - official journal of the International Society on Toxinology (ENGLAND) Oct. 1995; 33 (10): p1383-6, ISSN 0041-0101 Journal Code: 1307333 Document type: Journal Article, Review, Review, Tutorial Languages: ENGLISH
Main Citation Owner: NLM Record type: Completed

207/99 DIALOG/RJfile 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
09916932 21826459 PMID: 11741886
The binary Clostridium botulinum C2 toxin as a protein delivery system: identification of the minimal protein region necessary for interaction of toxin components.

25. D-79104 Freiburg Germany, barthh@uni-freiburg.de
Journal of biological Chemistry (United States) Feb 15 2002. 277 (7) p5674-81. ISSN 0021-9258 Journal Code: 2965121R
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
The binary Clostridium botulinum C2 toxin is composed of the enzyme component C2i and the binding component C2ii, which are individual and non-linked proteins. Activated C2iia mediates cell binding and translocation of C2i into the cytoplasm. C2i

ADP-ribosylates G-actin at Arg-177 to depolymerize actin filaments. A fusion toxin containing the N-terminal domain of C21 (residues 1-225) transports C3 ADP-ribosyltransferase from *Clostridium botulinum* into cells (Barth, H., Hofmann, F., Olenik, C., Just, I., and Aktories, K. (1998) *Infect. Immun.* 66, 1364-1369). We characterized the adaptor function of C21 and its interaction with C21a. The fusion toxin GST-C21(1-225)-C3 was efficiently transported by C21a, indicating that C21a translocates proteins into the cytosol even when the C21(1-225) adaptor was positioned in the middle of a fusion protein. Amino acid residues 1-87 of C21 were sufficient for interaction with C21a and for translocation of C21 fusion toxins into HeLa cells. Residues 1-87 were the minimal part of C21 to bind to C21a on the cell surface, as detected by fluorescence-activated cytometry. An excess of C21(1-87) but not of further truncated C21 fragments) competed with Alexa488-labeled C21 for binding to C21a. Also, the fragment C21(3-431) and the fusion toxin C21(30-225)-C3 competed with C21-Alexa488 for binding to C21a. C21(30-225)-C3 did not induce cytotoxic effects on cells when applied together with C21a, indicating that amino acid residues 1-25 are involved in translocation of C21 but are not absolutely essential for binding to C21a. Record Date Created: 20020221 Record Date Completed: 20020323

21/6/3 10600306 95417858 PMID: 882049

A Salmonella typhimurium hit a live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Feb 1996

expression and purification of the light chain of volumin (newcastle A. a single mutation abolishes its cleavage of viral -23 and nonviral after reconstitution with the heavy chain. Nov 21 1995

206/101 09786731 21593241 PMID: 11757697
New strategies for vaccination and immunomodulation in NHL. 2001

2016/103 09784045 21590233 PMID: 11733060
Remodeling of synaptic actin induced by photoconductive stimulation. Nov 30 2001

206/105 09683906 21475804 PMID: 11591816
Rho-dependent transfer of Citron-kinase to the cleavage furrow of dividing cells Sep 2001

206/107 09588715 21372433 PMID: 11479570
Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Aug 2001

206/109 09574549 21357442 PMID: 11464916
Lactic acid bacteria as live vaccines. Jan 2000

206/11 09544048 21324877 PMID: 11431570
Conditional restoration of hippocampal synaptic potentiation in Glu-A-deficient mice Jun 29 2001

206/113 09490505 21267040 PMID: 11356871
A common exocytic mechanism mediates axonal and dendritic outgrowth. Jun 1 2001

- 206/114 09481963 21268150 PMID: 11358482
Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment. May 2001
- 206/115 09445588 21217457 PMID: 11321150
Heterologous gene expression in bacterial systems under reduced oxygen tensions. Small-scale optimization precedes industrial fermentation. Feb 2001
- 206/116 09414709 21181853 PMID: 11285284
Restriction of secretory granule motion near the plasma membrane of chromaffin cells. Apr 2 2001
- 206/117 09410039 21176902 PMID: 11281322
Sup3p yeast prion-like protein as an adapter for production of the Gag-p55 antigen of HIV-1 and the L-chain of botulinum neurotoxin in *Saccharomyces cerevisiae*. Jan-Feb 2001
- 206/118 09384540 21148517 PMID: 11253870
Recombinant vaccines against infectious hematopoietic necrosis virus: production by the *Caulobacter crescentus* S-layer protein secretion system and evaluation in laboratory trials. Jan 26 2001
- 206/119 09382538 21145885 PMID: 11248119
Genetically altered AMPA-type glutamate receptor kinetics in interneurons disrupt long-range synchrony of gamma oscillation. Mar 13 2001
- 206/120 09355316 21116968 PMID: 11179324
Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Mar 2001
- 206/121 08342103 21101372 PMID: 11165271
Assessment of a vaccinia virus vectored multi-epitope live vaccine candidate for Plasmodium falciparum. Jan 2001
- 206/122 09341772 21100916 PMID: 11168632
Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell proliferation and can prevent the induction of non-responsiveness by CTLA-4g. Jan 2001
- 206/123 09292031 21029392 PMID: 11191108
RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Sep-Oct 2000
- 206/124 09182865 20489211 PMID: 11036518
Rho GTPases: secretion and actin dynamics in permeabilized mast cells. 2000
- 206/125 09149087 20451065 PMID: 10995446
- 206/126 09112657 20411243 PMID: 10954418
Membrane localization and biological activity of SNAP-25 cysteine mutants in insulin-secreting cells. Sep 2000
- 206/127 09104452 20402597 PMID: 10944231
Ca2+-dependent regulation of synaptic SNARE complex assembly via a calmodulin- and phospholipid-binding domain of synaptobrevin. Aug 15 2000
- 206/128 09092184 20389730 PMID: 10930684
Cloning, expression and evaluation of a recombinant sub-unit vaccine against *Clostridium botulinum* type F toxin. Sep 15 2000
- 206/129 09030890 20324939 PMID: 10865133
Measurement of exocytosis by amperometry in adrenal chromaffin cells: effects of clostridial neurotoxins and activation of protein kinase C on fusion pore kinetics. May 2000
- 206/130 09002366 20294906 PMID: 10833399
Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A. Jun 2000
- 206/131 08996880 20289121 PMID: 10830309
The activation of phospholipase D by endothelin-1, angiotensin II, and platelet-derived growth factor in vascular smooth muscle A10 cells is mediated by small G proteins of the ADP-ribosylation factor family. Jun 2000
- 206/132 08990056 20281858 PMID: 10820215
Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. Jun 2000
- 206/133 08953915 20243570 PMID: 10779774
Characterization of human inducible costimulator ligand expression and function. May 1 2000
- 206/134 08942669 20231879 PMID: 10769020
EpHn-A5 induces collapse of growth cones by activating Rho and Rho kinase. Apr 17 2000
- 206/135 08942573 20231782 PMID: 10768937
Tetanus toxin fragment C expressed in live *Salmonella* vaccines enhances antibody responses to its fusion partner Schistosoma haematobium glutathione S-transferase. May 2000
- 206/136 08922959 20211255 PMID: 10744952
High-level expression of tetanus toxin fragment C-thioredoxin fusion protein in *Escherichia coli*. Apr 2000
- 206/137 08916837 20203748 PMID: 10741704
Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Mar 2000
- 206/138 08914955 20202759 PMID: 10736202
Ecopic expression of NCAM in skeletal muscle of transgenic mice results in terminal sprouting at the neuromuscular junction and altered structure but not function. Mar 2000
- 206/139 08912838 20200471 PMID: 10734125
Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. Mar 31 2000
- 206/140 08900494 20187498 PMID: 10722622
Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Apr 2000
- 206/141 08900479 20187483 PMID: 10722607
Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelli merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19). Apr 2000
- 206/142 08883909 20170179 PMID: 10707906
A somatic gene transfer approach using recombinant fusion proteins to map muscle-motoneuron projections in *Xenopus* spinal cord. Nov 1999
- 206/143 08873167 20158951 PMID: 10692440
G protein modulation of N-type calcium channels is facilitated by physical interactions between syntaxin 1A and Gbetagamma. Mar 3 2000
- 206/144 08865185 20141225 PMID: 10676534
Identification and characterization of functional subunits of *Clostridium botulinum* type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. Feb 11 2000
- 206/145 08766143 20047427 PMID: 10582602
Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis. Dec 1999
- 206/146 08715029 95403634 PMID: 7673393
Generation of an expression library in the baculovirus expression vector system. Jun 1995
- 206/147 08659250 95347847 PMID: 7622252
Characterization of recombinant tetanus toxin derivatives suitable for vaccine development. Aug 1995
- 206/148 08649251 95337845 PMID: 7613218
Cloning of human anti-IgE autoantibodies and their role in the regulation of IgE synthesis. May-Jun 1995
- 206/149 08638422 95326951 PMID: 7603339
Engine ring human monoclonal antibody fragments: a recombinant enzyme-linked Fab. Apr 1995
- 206/150 08621485 95310012 PMID: 7790070
Influence of preimmunization with tetanus toxoid on immune responses to tetanus toxin fragment C-guest antigen fusions in a *Salmonella* vaccine carrier. Jul 1995
- 206/151 08548161 95238461 PMID: 7720079
Utilization of soluble fusion proteins for induction of T cell proliferation. Feb 1995
- 206/152 08508902 95197178 PMID: 7534271
Immunogenic combinations of HIV-1 B- and heterologous T-cell epitopes. Oct 1994
- 206/153 08490963 95179179 PMID: 7874174
Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nov 1994
- 206/154 08393632 95081611 PMID: 7527446
Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live attenuated vaccine strain of *Salmonella*. Dec 15 1994
- 206/155 08363150 95051122 PMID: 7962205
Probing the action of *Clostridium difficile* toxin B in *Xenopus laevis* oocytes. Jun 1994
- 206/156 08326441 95014411 PMID: 7929302

Activation of rat liver phospholipase D by the small GTP-binding protein RhoA. Oct 21 1994

20/6/157 08323681 95011651 PMID: 7926831
Phage display of a human antibody against Clostridium tetani toxin. Oct 11 1994

20/6/158 08289729 94355968 PMID: 8075633
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain VACs. May 1994

20/6/159 08248894 94314916 PMID: 7913711
Autoantigen-specific T cell proliferation induced by the ribosomal P2 protein in patients with systemic lupus erythematosus. Jul 1994

20/6/160 08217913 94283856 PMID: 8013871
Cloning, sequencing and expression in *Escherichia coli* of the gene encoding component S of the coenzyme B12-dependent glutamate mutase from *Clostridium coccleatum*. May 1 1994

20/6/161 08214919 94280880 PMID: 8011337
A post-docking role for synaptobrevin in synaptic vesicle fusion. Jun 1994

20/6/162 08198098 94264020 PMID: 7911329
A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Jun 7 1994

20/6/163 08193553 94259475 PMID: 8200692
Assays for adjuvanticity of new formulations and of carrier proteins for inducing antibody responses to selected immunogens in the squirrel monkey *Samiti sciureus*. Apr 1994

20/6/164 08065830 94131577 PMID: 7507893
Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Feb 1994

20/6/165 08043965 94109700 PMID: 8282204
Cloning in a bacteriophage lambda vector for the display of binding proteins on filamentous phage. Dec 27 1993

20/6/166 07907600 93368431 PMID: 8361360
Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Jun 1993

20/6/167 07882039 93342856 PMID: 8333605
Comparison of the effects of adjuvants and adjuvant doses on the quantitative and qualitative antibody response to selected antigens in New World squirrel monkeys *Samiti sciureus*. 1993

20/6/168 07845929 93301597 PMID: 7686212
Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. Jul 1 1993

20/6/169 07843212 93258880 PMID: 8618367
Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. Apr 1993

20/6/170 07829910 93265459 PMID: 8508952
A bacteriophage lambda vector for the cloning and expression of immunoglobulin Fab fragments on the surface of filamentous phage. Jun 15 1993

20/6/171 07753752 93209239 PMID: 8458345
A chimeric toxin to study the role of the 21 kDa GTP binding protein rho in the control of actin microfilament assembly. Mar 1993

20/6/172 07707454 93162704 PMID: 1286873
Therapeutic human antibodies derived from PCR amplification of B-cell variable regions. Dec 1992

20/6/173 07386559 92249751 PMID: 1577256
Cloning of a *Clostridium botulinum* type B toxin gene fragment encoding the N-terminus of the heavy chain. Feb 1 1992

20/6/174 07351768 92214927 PMID: 1805685
Effects of a soluble CDA and CDA-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro. Oct 1991

20/6/175 07134855 91376069 PMID: 1896445
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Sep 15 1991

20/6/176 07131767 91372981 PMID: 1910014
Characterization of the C3 gene of *Clostridium botulinum* types C and D and its expression in *Escherichia coli*. Oct 1991

20/6/177 06865780 91105879 PMID: 1988163
Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein. Feb 1991

20/6/178 06410899 90035423 PMID: 2478475
Expression of tetanus toxin subfragments in vitro and characterization of epitopes. Nov 1989

20/7/136 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
089229395 20211255 PMID: 10744952
High-level expression of tetanus toxin fragment C-thioredoxin fusion protein in *Escherichia coli*.
Rivas A V, Ho P L, Tanizaki M M, Raw I, Nascimento A L
Center of Biotechnology, Instituto Butantan, Av. Vital Brasil, 1500, CEP 05503-900, Sao Paulo, SP, Brazil.
Biotechnology and applied biochemistry (ENGLAND) Apr 2000, 31 (Pt 2) p91-4, ISSN 0885-4513 Journal Code: 860946
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
An insert of *Clostridium tetani* DNA corresponding to fragment C of tetanus toxin was amplified by PCR. This 1.4 kb fragment was cloned into the high-expression vector DE1732a, under control of the T7 promoter. Expression of this plasmid in *Escherichia coli* BL21(DE3) resulted in the production of a fusion protein (approximately 62 kDa) consisting of 112 amino acids of thioredoxin and approximately 450 amino acids of fragment C. This fusion protein was recognized by anti-tetanus toxinoid antiserum in an ELISA and an immunoblot. The recombinant fragment-C-thioredoxin protein was purified significantly in one step by Ni(2+)-chelex Sepharose, the final yield being approximately 35 mg/l. Immunization of animals with the recombinant protein produce antibodies that were able to recognize the tetanus toxin. By using this gene-fusion expression system we produced soluble fragment C of tetanus toxin in a high yield, preventing many problems inherent in the use of other expression systems that produce either insoluble fragment C in inclusion bodies, or a soluble form, but in low yield, using *E. coli* as the expression host Record Date Created: 20000525 Record Date Completed: 20000525

20/7/132 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
089900056 20281858 PMID: 10820215
Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: potential vector for delivering heterologous proteins to neurons.
Francis J W, Brown R H, Figueiredo D, Remington M P, Castillo O, Schwarzschild M A, Fishman P S, Murphy J R, van der Spek J C
Cecil B. Day Center for Neuromuscular Research, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA, francis@helix.harvard.edu
Journal of neurochemistry (UNITED STATES) Jun 2000, 74 (6) p2528-36, ISSN 0022-3042 Journal Code: 2985190R
Contract/Grant No.: 1P01NS31248-02; NS; NINDS; 5F32HS10064; HS; AHCPR; R01 NS38679-01; NS; NINDS
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
This study describes the expression, purification, and characterization of a recombinant fusion toxin, DAB(389)TTC, composed of the catalytic and membrane translocation domains of diphtheria toxin (DAB(389)) linked to the receptor binding fragment of tetanus toxin (C-fragment). As determined by its ability to inhibit cellular protein synthesis in primary neuron cultures, DAB(389)TTC was approximately 1,000-fold more cytotoxic than native diphtheria toxin or the previously described fusion toxin DAB(389)NSH. The cytotoxic effect of DAB(389)TTC on cultured cells was specific toward neuronal-type cells and was blocked by coinubation of the chimeric toxin with tetanus antitoxin. The toxicity of DAB(389)TTC, like that of diphtheria toxin, was dependent on passage through an acidic compartment and ADP-ribosyltransferase activity of the DAB(389) catalytic fragment. These results suggest that a catalytically inactive form of DAB(389)TTC may be useful as a nonviral vehicle to deliver exogenous proteins to the cytosolic compartment of neurons. Record Date Created: 20000602 Record Date Completed: 20000602

20/7/114 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
09481983 21258150 PMID: 11358482
Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment.
Bordet T, Caselhan-Parkline L, Fauchereau F, Frocourt G, Kahn A, Haase G
INSERM U.129, Institut Cochin de Genetique Moleculaire, 24 Rue du Faubourg St Jacques, 75014 Paris, France.
Molecular and cellular neurosciences (United States) May 2001, 17 (5) p842-54, ISSN 1044-7431 Journal Code: 910009
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
Cardiotrophin-1 (CT-1) is a potent neurotrophic factor for motoneurons but its clinical use in motor neuron diseases is precluded by side effects on the heart and liver. We explored the possibility of targeting CT-1 to neurons by coupling with the tetanus toxin fragment TTC. Genetic fusion proteins between CT-1 or GFP and TTC were produced in *Escherichia coli* and assayed in vitro contrast to uncoupled CT-1 or GFP. TTC-coupled proteins bound with high affinity to cerebral neurons and spinal cord motoneurons and were rapidly internalized. Glia, hepatocytes, or cardiomyocytes did not show detectable binding or uptake of TTC-coupled proteins. Similar to CT-1, TTC-coupled CT-1 induced IL-6 secretion by KB cells, activated Reg-2 gene expression and promoted motoneuron survival in a dose-dependent manner. In vivo studies will test whether TTC-coupled CT-1 might be targeted to degenerating spinal cord or brain-stem motoneurons and migrate trans-synaptically to cortical motoneurons, which are also affected in amyotrophic lateral sclerosis. Copyright 2001 Academic Press. Record Date Created: 20010518 Record Date Completed: 20010809

Tags: Animal, Human, Support, Non-U.S. Gov't Descriptors: Cells, Cultured--drug effects--DE, *Cytokines--pharmacology--PD, *Motor Neuro Disease--drug therapy--DT, *Motor Neurons--drug effects--DE, *Nerve Growth Factors--pharmacology--PD, *Peptide Fragments--pharmacology--PD, *Recombinant Fusion Proteins--pharmacology--PD, *Tetanus Toxin--pharmacology--PD, Brain--cytology--CY, Brain-

drug effects--DE; Brain-metabolism--ME; Cell Survival--drug effects--DE; Cell Survival--physiology--PH; Cells, Cultured--cytology--CY; Cells, Cultured--metabolism--ME; Cytokines--genetics--GE; Dose-Response Relationship, Drug; Escherichia coli--genetics--GE; Feus; Gene Expression--drug effects--DE; Gene Expression--physiology--PH; Heart--drug effects--DE; Heart--physiology--PH; Hepatocytes--cytology--CY; Hepatocytes--drug effects--DE; Hepatocytes--metabolism--ME; Interleukin-6--genetics--GE; Interleukin-6--metabolism--ME; Interleukin-6--secretion--SE; Luminescent Proteins--analysis--AN; Luminescent Proteins--genetics--GE; Motor Neuron Disease--metabolism--ME; Motor Neuron Disease--physiology--CY; Motor Neurons--cytology--CY; Motor Neurons--metabolism--ME; Nerve Growth Factors--genetics--GE; Peptide Fragments--genetics--GE; Protein Engineering--methods--MT; Recombinant Fusion Proteins--chemical synthesis--CS; Recombinant Fusion Proteins--genetics--GE; Signal Transduction--drug effects--DE; Signal Transduction--genetics--GE; Spinal Cord--cytology--CY; Spinal Cord--drug effects--DE; Spinal Cord--metabolism--ME; Tetanus Toxin--genetics--GE; CAS Registry No.: 0 (Cytokines); 0 (Interleukin-6); 0 (Luminescent Proteins); 0 (Nerve Growth Factors); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Tetanus Toxin); 0 (Dialcophen 1); 0 (Tetanus toxin fragment C); 147336-22-9 (green fluorescent protein)

207/151 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

08548161 95256461 PMID: 7720079

Utilization of soluble fusion proteins for induction of T cell proliferation.

Kirschman D A; De Ciecti P A; Bono C P; Zachris M L; Schwartz B D; Wouffe S L

Department of Immunology and Glycobiology, Monsanto Corporate Research&G, D. Seate, St. Louis, Missouri 63198, USA.

Cellular immunology (UNITED STATES) Feb 1995, 160 (2) p193-8, ISSN 0008-8749 Journal Code: 1246405

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

A peptide display library was evaluated as a means to identify peptide binding motifs for class II molecules. Peptides expressed as part of a soluble fusion protein with a maltose binding protein (malE) were produced by Escherichia coli. Constructs containing the high-affinity binding influenza hemagglutinin peptide 307W-319 (mal-HA) or the low-affinity binding tetanus toxoid peptide 830-843 (mal-TT) were used as controls. mal-HA, but not mal-TT, inhibited synthetic biotinylated-HA peptide from binding to purified DR4 DW4 molecules in a dose-dependent manner. The fusion-peptide presentation system was also evaluated for its ability to induce antigen-specific T cell proliferation. DR4 DW4-B cells pulsed with mal-HA, but not mal-TT, induced dose-dependent proliferation of an HA-specific DR4 DW4-restricted T cell line to the same extent as synthetic HA peptide. Using this type of peptide display library, it may be possible to determine the antigenic specificity of T cell clones isolated from patients with autoimmune diseases. Record Date Created: 19950522 Record Date Completed: 19950522

207/164 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

08065830 94131577 PMID: 7507893

Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Boucher P; Sato H; Sato Y; Loeth C

Laboratoire de Microbiologie Genetique et Moleculaire, Institut Pasteur de Lille, France.

Infection and immunity (UNITED STATES) Feb 1994, 62 (2) p449-56, ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The currently available diphtheria-tetanus-whole-cell pertussis (DTP) vaccines are associated with a variety of problems, including undesirable side effects and inconsistent efficacy. These problems are probably related to the poor definition of such vaccines, especially with respect to the whole-cell component against pertussis. Ideal vaccines should include only immunoprotective antigens with no toxin activity. As an initial step towards obtaining a well-defined and simplified DTP vaccine, a pertussis toxin-tetanus toxin chimeric protein was constructed. A soluble form of the pertussis toxin S1 subunit was fused to the protective fragment C of tetanus toxin, and the recombinant hybrid protein was produced in Escherichia coli. The 75-kDa fusion protein (p75) was overexpressed as a soluble molecule and purified to near homogeneity by two consecutive chromatographic steps. Purified p75 retained its ability to bind to ganglioside GT1b, the receptor for tetanus toxin, and to be recognized by protective and neutralizing anti-pertussis toxin antibodies specific for conformational epitopes. When administered to mice, the hybrid protein was found to be nontoxic but immunogenic. In addition, it was capable of inducing strong protection against tetanus and some protection against pertussis, as well as eliciting a pertussis toxin-neutralizing antibody response. Although the levels of anti-pertussis toxin antibodies were rather low, neutralizing titers of the immunized mice correlated well with anti-pertussis toxin titers, indicating that protective epitopes are conserved in the recombinant protein. Record Date Created: 19940304 Record Date Completed: 19940304

237/1 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11119318 97413668 PMID: 9270054

Postischemic infusion of Cu/Zn superoxide dismutase or SOD1:e451 reduces cerebral infarction following focal ischemia/reperfusion in rats.

Francis J W; Ren J; Warren L; Brown R H; Finkbein S P

Cecil B. Day Laboratory for Neuromuscular Research, Massachusetts General Hospital, Charlestown 02129, USA.

Experimental neurology (UNITED STATES) Aug 1997, 146 (2) p435-43, ISSN 0014-4886 Journal Code: 0370712

Contract/Grant No.: 1P01AG12992-01; AG; NIA; 1P01NS31248-04; NS; NINDS; P01 NS 10828; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Oxygen-free radicals play a major role in neuronal cell injury following cerebral ischemia/reperfusion. The free-radical scavenging enzyme, Cu/Zn superoxide dismutase (SOD-1), ameliorates various types of brain injury resulting from temporary CNS ischemia. We have compared the cerebroprotective properties of human SOD-1 (hSOD-1) with a novel recombinant SOD-1

hybrid protein, SOD1:e451, composed of hSOD-1 linked to the neuronal binding fragment of tetanus toxin (TTXC). Following of temporary middle cerebral artery occlusion, rats infused with equivalent activities of either hSOD-1 or SOD1:e451 for the initial 3 h of reperfusion showed reductions in cerebral infarct volume of 43 and 57%, respectively, compared to saline-treated controls (P < 0.01). Serum hSOD-1 concentrations in rats receiving SOD1:e451 were seven-fold higher than those in rats receiving the native enzyme. Animals treated with SOD1:e451 also demonstrated an extended persistence of hSOD-1 in the bloodstream during drug washout as compared to animals given free enzyme. Immunohistochemical examination of brain sections from an SOD1:e451-treated ischemic rat showed positive immunoreactivity in the ipsilateral cerebral cortex using eit anti-TTXXC or anti-human SOD-1 antibodies. Our results document that both hSOD-1 and SOD1:e451 significantly reduce bra infarct volume in a model of transient focal ischemia/reperfusion in rats. Additionally, our findings suggest that the cerebroprotective effects of SOD-1 may be enhanced by neuronal targeting as seen with the hybrid protein SOD1:e451. Reco Date Created: 19970919 Record Date Completed: 19970919

237/2 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11056318 97413668 PMID: 9270054

Postischemic infusion of Cu/Zn superoxide dismutase or SOD1:e451 reduces cerebral infarction following focal ischemia/reperfusion in rats.

Francis J W; Ren J; Warren L; Brown R H; Finkbein S P

Cecil B. Day Laboratory for Neuromuscular Research, Massachusetts General Hospital, Charlestown 02129, USA.

Experimental neurology (UNITED STATES) Aug 1997, 146 (2) p435-43, ISSN 0014-4886 Journal Code: 0370712

Contract/Grant No.: 1P01AG12992-01; AG; NIA; 1P01NS31248-04; NS; NINDS; P01 NS 10828; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Oxygen-free radicals play a major role in neuronal cell injury following cerebral ischemia/reperfusion. The free-radical scavenging enzyme, Cu/Zn superoxide dismutase (SOD-1), ameliorates various types of brain injury resulting from temporary CNS ischemia. We have compared the cerebroprotective properties of human SOD-1 (hSOD-1) with a novel recombinant SOD hybrid protein, SOD1:e451, composed of hSOD-1 linked to the neuronal binding fragment of tetanus toxin (TTXXC). Following of temporary middle cerebral artery occlusion, rats infused with equivalent activities of either hSOD-1 or SOD1:e451 for the initial 3 h of reperfusion showed reductions in cerebral infarct volume of 43 and 57%, respectively, compared to saline-treated controls (P < 0.01). Serum hSOD-1 concentrations in rats receiving SOD1:e451 were seven-fold higher than those in rats receiving the native enzyme. Animals treated with SOD1:e451 also demonstrated an extended persistence of hSOD-1 in the bloodstream during drug washout as compared to animals given free enzyme. Immunohistochemical examination of brain sections from an SOD1:e451-treated ischemic rat showed positive immunoreactivity in the ipsilateral cerebral cortex using eit anti-TTXXC or anti-human SOD-1 antibodies. Our results document that both hSOD-1 and SOD1:e451 significantly reduce bra infarct volume in a model of transient focal ischemia/reperfusion in rats. Additionally, our findings suggest that the cerebroprotective effects of SOD-1 may be enhanced by neuronal targeting as seen with the hybrid protein SOD1:e451. Reco Date Created: 19970919 Record Date Completed: 19970919

237/3 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

08990056 20281858 PMID: 10820215

Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: potential vector for delivering heterologous proteins to neurons.

Francis J W; Brown R H; Figueiredo D; Remington M P; Castillo O; Schwarzschild M A; Fishman P S; Murphy J R; vanderSpek J C

Cecil B. Day Center for Neuromuscular Research, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown MA 02129, USA. francis@helix.mgh.harvard.edu

Journal of neurochemistry (UNITED STATES) Jun 2000, 74 (6) p2528-36, ISSN 0022-3042 Journal Code: 2985190R

Contract/Grant No.: 1P01NS31248-02; NS; NINDS; 5F32HS10064; HS; AHCPR; R01 NS38679-01; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

This study describes the expression, purification, and characterization of a recombinant fusion toxin, DAB(389)JTTTC, compose of the catalytic and membrane translocation domains of diphtheria toxin (DAB(389)) linked to the receptor binding fragment of tetanus toxin (C-fragment). As determined by its ability to inhibit cellular protein synthesis in primary neuron cultures, DAB(389)JTTTC was approximately 1,000-fold more cytotoxic than native diphtheria toxin or the previously described fusion toxin DAB(389)MSH. The cytotoxic effect of DAB(389)JTTTC on cultured cells was specific toward neuronal-type cells and was blocked by concoluation of the chimeric toxin with tetanus antitoxin. The toxicity of DAB(389)JTTTC, like that of diphtheria toxin, was dependent on passage through an acidic compartment and ADP-ribosyltransferase activity of the DAB(389) catalytic fragment

These results suggest that a catalytically inactive form of DAB(389)JTTTC may be useful as a nonviral vehicle to deliver exogenous proteins to the cytosolic compartment of neurons. Record Date Created: 20000602 Record Date Completed: 20000602

Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S. Descriptors: Hippocampus--metabolism--ME; Immunotoxicity--metabolism--ME; Neurons--metabolism--ME; Peptide Fragments--metabolism--ME; Superoxide Dismutase metabolism--ME; Tetanus Toxin--metabolism--ME; Base Sequence; Biological Transport; Blotting, Western; Cell Line; Cells, Cultured; Cloning Molecular; DNA Primers; Electrophoresis; Polysaccharide Gel; Immunotoxicity; Immunotoxins--administration and dosage--AD; Kinetics Molecular Sequence Data; Peptide Fragments--administration and dosage--AD; Peptide Fragments--biosynthesis--BI; Polymerase Chain Reaction; Protein Hybridization; Rats; Restriction Mapping; Superoxide Dismutase--administration and dosage--AD; Superoxide Dismutase--

bioynthesis-BI; Tetanus Toxin--administration and dosage-AD; Tetanus Toxin--biosynthesis-BI (CAS Registry No.: 0 (DNA Primers); 0 (Immunotoxins); 0 (Peptide Fragments); 0 (Tetanus Toxin); 0 (Tetanus toxin fragment C); Enzyme No.: EC 1.15.1.1 (Superoxide Dismutase)

23/6/4 09629500 95318117 PMID: 7797532
CuZn superoxide dismutase (SOD-1); tetanus toxin fragment C hybrid protein for targeted delivery of SOD-1 to neuronal cells. Jun 23 1995

09Jan04 12:55:17 User208600 Session D1604.3

File 34:SciSearch(R) Cited Ref Sci 1990-2004Jan W1 (c) 2004 Inst for Sci Info

Set Items Description

*** *****

Ref Items Index:tem
E1 1 CR=FRANCIS J, 1994, V40, P829, J AM GERIATR SOC
E2 1 CR=FRANCIS J, 1994, V99, P395, J GEOPHYS RES
E3 0 CR=FRANCIS J, 1995
E4 1 CR=FRANCIS J, 1995, BERICHT KARTZEHN
E5 1 CR=FRANCIS J, 1995, BLOOD CONSERVATION A
E6 1 CR=FRANCIS J, 1995, P26, WORLD INGRES MAR
E7 1 CR=FRANCIS J, 1995, P34, WORLD INGRES MAR
E8 2 CR=FRANCIS J, 1995, P7, TRANSFORMATION TROP
E9 1 CR=FRANCIS J, 1995, V19, P383, J ACCOUNT ECON
E10 1 CR=FRANCIS J, 1995, V329, P208, NEW ENGL J MED
E11 4 CR=FRANCIS J, 1995, V43, P565, J AM GERIATR SOC
E12 1 CR=FRANCIS J, 1995, V50, P581, PHARMACOL BIOCHEM
E13 6 CR=FRANCIS J, 1995, V50, P581, PHARMACOL BIOCHEM
E14 1 CR=FRANCIS J, 1996, DRAUGHT ANIMAL POWER
E15 1 CR=FRANCIS J, 1996, P326, NATURAL FOOD COLORAN
E16 1 CR=FRANCIS J, 1996, P67, IMPROVING RUMINANT P
E17 3 CR=FRANCIS J, 1996, P917, GERIATRIC MED
E18 1 CR=FRANCIS J, 1996, V125, P421, ANN INTERN MED
E19 6 CR=FRANCIS J, 1996, V5, P103, CNS DRUGS

E20 1 CR=FRANCIS J, 1996, V77, PS290, OXYGEN ISOTOPIC Z
E21 1 CR=FRANCIS J, 1996, V9, P861, COLLOID SURF A
E22 1 CR=FRANCIS J, 1997, INTERDISCIPLINARY SU
E23 1 CR=FRANCIS J, 1997, J PROCESSES MECH ENG
E24 1 CR=FRANCIS J, 1997, J JOURNEY ARUSHA SEYCH

Ref Items Index:tem
E1 3 CR=FRANCIS JW, 1996, V112, P317, J MOL CATAL A-CH
E2 1 CR=FRANCIS JW, 1996, V26, P192, J COLL SCI TEACH
E3 0 CR=FRANCIS JW, 1997
E4 12 CR=FRANCIS JW, 1997, V146, P435, EXP NEUROL
E5 1 CR=FRANCIS JW, 1997, V23, SOC NEUR ABSTR
E6 29 CR=FRANCIS JW, 1998, V95, P6492, P NATL ACAD SCI
E7 2 CR=FRANCIS JW, 2000, V62, P90, AM BIOL TEACH
E8 7 CR=FRANCIS JW, 2000, V74, P2528, J NEUROCHEM
E9 1 CR=FRANCIS K, UNPUB
E10 1 CR=FRANCIS K, V92, P3616, BLOOD
E11 1 CR=FRANCIS K, 1995, V45, AM J PUBLIC HLTH 2 S
E12 1 CR=FRANCIS K, 1971, NZ KIWI

Ref Items Index:tem
E1 1 CR=FRANCIS JW, 1994, V17, P7, NEUROTOXICOL TERATO
E2 1 CR=FRANCIS JW, 1994, V56, P464, AM BIOL TEACH
E3 0 CR=FRANCIS JW, 1995
E4 25 CR=FRANCIS JW, 1995, V17, P7, NEUROTOXICOL TERATO
E5 2 CR=FRANCIS JW, 1995, V270, P15432, J BIOL CHEM
E6 22 CR=FRANCIS JW, 1995, V270, P15434, J BIOL CHEM

3/6/1 11080385 Genuine Article#: 602XU Number of References: 129
Title: Clostridial neurotoxins (ABSTRACT AVAILABLE) Publication date: 20020000

3/6/2 09710099 Genuine Article#: 437CE Number of References: 58

Title: Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment (ABSTRACT AVAILABLE) Publication date: 20010500

3/6/3 08930221 Genuine Article#: 345OX Number of References: 46

Title: Protective effect of supplemental superoxide dismutase on survival of neuronal cells during starvation - Requirement for cytosolic distribution (ABSTRACT AVAILABLE) Publication date: 20000600

3/6/4 08657931 Genuine Article#: 312XG Number of References: 52

Title: Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: A potential vector for delivering heterologous proteins to neurons (ABSTRACT AVAILABLE) Publication date: 20000600

3/6/5 08604608 Genuine Article#: 306PP Number of References: 26

Title: High-level expression of tetanus toxin fragment C-histidine fusion protein in Escherichia coli (ABSTRACT AVAILABLE) Publication date: 20000400

3/6/6 08346824 Genuine Article#: 274MM Number of References: 41

Title: A somatic gene transfer approach using recombinant fusion proteins to map muscle-motoneuron projections in Xenopus spinal cord (ABSTRACT AVAILABLE) Publication date: 19931100

3/6/7 07482407 Genuine Article#: 171LB Number of References: 149

Title: Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses (ABSTRACT AVAILABLE) Publication date: 19902228

3/6/8 07199829 Genuine Article#: 135NQ Number of References: 42

Title: Tracing axons (ABSTRACT AVAILABLE) Publication date: 19981000

3/6/9 06171745 Genuine Article#: YA203 Number of References: 30

Title: Structure of the receptor binding fragment H-C of tetanus neurotoxin (ABSTRACT AVAILABLE) Publication date: 19971000

3/6/10 06055012 Genuine Article#: XRT65 Number of References: 41

Title: Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system (ABSTRACT AVAILABLE) Publication date: 19970819

E7 1 CR=FRANCIS JW, 1995, V270, P5434, J BIOL CHEM
E8 1 CR=FRANCIS JW, 1995, V99, P77, J MOL CATAL
E9 13 CR=FRANCIS JW, 1995, V99, P77, J MOL CATAL A-CHEM
E10 1 CR=FRANCIS JW, 1996, V101, P317, J MOL CATAL A-CH
E11 3 CR=FRANCIS JW, 1996, V112, P317, J MOL CATAL A-CH
E12 1 CR=FRANCIS JW, 1996, V26, P192, J COLL SCI TEACH
E13 12 CR=FRANCIS JW, 1997, V146, P435, EXP NEUROL
E14 1 CR=FRANCIS JW, 1997, V23, SOC NEUR ABSTR
E15 29 CR=FRANCIS JW, 1998, V95, P6492, P NATL ACAD SCI
E16 2 CR=FRANCIS JW, 2000, V62, P90, AM BIOL TEACH
E17 7 CR=FRANCIS JW, 2000, V74, P2528, J NEUROCHEM
E18 1 CR=FRANCIS K, UNPUB
E19 1 CR=FRANCIS K, V92, P3616, BLOOD
E20 1 CR=FRANCIS K, 1995, V45, AM J PUBLIC HLTH 2 S
E21 1 CR=FRANCIS K, 1971, NZ KIWI
E22 1 CR=FRANCIS K, 1979, V35, P23, EXPERIENTIA
E23 1 CR=FRANCIS K, 1982, V52, P11, P NATL ACAD SCI IND
E24 6 CR=FRANCIS K, 1985, V26, P1195, PLANT CELL PHYSIO

S1 50 E4-E7
S2 159230 FUS?
S3 11 S1 AND S2
S4 254001 CHIMER? OR HYBRID?
S5 4 S1 AND S4 NOT S3

3/6/11 05946700 Genuine Article#: XLS37 Number of References: 50
Title: Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport (ABSTRACT AVAILABLE) Publication date: 19970600

3/7/7 DIALOG(R)File 34:SciSearch(R) Cited Ref Sci (c) 2004 Inst for Sci Info. All rts. reserv.
07482407 Genuine Article#: 171LB Number of References: 149

Title: Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses
Author(s): Pelizzari R, Rossetto O, Schiavo G, Montecucco C (REPRINT)
Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR, VIA G COLOMBO 31-35100 PADUA/ITALY (REPRINT); UN
PADUA,CTR BIOMEMBRANE, CNR/35100 PADUA/ITALY; UNIV PADUA,DIPARTIMENTO SCI BIOMEDI/35100

PADUA/ITALY; IMPERIAL CANC RES FUND LAB NEUROBIO/AT/OLONDON WC2A 3PX/ENGLAND/
Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES
1999, V354, N1381 (FEB 28), P259-268 ISSN: 0962-8436 Publication date: 19990228
Publisher: ROYAL SOC LONDON, 6 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND

Language: English Document Type: ARTICLE
Abstract: The clostridial neurotoxins responsible for tetanus and botulism are proteins consisting of three domains endowed w

different functions: neurospecific binding, membrane translocation and proteolysis for specific components of the
neuroexocytosis apparatus. Tetanus neurotoxin (TeNT) binds to the presynaptic membrane of the neuromuscular junction, is
internalized and transported retroaxonally to the spinal cord. The spastic paralysis induced by the toxin is due to the blockade
neurotransmitter release from spinal inhibitory interneurons. In contrast, the seven serotypes of botulinum neurotoxins (BoNT
TeNT and BoNT serotypes B, D, F and G cleave specifically at single but different peptide bonds, of the vesicle associated
membrane protein (VAMP) synaptobrevin, a membrane protein of small synaptic vesicles (SSVs). BoNT types A, C and E
cleave SNAP-25 at different sites located within the carboxy-terminus, while BoNT type C: additionally cleaves syntaxin. The
remarkable specificity of BoNTs is exploited in the treatment of human diseases characterized by a hyperfunction of choliner
terminals.

3/7/11 DIALOG(R)File 34:SciSearch(R) Cited Ref Sci (c) 2004 Inst for Sci Info. All rts. reserv.

05946700 Genuine Article#: XLS37 Number of References: 50

Title: Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axona
transport

Author(s): Figueiredo DM, Halliwell RA (REPRINT) ; Chen LL, Fairweather NF, Dougan G, Savitt JM, Parks DA, Fishman PS
Corporate Source: UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED DEPT BIOCHEM LONDON SW7 2AZ/ENGLAND/
(REPRINT); UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED DEPT BIOCHEM LONDON SW7 2AZ/ENGLAND/
MARYLAND, SCH MED, VAMC, NEUROL SERV/BALTIMORE/MD/21201; UNIV MARYLAND, SCH MED, VAMC, DEPT
NEUROL/BALTIMORE/MD/21201
Journal: EXPERIMENTAL NEUROLOGY, 1997, V145, N2 (JUN), P546-554 ISSN: 0014-4886 Publication date: 19970600
Publisher: ACADEMIC PRESS INC JNL COMP SUBSCRIPTIONS, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
Language: English Document Type: ARTICLE
Abstract: The nontoxic C fragment of tetanus toxin (TC) can transport other proteins from the circulation to central nervous system (CNS) motor neurons. Increased levels of Cu/Zn superoxide dismutase (SOD) are protective in experimental models of stroke and Parkinson's disease, whereas mutations in SOD can cause motor neuron disease. We have linked TC to SOD and purified the active recombinant proteins in both the TC-SOD and SOD-TC orientations. Light microscopic immunohistochemistry and quantitative enzyme-linked immunosorbent assays (ELISA) of mouse brainstem, after intramuscular injection, demonstrate that the fusion proteins undergo retrograde axonal transport and transsynaptic transfer as efficiently as TC alone. (C) 1997 Academic Press.

5/6/1 09361245 Genuine Article#: 396BM Number of References: 39
Title: Interaction of tetanus toxin derived hybrid proteins with neuronal cells (ABSTRACT AVAILABLE) Publication date: 20001100

5/6/2 07912310 Genuine Article#: 223EZ Number of References: 43
Title: Hybrid enzymes (ABSTRACT AVAILABLE) Publication date: 19990800

5/6/3 07467070 Genuine Article#: 169FN Number of References: 35
Title: Non-viral neuronal gene delivery mediated by the H-C fragment of tetanus toxin (ABSTRACT AVAILABLE) Publication date: 19990200

5/6/4 06042440 Genuine Article#: XR266 Number of References: 47
Title: Posts ischemic infusion of Cu/Zn superoxide dismutase or SOD-Tet451 reduces cerebral infarction following focal ischemia/reperfusion in rats (ABSTRACT AVAILABLE) Publication date: 19970800

5/7/2 DIALOG(R)/File 34:SciSearch(R) Cited Ref Sci (c) 2004 Inst for Sci Info. All its. reserv.
07912310 Genuine Article#: 223EZ Number of References: 43

Title: Hybrid enzymes
Author(s): Beguin P (REPRINT)

Corporate Source: INST PASTEUR, DEPT BIOTECHNOL, UNITE PHYSIOL CELLULAIRE, 28 RUE DR ROUX/F-75724 PAR
15/FRANCE/(REPRINT)
Journal: CURRENT OPINION IN BIOTECHNOLOGY, 1999, V10, N4 (AUG), P336-340 ISSN: 0958-1669 Publication date:
19990800 Publisher: CURRENT BIOLOGY LTD, 34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND
Language: English Document Type: REVIEW
Abstract: Combining structural elements belonging to different proteins is a powerful method for generating proteins with new properties. Progress based on detailed structural and functional analysis enables a better integration of the elements to be fit together while preserving or creating functional interactions between them.

5/7/3 DIALOG(R)/File 34:SciSearch(R) Cited Ref Sci (c) 2004 Inst for Sci Info. All its. reserv.
07467070 Genuine Article#: 169FN Number of References: 35

Title: Non-viral neuronal gene delivery mediated by the H-C fragment of tetanus toxin
Author(s): Knight A (REPRINT) ; Carvajal J, Schneider H, Couelle C, Chamberlain S, Fairweather N
Corporate Source: UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED SCH MED CYST FIBROSIS GENE THERAPY
RES GRP/LONDON SW7 2AZ/ENGLAND/(REPRINT); UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED SCH MED
GENE THERAPY RES GRP, SECT MOL GENET/LONDON/ENGLAND/; UNIV LONDON IMPERIAL COLL SCI TECHNOL &
MED SCH MED, ATAXIA GRP, SECT MOL GENET, DIV BIOMED SCI/LONDON/ENGLAND/; UNIV LONDON IMPERIAL
COLL SCI TECHNOL & MED DEPT BIOCHEM LONDON/ENGLAND/
Journal: EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, V259, N3 (FEB), P762-769 ISSN: 0014-2956 Publication date:
19990200 Publisher: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010 Language: English Document Type:
ARTICLE

Abstract: Many inherited neurological diseases and cancers could potentially benefit from efficient targeted gene delivery to neurons of the central nervous system. The nontoxic fragment C (H-C) of tetanus toxin retains the specific nerve cell binding and transport properties of tetanus holotoxin. The H-C fragment has previously been used to promote the uptake of attached proteins such as horseradish peroxidase, beta-galactosidase and superoxide dismutase into neuronal cells in vitro and in vivo. We report the use of purified recombinant H-C fragment produced in yeast and covalently bound to polylysine [poly(K)] to enable binding of DNA. We demonstrate that when used to transfect cells, this construct results in nonviral gene delivery and marker gene expression in vitro in N18 RE 105 cells (a neuroblastoma x glioma mouse/rat hybrid cell line) and F98 (a glioma cell line). Transfection was dependent on H-C and was neuronal cell type specific. H-C may prove a useful targeting ligand to future neuronal gene therapy

Mark a special word or phrase in this record:

Mark!All organism
Clostridium tetani

Select one or more organism in this record:

Submit**EC NUMBER COMMENTARY**

3.4.24.68

RECOMMENDED NAME GeneOntology No.**Tentoxilysin****GO:0000000****SYSTEMATIC NAME**

No entries in this field

SYNONYMS

More

Tentoxylisin**Tetanus neurotoxin****ORGANISM COMMENTARY LITERATURE**

cf. EC 3.4.24.69

SwissProt

CAS REGISTRY NUMBER COMMENTARY

107231-12-9

REACTIONSynaptobrevin + H₂O = hydrolyzed synaptobrevin**COMMENTARY**

Clostridium tetani: structure and mechanism <2, 5, 6>

REACTION TYPE

hydrolysis of peptide bond

ORGANISM COMMENTARY LITERATURE**ORGANISM****Clostridium**
tetani**COMMENTARY**


toxigenic strains N3911 <1>; E 88 (non-sporulating) <3>; Harvard <6>; all toxigenic strains synthesize only one type of neurotoxin <5, 6>


LITERATURE**1-6****SUBSTRATE****PRODUCT****REACTION
DIAGRAM****ORGANISM****COMMENTARY/**
Substrate
r:=reversible
ir:=irreversible**LITERATURE/**
Substrate**COMMENTARY/**
Product**LITERATURE/**
Product

More

?

Clostridium
tetanino substrates are rat
<4,5>; or chicken
<5>; synaptobrevin-1
(with Val76 instead of
Gln76) or short
peptides containing
the cleavage site of
the target protein
<5,6>; catalytic
activity requires
reduction of the
single interchain
disulfide bond of the
neurotoxin <4>i.e. VAMP <5,6>;
neuronal vesicle-
associated**4, 5, 6**

Synaptobrevin + H2O	Hydrolyzed synaptobrevin		Clostridium tetani	membrane protein, MW 19000 <4>; with 2 isoforms in human <4>; chicken <5>; or rat brain <4,5>; ; synaptobrevin/VAMP- 1 and synaptobrevin/VAMP- 2, cleaves at Gln76- Phe77, the same site as botulin neurotoxin B <5,6>	<u>1</u> , <u>2</u> , <u>3</u> , <u>4</u> , <u>5</u> , <u>6</u>	2 peptide fragments, MW 12000 and MW 7000	<u>4</u>
------------------------	-----------------------------	---	-----------------------	---	--	--	----------

NATURAL SUBSTRATE	NATURAL PRODUCT	REACTION DIAGRAM	ORGANISM	COMMENTARY SUBSTRATE	LITERATURE (Substrate)	COMMENTARY PRODUCT	LITERATURE (Product)	ORGANISM (Product)
Synaptobrevin + H2O	-		Clostridium tetani	i.e. VAMP, neuronal vesicle-associated membrane protein, predominantly exposed to cytosol <5>; neurotoxin blocks neurotransmitter release in Aplysia neurons <4>; tetanus neurotoxin receptors are located on the motor neuron plasmalemma at neuromuscular junction, after binding the toxin is internalized inside vesicles of unknown nature and then translocated across the vesicle membrane <5>; enzyme disables neuroexocytosis apparatus, acts at spinal inhibitory interneurons, blocking release of various neurotransmitters to produce spastic paralysis, clostridial neurotoxins are described as the most toxic substances known	<u>4</u> , <u>5</u> , <u>6</u>	-	-	-

COFACTOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

METAL IONS	ORGANISM	COMMENTARY	LITERATURE
Cobalt	Clostridium tetani	zinc-dependent endoproteinase, can replace zinc	<u>5</u>
Nickel	Clostridium tetani	zinc-dependent endoproteinase, can replace zinc	<u>5</u>
Zinc	Clostridium tetani	zinc-dependent endoproteinase <2,4,5,6>; L-chain: form of zinc-endopeptidase, 0.8-1 gatom zinc/mol toxin, bound to light or L-chain <6>; 1 atom zinc per molecule toxin, zinc-binding motif: His- Glu-X-X-His, nickel or cobalt can replace zinc <5>; toxin surface topography of His-residues <2>	<u>2</u> , <u>4</u> , <u>5</u> , <u>6</u>

INHIBITORS	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Ala-Ser-Gln-Phe-Glu- Thr-Ser	Clostridium tetani	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of Aplysia californica	<u>4</u>	● <u>2D-</u> <u>image</u>
	Clostridium			● <u>2D-</u>

Captopril	tetani	-	4, 5	image
EDTA	Clostridium tetani	-	4	2D-image
Gln-Phe-Glu-Thr	Clostridium tetani	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of Aplysia californica	4	2D-image
NaOCl	Clostridium tetani	inactivation	6	2D-image

ACTIVATING COMPOUND	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Proteases	Clostridium tetani	activation by rapid cleavage within an exposed loop of the single inactive MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5,6>; bacterial <5,6>; or tissue proteases <5>	5,6	-

KM VALUE [mM] KM VALUE [mM] Maximum SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

Ki VALUE [mM] Ki VALUE [mM] Maximum INHIBITOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

TURNOVER NUMBER TURNOVER NUMBER MAXIMUM SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

SPECIFIC ACTIVITY [μM/min/mg]	SPECIFIC ACTIVITY MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
additional information	-	Clostridium tetani	in neurotoxin-injected Aplysia neurons 4-10 molecules of L-chains are sufficient to cause blockade of neurotransmitter release with a t1/2 of 20-40 min at 20°C	5

pH OPTIMUM pH MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

pH RANGE pH RANGE MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE OPTIMUM TEMPERATURE OPTIMUM MAXIMUM ORGANISM COMMENTARY LITERATURE

37 - Clostridium tetani assay at 4, 6

TEMPERATURE RANGE TEMPERATURE MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

SOURCE TISSUE ORGANISM COMMENTARY LITERATURE

culture supernatant Clostridium tetani - 6

LOCALIZATION ORGANISM COMMENTARY GeneOntology No. LITERATURE

cytosol Clostridium tetani accumulates until bacterial lysis [GO:0005829](#) 5, 6

ACCESSION CODE ENTRY NAME ORGANISM NO. OF AA MOLECULAR WEIGHT[Da] SOURCE Sequence

No entries in this field

PDB ORGANISM

[1A8D](#), [download](#) Clostridium tetani

[1AF9, download](#) Clostridium tetani
[1DFQ, download](#) Clostridium tetani
[1DIW, download](#) Clostridium tetani
[1DLL, download](#) Clostridium tetani
[1FV2, download](#) Clostridium tetani

MOLECULAR WEIGHT	MOLECULAR WEIGHT MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
150700	-	Clostridium tetani	Clostridium tetani, calculated from amino acid sequence	6
additional information	-	Clostridium tetani	amino acid sequence homologies between tetanus toxin TeNT and botulinum toxins BoNT/A, B and E	3

SUBUNITS	ORGANISM	COMMENTARY	LITERATURE
More	Clostridium tetani	the enzyme consists of a heavy (H) chain and a light (L) chain <2,3>; held together by a single disulfide bond and non-covalent forces <2>; MW 52288 (L-chain) and MW 98300 (H-chain), calculated from amino acid sequence <3>	2 , 3

POSTTRANSLATIONAL MODIFICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

Crystallization/COMMENTARY ORGANISM LITERATURE

No entries in this field

pH STABILITY pH STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE STABILITY TEMPERATURE STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

GENERAL STABILITY ORGANISM LITERATURE

No entries in this field

ORGANIC SOLVENT ORGANISM COMMENTARY LITERATURE

No entries in this field

OXIDATION STABILITY ORGANISM LITERATURE

- Clostridium tetani [6](#)

STORAGE STABILITY	ORGANISM	COMMENTARY	LITERATURE
-80°C, in 10 mM HEPES buffer, pH 7.2, 50 mM NaCl, after freezing in liquid N2, stable	Clostridium tetani	-	6

Purification/COMMENTARY	ORGANISM	LITERATURE
single-chain, two-chain and L-chain form <6>; very toxic! Booster injection of tetanus toxoid before starting research with tetanus toxin advisable, human anti-tetanus neurotoxin antibodies available <6>	Clostridium tetani	2 , 6

Cloned/COMMENTARY	ORGANISM	LITERATURE
Clostridium tetani <1,3>; expressed in Escherichia coli JM101 using three different plasmid vectors <3>	Clostridium tetani	1 , 3

ENGINEERING ORGANISM COMMENTARY LITERATURE

No entries in this field

Renatured/COMMENTARY ORGANISM LITERATURE

No entries in this field

APPLICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

DISEASE TITLE OF PUBLICATION LINK TO PUBMED

No entries in this field

REF.	AUTHORS	TITLE	JOURNAL	VOL.	PAGES	YEAR	ORGANISM	COMMENTARY	LINK TO PUBMED
1	Fairweather, N.F.; Lyness, V.A.	The complete nucleotide sequence of tetanus toxin	Nucleic Acids Res.	14	7809- 7813	1986	Clostridium tetani	-	● PubMed
2	Rossetto, O.; Schiavo, G.; Polverino de Laureto, P.; Fabbiani, S.; Montecucco, C.	Surface topography of histidine residues of tetanus toxin probed by immobilized-metal-ion affinity chromatography	Biochem. J.	285	9-12	1992	Clostridium tetani	-	● PubMed
3	Eisel, U.; Jarusch, W.; Goretzki, K.; Engels, J.; Weller, U.; Hudel, M.; Habermann, E.; Niemann, H.	Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins	EMBO J.	5	2495- 2502	1986	Clostridium tetani	-	● PubMed
4	Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C.	Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]	Nature	359	832- 835	1992	Clostridium tetani	-	● PubMed
5	Montecucco, C.; Schiavo, G.	Mechanism of action of tetanus and botulinum neurotoxins	Mol. Microbiol.	13	1-8	1994	Clostridium tetani	review	● PubMed
6	Schiavo, G.; Montecucco, C.	Tetanus and botulism neurotoxins: isolation and assay	Methods Enzymol.	248	643- 652	1995	Clostridium tetani	review	● PubMed

LINKS TO OTHER DATABASES (specific for EC-Number 3.4.24.68)

[ExPASy](#)

[Online Mendelian Inheritance in Man](#)

[KEGG](#)

NCBI: [PubMed](#), [Protein](#), [Nucleotide](#), [Structure](#), [Genome](#), [OMIM](#), [Domains](#)

[IUBMB Enzyme Nomenclature](#)

[WIT database](#)

[EMP Project](#)

[PDB database\(3D structure\)](#)

[PROSITE Database of protein families and domains](#)

[SYSTEMS](#)

[Protein Mutant Database](#)

Mark a special word or phrase in this record:

Mark!

All organism
Clostridium barati
Clostridium botulinum
Clostridium butyricum
Clostridium sp.

Select one or more organism in this record:

Submit

EC NUMBER COMMENTARY

3.4.24.69

RECOMMENDED NAME GeneOntology No.

Bontoxilysin

GO:0000000

SYSTEMATIC NAME

No entries in this field

SYNONYMS

ORGANISM COMMENTARY LITERATURE

BoNT	-	-	-
BoNT/B	-	SwissProt	-
BoNT/C1	-	SwissProt	-
BoNT/D	-	SwissProt	-
BoNT/E	-	SwissProt	-
BoNT/F	-	SwissProt	-
BoNT/G	-	SwissProt	-
Bontoxilysin C1	-	SwissProt	-
Botulinum neurotoxin	-	-	-
More	-	cf. EC 3.4.24.68	-

CAS REGISTRY NUMBER COMMENTARY

107231-12-9

REACTION

COMMENTARY

Protein + H₂O = hydrolyzed protein

Clostridium botulinum: mechanism <4>; Clostridium botulinum, Clostridium barati, Clostridium butyricum: structure/function relationship <5>

REACTION TYPE

ORGANISM COMMENTARY LITERATURE

hydrolysis of peptide bond

ORGANISM

COMMENTARY

LITERATURE

Clostridium barati

5

Clostridium botulinum

strains 62A (serotype A) or Beluga (serotype E) <10>; type G strain <15>; 7 serologically different neurotoxin types: BoNT/A-G <2, 3, 5, 6>; serotypes BoNT/A, BoNT/B <1, 4, 8, 15>; BoNT/C, BoNT/D <15>; BoNT/E <1, 4, 8>









1-10, 12, 15

Clostridium butyricum

5

Clostridium sp. serotypes BoNT/A, B, D, E <13>; F <13, 14>

6, 11, 13, 14

SUBSTRATE	PRODUCT	REACTION DIAGRAM	ORGANISM	Substrate r:=reversible ir:=irreversible	LITERATURE/ Substrate	COMMENTARY/ Product	LITERATURE/ Product
More	?		Clostridium botulinum	catalytic activity requires reduction of the single interchain disulfide bond of the neurotoxin <4,15>; activating protease activity is localized on light or L-chain of neurotoxin <4>; the clostridial neurotoxins differ from other proteases in the recognition of the tertiary structure of the target rather than the sequence of the peptide bond to be cleaved <15>; neuroparalytic activity tested by intravenous injection into Balb/c mice <1>; no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5,6>; synaptotagmin, synaptophysin <15>	<u>1</u> , <u>4</u> , <u>5</u> , <u>6</u> , <u>15</u>	-	-
More	?		Clostridium barati	no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5>	<u>5</u>	-	-
More	?		Clostridium butyricum	no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5>	<u>5</u>	-	-
More	?		Clostridium sp.	the botulinum neurotoxins are divided into two groups: the A-E type and the B-D-F- tetanus toxin type <13>; no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <6>; N- ethylmaleimide sensitive factor (i.e. NSF), alpha/beta-SNAP or gamma-SNAP <13>	<u>6</u> , <u>13</u>	-	-
Proteins of neuroexocytosis apparatus + H2O	?		Clostridium botulinum	-	<u>2</u> , <u>3</u> , <u>5</u> , <u>6</u>	-	-
Proteins of neuroexocytosis apparatus + H2O	?		Clostridium barati	-	<u>5</u>	-	-
Proteins of neuroexocytosis apparatus + H2O	?		Clostridium butyricum	-	<u>5</u>	-	-
Proteins of neuroexocytosis apparatus + H2O	?		Clostridium sp.	-	<u>6</u>	-	-
Recombinant glutathione S- methyltransferase	Hydrolyzed recombinant glutathione S-		Clostridium	-	<u>15</u>	2 proteolytic fractions. MW	<u>15</u>

VAMP-2 fusion
protein + H₂O

methyltransferase
VAMP-2 fusion protein



botulinum

36000 and MW
6000

i.e. VAMP <5,6,12,15>;
synaptic vesicle-
associated membrane
protein <4,6,15>; MW
19000 <4>; two
isoforms in human <4>;
chicken <5>; or rat
brain <4,5>; ;
synaptobrevin/VAMP-1
(VAMP-1 from chicken,
#Clostridium
botulinum,5#Clostridium
barati,o#Clostridium
butyricum# <5> or rat
brain, #Clostridium
botulinum,n#Clostridium
barati,#Clostridium
butyricum# <4, 5>
carrying Val76 instead
of Gln76 is not
hydrolyzed by serotype
BoNT/B, #Clostridium
botulinum,o#Clostridium
barati,i#Clostridium
butyricum# <4, 5>)

Synaptobrevin +
H₂O

Hydrolyzed
synaptobrevin



Clostridium
botulinum



<4,5,6,15>; both
isoforms are cleaved at
the same rate <15>;
highly specific
neurotoxins <4,5,6,15>;
serotype BoNT/B:
cleavage at Ser-Gln-+-
Phe-Glu (at the same
site as the tetanus
neurotoxin) <5>; or
Gln76-Phe77 <4>; or
Gln-Lys-+-Leu-Ser <5>;
or-Asp-Gln-+-Lys-Leu-,
serotype BoNT/G:
cleavage at Ala83-
Ala84 (VAMP-1), Ala81-
Ala82 (VAMP-2) <15>;
or Ser-Ala-+-Ala-Lys
<5>; hydrolyzed by
serotypes BoNT/B
<4,5,6>; D, F or G
<5,6>; in vitro, in
synaptosomes and in
injected Aplysia
neurons <5>; no
substrate of serotype
BoNT/A or E <4,12>;
the term -+- depicts the
points of cleavage





4 , 5 , 6 , 15






2 proteolytic
fragments, MW
12000 and MW
7000 <4>; MW
13000 and MW
6000 <15>


4 , 15

i.e. VAMP <6,13,14>;
synaptic vesicle-
associated membrane
protein <6,13,14>; ;
synaptobrevin/VAMP-1
(VAMP-1 from chicken,
#Clostridium
botulinum,t#Clostridium
barati,r#Clostridium
butyricum# <5> or rat
brain, #Clostridium
botulinum,y#Clostridium
barati,n#Clostridium
butyricum# <4, 5>
carrying Val76 instead

Synaptobrevin + H2O	Hydrolyzed synaptobrevin		Clostridium sp.	<p>of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum, r#Clostridium barati, n#Clostridium butyricum# <4, 5> <13>; and synaptobrevin/VAMP-2 <6, 13>; both isoforms are cleaved at the same rate <13, 14>; highly specific neurotoxins <6, 13, 14>; serotype BoNT/D: cleavage at Lys61-Leu62 <13>; serotype BoNT/F: cleavage at Gln-Lys <14>; hydrolyzed by serotypes BoNT/B <6>; D, F or G <6>; the term +- depicts the points of cleavage</p> <p>i.e. VAMP <5>; chicken <5>; or rat brain <5>; : synaptobrevin/VAMP-1 (VAMP-1 from chicken, #Clostridium botulinum, k#Clostridium barati, #Clostridium butyricum# <5> or rat brain, #Clostridium botulinum, o#Clostridium barati, m#Clostridium butyricum# <4, 5> carrying Val76 instead of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum, >#Clostridium barati, e#Clostridium butyricum# <4, 5>) <5>; and synaptobrevin/VAMP-2 <5>; highly specific neurotoxins <5>; serotype BoNT/B: cleavage at Ser-Gln+-Phe-Glu (at the same site as the tetanus neurotoxin) <5>; or Gln-Lys+-Leu-Ser <5>; or Ser-Ala+-Ala-Lys <5>; hydrolyzed by serotypes BoNT/B <5>; D, F or G <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; the term +- depicts the points of cleavage</p> <p>i.e. VAMP <5>; chicken <5>; or rat brain <5>; : synaptobrevin/VAMP-1 (VAMP-1 from chicken, #Clostridium botulinum, d#Clostridium barati, d#Clostridium butyricum# <5> or rat brain, #Clostridium botulinum, i#Clostridium barati, i#Clostridium butyricum# <4, 5> carrying Val76 instead</p>	6, 13, 14	MW 8000 and MW 9000 <13>	13
Synaptobrevin + H2O	Hydrolyzed synaptobrevin		Clostridium barati	<p>and synaptobrevin/VAMP-2 <5>; highly specific neurotoxins <5>; serotype BoNT/B: cleavage at Ser-Gln+-Phe-Glu (at the same site as the tetanus neurotoxin) <5>; or Gln-Lys+-Leu-Ser <5>; or Ser-Ala+-Ala-Lys <5>; hydrolyzed by serotypes BoNT/B <5>; D, F or G <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; the term +- depicts the points of cleavage</p> <p>i.e. VAMP <5>; chicken <5>; or rat brain <5>; : synaptobrevin/VAMP-1 (VAMP-1 from chicken, #Clostridium botulinum, d#Clostridium barati, d#Clostridium butyricum# <5> or rat brain, #Clostridium botulinum, i#Clostridium barati, i#Clostridium butyricum# <4, 5> carrying Val76 instead</p>	5		

Synaptobrevin + H2O	Hydrolyzed synaptobrevin		Clostridium butyricum	<p>of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum,u#Clostridium barati,u#Clostridium butyricum# <4, 5> <5>; and synaptobrevin/VAMP-2 <5>; highly specific neurotoxins <5>; serotype BoNT/B: cleavage at Ser-Gln-+-Phe-Glu (at the same site as the tetanus neurotoxin) <5>; or Gln-Lys-+-Leu-Ser <5>; or Ser-Ala-+-Ala-Lys <5>; hydrolyzed by serotypes BoNT/B <5>; D, F or G <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; native and recombinant protein <12>; highly specific neurotoxins <12>; serotype BoNT/A: cleavage at Gln197-Arg198 <12>; or Asn-Gln-+-Arg-Ala <5>; serotype BoNT/E: cleavage at Arg180-Ile181 <12>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5,6,12>; in vitro, in isolated synaptosomes <5,12>; and in injected Aplysia neurons <5>; no substrate of serotype BoNT/G <15>; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; or Asn-Gln-+-Arg-Ala <5>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5>; in vitro, in isolated synaptosomes <5>; and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; or Asn-Gln-+-Arg-Ala <5>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5>; in vitro, in isolated synaptosomes <5>; and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p>	5		
Synaptosome-associated protein + H2O	Hydrolyzed synaptosome-associated protein		Clostridium botulinum		5, 6, 12	2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)	12
Synaptosome-associated protein + H2O	Hydrolyzed synaptosome-associated protein		Clostridium barati		5	2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)	
Synaptosome-associated protein + H2O	Hydrolyzed synaptosome-associated protein		Clostridium butyricum		5	2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)	

Synaptosome-associated protein + H ₂ O	Hydrolyzed synaptosome-associated protein		Clostridium sp.	i.e. SNAP 25, protein of presynaptic membrane <13>; serotype BoNT/A and E <6,13>; the term- depicts the points of cleavage	<u>6</u> , <u>13</u>	2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)	-
Syntaxin + H ₂ O	?		Clostridium botulinum	serotype BoNT/C <5,6>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; no substrate of serotype BoNT/G <15>	<u>5</u> , <u>6</u>	-	-
Syntaxin + H ₂ O	?		Clostridium barati	serotype BoNT/C <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>	<u>5</u>	-	-
Syntaxin + H ₂ O	?		Clostridium butyricum	serotype BoNT/C <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>	<u>5</u>	-	-
Syntaxin + H ₂ O	?		Clostridium sp.	serotype BoNT/C <6>	<u>6</u>	-	-

NATURAL SUBSTRATE	NATURAL REACTION PRODUCT	REACTION DIAGRAM	ORGANISM	COMMENTARY SUBSTRATE	LITERATURE (Substrate)	COMMENTARY PRODUCT	LITERATURE (Product)	ORGANISM (Product)
Neuroexocytosis multi-subunit complex + H ₂ O	-		Clostridium botulinum	involved in limited hydrolysis of proteins of the neuroexocytosis apparatus, blocks release of neurotransmitter acetylcholine at neuromuscular junction <5>; causing flaccid paralysis, in contrast to spastic paralysis caused by EC 3.4.24.68, three functionally distinct domains: domain L blocks neuroexocytosis, domain HN governs cell penetration, domain HC responsible for neurospecific binding <5,6>; neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature	<u>5</u> , <u>6</u>	-	-	-

Neuroexocytosis
multi-subunit
complex + H₂O



Clostridium
barati

involved in limited
hydrolysis of
proteins of the
neuroexocytosis
apparatus, blocks
release of
neurotransmitter
acetylcholine at
neuromuscular
junction <5>;
causing flaccid
paralysis, in contrast
to spastic paralysis
caused by EC
3.4.24.68, three
functionally distinct
domains: domain L
blocks
neuroexocytosis,
domain HN governs
cell penetration,
domain HC
responsible for
neurospecific
binding <5>;
neurotoxin binds
specifically to nerve
cells, botulin
neurotoxin-receptors
are located on the
motor neuron
plasmalemma at
neuromuscular
junctions, neurotoxin
binds via protein and
lipid interaction, after
binding it is
internalized inside
vesicles of unknown
nature

5










Neuroexocytosis
multi-subunit
complex + H₂O



Clostridium
butyricum

involved in limited
hydrolysis of
proteins of the
neuroexocytosis
apparatus, blocks
release of
neurotransmitter
acetylcholine at
neuromuscular
junction <5>;
causing flaccid
paralysis, in contrast
to spastic paralysis
caused by EC
3.4.24.68, three
functionally distinct
domains: domain L
blocks
neuroexocytosis,
domain HN governs
cell penetration,
domain HC
responsible for
neurospecific
binding <5>;
neurotoxin binds
specifically to nerve
cells, botulin
neurotoxin-receptors
are located on the
motor neuron
plasmalemma at
neuromuscular
junctions, neurotoxin

5

			binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature				
			causing flaccid paralysis, in contrast to spastic paralysis caused by EC 3.4.24.68, three functionally distinct domains: domain L blocks neuroexocytosis, domain HN governs cell penetration, domain HC responsible for neurospecific binding <6>; neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature				
Neuroexocytosis multi-subunit complex + H2O	-		Clostridium sp.	neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature	<u>6</u>	-	-
Synaptobrevin + H2O	-		Clostridium botulinum	i.e. VAMP <5,6,12>; synaptic vesicle-associated membrane protein, neurotoxin responsible for human and animal botulism <12>	<u>4, 5, 6, 12</u>	-	-
Synaptobrevin + H2O	-		Clostridium barati	i.e. VAMP <5>	<u>5</u>	-	-
Synaptobrevin + H2O	-		Clostridium butyricum	i.e. VAMP <5>	<u>5</u>	-	-
Synaptobrevin + H2O	-		Clostridium sp.	i.e. VAMP <6>	<u>6</u>	-	-
Synaptosome-associated protein + H2O	-		Clostridium botulinum	i.e. SNAP 25, protein of presynaptic membrane	<u>5</u>	-	-
Synaptosome-associated protein + H2O	-		Clostridium barati	i.e. SNAP 25, protein of presynaptic membrane	<u>5</u>	-	-
Synaptosome-associated protein + H2O	-		Clostridium butyricum	i.e. SNAP 25, protein of presynaptic membrane	<u>5</u>	-	-
Synaptosome-associated protein + H2O	-		Clostridium sp.	i.e. SNAP 25, protein of presynaptic membrane	<u>13</u>	-	-

COFACTOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

METAL IONS	ORGANISM	COMMENTARY	LITERATURE
More	Clostridium botulinum	no involvement of cobalt, copper, iron, manganese or nickel, atomic absorption spectroscopy	1
More	Clostridium sp.	no involvement of cobalt, copper, iron, manganese or nickel, atomic absorption spectroscopy	14
Zinc	Clostridium botulinum	zinc-dependent endopeptidase (serotype BoNT/B, #Clostridium botulinum,t#Clostridium sp.# <4, 6>) <4,6,12,15>; atom absorption spectroscopy <1,5,6>; : 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, #Clostridium botulinum# <1>), bound to light chain (i.e. L-chain) <5>; the L-chain of BoNT/B is a form of zinc-endopeptidase <6>; 0.8-1 gatom zinc/mol neurotoxin <6>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <1,5,15>; or His223-Glu-Leu-Ile-His-X-X-His230 <10>; activation requires reduction of interchain disulfide bond <4,15>	1 , 4 , 5 , 6 , 10 , 12 , 15
Zinc	Clostridium barati	atom absorption spectroscopy <5>; : 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, #Clostridium botulinum# <1>), bound to light chain (i.e. L-chain) <5>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <5>	5
Zinc	Clostridium butyricum	atom absorption spectroscopy <5>; : 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, #Clostridium botulinum# <1>), bound to light chain (i.e. L-chain) <5>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <5>	5
Zinc	Clostridium sp.	zinc-dependent endopeptidase (serotype BoNT/B, #Clostridium botulinum,n#Clostridium sp.# <4, 6>) <6,13,14>; atom absorption spectroscopy <6,14>; : 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, #Clostridium botulinum# <1>), bound to light chain (i.e. L-chain) <14>; the L-chain of BoNT/B is a form of zinc-endopeptidase <6>; 0.8-1 gatom zinc/mol neurotoxin <6>	6 , 13 , 14

INHIBITORS	ORGANISM	COMMENTARY	LITERATURE	IMAGE
1,10-Phenanthroline	Clostridium botulinum	-	1 , 15	● 2D-image
1,10-Phenanthroline	Clostridium sp.	r, Zn ²⁺ restores <14>	14	● 2D-image
Ala-Ser-Gln-Phe-Glu-Thr-Ser	Clostridium botulinum	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of Aplysia californica, serotype BoNT/B, not A or E	4	● 2D-image
Captopril	Clostridium botulinum	serotype BoNT/B <4>	4 , 5 , 15	● 2D-image
Captopril	Clostridium barati	-	5	● 2D-image
Captopril	Clostridium butyricum	-	5	● 2D-image
Captopril	Clostridium sp.	-	13 , 14	● 2D-image
Dipicolinic acid	Clostridium botulinum	-	1	● 2D-image
EDTA	Clostridium botulinum	r, Zn ²⁺ restores <1>; serotype BoNT/B <4>	1 , 4 , 15	● 2D-image
EDTA	Clostridium sp.	r, Zn ²⁺ restores <14>	13 , 14	● 2D-image
Gln-Phe-Glu-Thr	Clostridium botulinum	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of Aplysia californica, serotype BoNT/B, not A or E	4	● 2D-image

ACTIVATING COMPOUND	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Proteases	Clostridium botulinum	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5,6>; bacterial or tissue proteases <5>	5,6	-
Proteases	Clostridium barati	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5>; bacterial or tissue proteases <5>	5	-

Proteases	Clostridium butyricum	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5>; bacterial or tissue proteases <5>	5	-
Proteases	Clostridium sp.	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <6>	6	-

KM VALUE [mM] KM VALUE [mM] Maximum SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

Ki VALUE [mM] Ki VALUE [mM] Maximum INHIBITOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

TURNOVER NUMBER TURNOVER NUMBER MAXIMUM SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

SPECIFIC ACTIVITY [μM/min/mg] SPECIFIC ACTIVITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

pH OPTIMUM pH MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

pH RANGE pH RANGE MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE OPTIMUM	TEMPERATURE OPTIMUM MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
37	-	Clostridium botulinum	assay at	4 , 6 , 12 , 15
37	-	Clostridium sp.	assay at	6 , 13 , 14

TEMPERATURE RANGE TEMPERATURE MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

SOURCE TISSUE ORGANISM COMMENTARY LITERATURE

No entries in this field

LOCALIZATION	ORGANISM	COMMENTARY	GeneOntology No.	LITERATURE
cytosol	Clostridium botulinum	accumulates until bacterial lysis	GO:0005829	5 , 6
cytosol	Clostridium barati	accumulates until bacterial lysis	GO:0005829	5
cytosol	Clostridium butyricum	accumulates until bacterial lysis	GO:0005829	5
cytosol	Clostridium sp.	accumulates until bacterial lysis	GO:0005829	6

ACCESSION CODE ENTRY NAME ORGANISM NO. OF AA MOLECULAR WEIGHT[Da] SOURCE Sequence

No entries in this field

PDB	ORGANISM
1E1H , download	Clostridium botulinum
1EPW , download	Clostridium botulinum
1F31 , download	Clostridium botulinum
1F82 , download	Clostridium botulinum
1F83 , download	Clostridium botulinum
1FQH , download	Clostridium botulinum
1G9A , download	Clostridium botulinum

[1G9B, download](#) Clostridium botulinum
[1G9C, download](#) Clostridium botulinum
[1G9D, download](#) Clostridium botulinum
[1I1E, download](#) Clostridium botulinum
[3BTA, download](#) Clostridium botulinum

MOLECULAR WEIGHT	MOLECULAR WEIGHT MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
155000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/B, calculated from amino acid sequence	<u>8</u>
152000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/E, calculated from amino acid sequence	<u>8</u>
150000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, SDS-PAGE, calculated from amino acid sequence	<u>8</u>
149500	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, calculated from nucleotide sequence	<u>9</u>
149400	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, calculated from nucleotide sequence	<u>10</u>
148700	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/C1, calculated from nucleotide sequence	<u>3</u>
146900	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/D, calculated from nucleotide sequence	<u>2</u>
additional information	-	Clostridium botulinum	amino acid content <8>; comparison of amino acid sequences of H- and L-chains of serotypes A, B and E <8>; comparison of amino acid sequences of botulinum serotype BoNT/A and tetanus neurotoxin <9,10>; amino acid sequence similarity of clostridial neurotoxins	<u>8</u> , <u>9</u> , <u>10</u>
additional information	-	Clostridium sp.	amino acid content; comparison of amino acid sequences of H- and L-chains of serotypes A, B and E; comparison of amino acid sequences of botulinum serotype BoNT/A and tetanus neurotoxin; amino acid sequence similarity of clostridial neurotoxins <14>	<u>14</u>

SUBUNITS	ORGANISM	COMMENTARY	LITERATURE
Dimer	Clostridium botulinum	1 * 50000 + 1 * 102000, Clostridium botulinum, serotype BoNT/E, calculated from amino acid sequence, 1 * 51000 + 1 * 104000, Clostridium botulinum, serotype BoNT/B, calculated from amino acid sequence, 1 * 53000 + 1 * 97000, Clostridium botulinum, serotype BoNT/A, calculated from amino acid sequence	<u>8</u>
More	Clostridium botulinum	synthesized as single-chain polypeptide of about MW 150000, proteolytic activation yields 2-chain neurotoxin with N-terminal light (MW 50000) and C-terminal heavy chains (MW 100000) connected by single disulfide bonds <2,3,6>; serotype BoNT/E: single-chain polypeptide, serotype BoNT/B: mixture of single- and 2-chain molecules, serotype BoNT/A: 2-chain molecule <8>	<u>2</u> , <u>3</u> , <u>6</u> , <u>8</u>
More	Clostridium sp.	synthesized as single-chain polypeptide of about MW 150000, proteolytic activation yields 2-chain neurotoxin with N-terminal light (MW 50000) and C-terminal heavy chains (MW 100000) connected by single disulfide bonds <6>; serotype BoNT/E: single-chain polypeptide, serotype BoNT/B: mixture of single- and 2-chain molecules, serotype BoNT/A: 2-chain molecule	<u>6</u>

POSTTRANSLATIONAL MODIFICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

Crystallization/COMMENTARY ORGANISM LITERATURE

No entries in this field

pH STABILITY pH STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE STABILITY TEMPERATURE STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

GENERAL STABILITY ORGANISM LITERATURE

No entries in this field

ORGANIC SOLVENT ORGANISM COMMENTARY LITERATURE

No entries in this field

OXIDATION STABILITY ORGANISM LITERATURE

- Clostridium botulinum 6

STORAGE STABILITY

-80°C, in 10 mM HEPES buffer, pH 7.2, 50 mM NaCl, after freezing in liquid N2, stable

ORGANISM

Clostridium botulinum

COMMENTARY LITERATURE

- 6

Purification/COMMENTARY

serotypes BoNT/A to F

ORGANISM

Clostridium sp.

LITERATURE

11

serotypes BoNT/A, B, E (and their H-chain and L-chain <8>) <6,8>; C, D, F <6> Clostridium botulinum 6, 8

Cloned/COMMENTARY

Clostridium botulinum <2,3>; serotypes BoNT/A (3 fragments encompassing the structural gene <9>) <9,10>; C1 <2,3>; or D <2>; expressed in Escherichia coli TG1 <9>

ORGANISM

Clostridium botulinum

LITERATURE

2, 3, 9, 10

ENGINEERING ORGANISM COMMENTARY LITERATURE

No entries in this field

Renatured/COMMENTARY ORGANISM LITERATURE

No entries in this field

APPLICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

DISEASE

TITLE OF PUBLICATION

LINK TO PUBMED

Blepharoptosis

-

● [PubMed](#)

Blepharoptosis

-

● [PubMed](#)

Botulism

-

● [PubMed](#)

Botulism

-

● [PubMed](#)

Botulism, Infantile

-

● [PubMed](#)

Botulism, Infantile

-

● [PubMed](#)

Nerve paralysis

-

● [PubMed](#)

Nerve paralysis

-

● [PubMed](#)

Nystagmus, Pathologic Treatment of acquired nystagmus with botulinum neurotoxin A.

● [PubMed](#)

REF. AUTHORS

TITLE

JOURNAL

VOL.

PAGES

YEAR

ORGANISM

COMMENTARY

LINK TO PUBMED

1

Schiavo, G.; Rossetto, O.; Santucci, A.; DasGupta, B.R.; Montecucco, C.

Botulinum neurotoxins are zinc proteins

J. Biol. Chem.

267

23479-23483

1992

Clostridium botulinum

-

● [PubMed](#)

2

Binz, T.; Kurazono, H.; Popoff, M.R.; Eklund, M.W.; Sakaguchi, G.; Kozaki, S.; Krieglstein, K.; Henschen, A.; Gill, D.M.; Niemann, H.

Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D

Nucleic Acids Res.

18

5556

1990

Clostridium botulinum

-

● [PubMed](#)

<u>3</u>	Hauser, D.; Eklund, M.W.; Kurazono, H.; Binz, T.; Niemann, H.; Gill, D.M.; Boquet, P.; Popoff, M.R.	Nucleotide sequence of Clostridium botulinum C1 neurotoxin	Nucleic Acids Res.	18	4924	1990	Clostridium botulinum	-	● PubMed
<u>4</u>	Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C.	Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]	Nature	359	832-835	1992	Clostridium botulinum	-	● PubMed
<u>5</u>	Montecucco, C.; Schiavo, G.	Mechanism of action of tetanus and botulinum neurotoxins	Mol. Microbiol.	13	1-8	1994	Clostridium botulinum, Clostridium barati, Clostridium butyricum	review	● PubMed
<u>6</u>	Schiavo, G.; Montecucco, C.	Tetanus and botulism neurotoxins: isolation and assay	Methods Enzymol.	248	643-652	1995	Clostridium botulinum, Clostridium sp.	review	● PubMed
<u>7</u>	Eisel, U.; Jarusch, W.; Goretzki, K.; Henschen, A.; Engels, J.; Weller, U.; Hudel, M.; Habermann, E.; Niemann, H.	Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins	EMBO J.	5	2495-2502	1986	Clostridium botulinum	-	● PubMed
<u>8</u>	Saathyamoorthy, V.; DasGupta, B.R.	Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E	J. Biol. Chem.	260	10461-10466	1985	Clostridium botulinum	-	● PubMed
<u>9</u>	Thompson, D.E.; Brehm, J.K.; Oultram, J.D.; Swinfield, T.-J.; Shone, C.C.; Atkinson, T.; Melling, J.; Minton, N.P.	The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene	Eur. J. Biochem.	189	73-81	1990	Clostridium botulinum	-	● PubMed
<u>10</u>	Binz, T.; Kurazono, H.; Wille, M.; Frevert, J.; Wernars, K.; Niemann, H.	The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins	J. Biol. Chem.	265	9153-9158	1990	Clostridium botulinum	-	● PubMed
<u>11</u>	Simpson, L.L.; Schmidt, J.J.; Middlebrook, J.L.	Isolation and characterization of the botulinum neurotoxins	Methods Enzymol.	165	76pp	1988	Clostridium sp.	-	-
<u>12</u>	Schiavo, G.; Santucci, A.; DasGupta, B.R.; Mehta, P.P.; Jontes, J.; Benfenati, F.; Wilson, M.C.; Montecucco, C.	Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds	FEBS Lett.	335	99-103	1993	Clostridium botulinum	-	● PubMed
<u>13</u>	Schiavo, G.; Rossetto, O.; Catsicas, S.; Polverino de Laureto, P.; DasGupta, B.R.; Benfenati, F.; Montecucco, C.	Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E	J. Biol. Chem.	268	23784-23787	1993	Clostridium sp.	-	● PubMed
<u>14</u>	Schiavo, G.; Shone, C.C.; Rossetto, O.; Alexander, F.C.G.; Montecucco, C.	Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin	J. Biol. Chem.	268	11516-11519	1993	Clostridium sp.	-	● PubMed
<u>15</u>	Schiavo, G.; Malizio, C.; Trimble, W.S.; Polverino de Laureto, P.; Milan, G.	Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a	J. Biol.	269	20213-	1994	Clostridium	-	● PubMed

Sugiyama, H.;
Johnson, E.A.;
Montecucco, C.

single Ala-Ala peptide
bond

Chem.

20216

botulinum

LINKS TO OTHER DATABASES (specific for EC-Number 3.4.24.69)

[ExPASy](#)

[Online Mendelian Inheritance in Man](#)

[KEGG](#)

NCBI: [PubMed](#), [Protein](#), [Nucleotide](#), [Structure](#), [Genome](#), [OMIM](#), [Domains](#)

[IUBMB Enzyme Nomenclature](#)

[WIT database](#)

[EMP Project](#)

[PDB database\(3D structure\)](#)

[PROSITE Database of protein families and domains](#)

[SYSTERS](#)

[Protein Mutant Database](#)